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Abstract 
Mounting evidence suggests that inflammation is involved in the etiology of 
neurodegenerative disorders such as Parkinson's disease. It has been reported that the 
long-term effect of five doses of lipopolysaccharide from Gram-negative bacteria in 
mice caused activation of microglia and dopaminergic neurodegeneration that was 
reflected as decreased locomotor activity. In the current study, it is hypothesized that 
IL-1 ~, a potent proinflammatory cytokine synthesized and released by glia cells, could 
be mediating the LPS-induced dopaminergic neurodegeneration and that the chronic 
low-grade inflammatory state caused by diet-induced obesity would exacerbate LPS-
induced neurodegeneration. 
To ascertain the participation of IL-1 ~, three strains of mice were employed: a control 
[wild type (WT)], a strain lacking the endogenous antagonist of IL-1, namely IL-1 
receptor antagonist (IL-lra-/-), and a mouse strain deficient in caspase-1 (Casp-1-/-), a 
protease that cleaves the immature IL-1 ~ into the mature, biologically active form. 
Mice of the three genotypes were fed a regular diet (RD) and additionally WT mice 
were fed a high-fat diet (HFD). All mouse groups were challenged with intraperitoneal 
injections of either saline or LPS (5 mg/kg; one or five times on a monthly basis). 
Significant genotype and diet effects were observed in behavioral, metabolic and 
inflammatory outcomes over a period of 9 to 15 months, whereas the effect of LPS was 
modest or undetectable. 
Compared to WT mice, Casp-1-/- mice preserved their locomotor activities, while IL-
. . 
lra-/- mice showed a time-dependent decline in motor and coordinative abilities. Non-
moto~ symptoms included age-related development of anxiety-like behavior in IL-lra-/-
mice. Impairment of cognitive function was observed in Casp-1-/- mice. Since insulin 
and leptin may modulate dopamine neurotransmission, plasma levels of these two 
hormones were assessed. Casp-1-/- mice had increased plasma insulin levels but were 
not glucose intolerant, whereas IL-lra-/- mice were hypoinsulinemic, but insulin 
sensitive. Leptin levels were reduced in both genotypes (Casp-1-/- and IL-lra-/-). Casp-
1-/- mice had intact dopamine neurons and less activated microglia cells. Dopamine 
neurodegeneration was observed in IL-lra-/- mice and accompanied by higher, but non-
significant activation of microglia. The connection between peripheral · and central 
vii 
inflammation was assessed by plasma level of monocyte chemoattractant protein- I 
(MCP-1). Plasma MCP-1 tended to be increased by repeated LPS injections in WT mice 
and surprisingly it was reduced by single and repeated LPS injections in both Casp-1-/-
and IL-I ra-/- mice. 
Significant differences m final outcomes were observed between the two diet-fed 
groups of mice. LPS treatments did not induce motor decline in RD and HFD-fed mice 
during nine months of experiments . However, HFD mice showed symptoms of akinesia, 
bradykinesia, dyskinesia and reduced coordinative abilities. Non-motor symptoms 
observed in HFD mice were anxiety-like behavior in novelty suppressed feeding test, 
cognitive and partial memory impairment. HFD mice displayed glucose intolerance, 
high levels of leptin and insulin. Dopamine neurons were not affected by HFD and 
significant decreases were induced by repeated LPS injections. Loss of neurons was not 
accompanied with increased activation of microglia cells and MCP-1. 
Overall, the data shown here emphasized the importance of the IL-1 signaling pathway 
in dopaminergic neurodegeneration. 
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1. Introduction 
The activation of innate and adaptive immune system has been associated with the 
progression of many neurodegenerative diseases [l, 2]. The activation of peripheral 
immune cells by intraperitoneal (i.p.) LPS injection induces the synthesis and release 
of proinflammatory cytokines in peripheral organs and within the brain [3]. The 
connection between the peripheral immune response and the neuroinflammatory 
process in the CNS will be discussed in the chapters 1.1-1.6. 
The sustained neuroinflammatory process in the brain has been shown to be involved 
in the pathobiology of Parkinson's disease [ 4]. The function of dopamine neurons 
and their susceptibility to neurodegeneration by the activation of microglia resident 
immune cells will be described in chapters 1. 7 -1.10. 
Although obesity has been initially described as the excessive storage of fat, it has 
been also recognized as a pathological condition that contributes to many metabolic 
disorders and the production of proinflammatory cytokines [5]. Excess accumulation 
of fat causes a chronic state of low-grade chronic inflammation since it has been 
reported that food high in fat and sugar can act as an inflammatory component 
triggering the activation of the innate immune system [ 6] . Thus, it is proposed that 
there might be a connection among obesity-induced metabolic disorders, 
inflammation and neurodegenerative diseases [7-9]. High-fat diet-related weight gain 
contributes to leptin and insulin resistance that might alter the proper function of the 
dopamine system [10-13]. Effects of obesity-related metabolic disorders such as 
leptin aJ:?,d insulin resistance on dopaminergic function will be described in chapter 
1.11. 
1.1 The immune system and inflammation 
1.1.1 The arms of the immune system 
One of the aspects of maintaining physiological homeostasis and normal functioning 
of an organism is the presence of a defense system that is active against external 
pathogens. Such protection is enabled by an immune system comprised of cells and 
molecules that are actively involved in the recognition and neutralization of foreign 
agents, carried out in a highly coordinated process. Based on the level of the immune 
1 
system and specificity in recogmzmg hostile microorganisms, immune cells are 
divided into two major groups: innate and adaptive immune cells [14, 15]. 
The first reaction of the immune system towards the invading pathogens is mediated 
by the activation of the innate immune system. The innate immune system is 
phylogenetically older and this line of defense is generally defined as a nonspecific 
response. The innate immune system is only able to recognize common structural 
components of microorganisms and therefore fails to differentiate other key features 
that are specific for each pathogen alone. Part of the innate immune system includes 
existence of physical barriers ( epithelial cells) that have the function of preventing 
entry of pathogens followed by the activation of various phagocytic cells [ 15]. 
The second line of the immune response is mediated by set of immune cells (T and B 
lymphocytes), which target pathogens in more specific way. Lymphocytes are 
specific in their ability to recognize a pathogen' s unique structural molecules and to 
memorize the previous pathological event in order to adapt their response for the 
next coming infection and execute its action more swiftly. In that sense this specific 
immune system is named as the adaptive immune system [ 14]. 
The innate and adaptive immune systems are inter-connected m their action to 
eliminate invading pathogens by orchestrating their response in two ways: 1) once 
activated, the innate immune system stimulates the activation of the adaptive 
immune system and also influences the level of its response; 2) the adaptive immune 
system recognizes and marks pathogens for destruction by employing the innate 
immune cells to eliminate microorganisms, closing in that manner the full cycle of 
the immune response [14, 16]. 
1.1.2 The inflammatory response 
The inflammatory response represents an early non-specific response of the 
organism to tissue damage or pathogen invasion. It is mainly driven by the activation 
of circulating leukocytes, which are also a part of the main surveillance system 
responsible for protection against invading pathogens [15]. 
As described previously in chapter 1.1.1, the first line of defense is exerted by a 
physical barrier ( epithelial cells of the skin) . The barrier is quite effective in keeping 
the foreign microorganisms isolated from the internal environment. If this barrier 
2 
becomes damaged and penetrable to the invading pathogens, such an event will 
trigger the activation of another set of innate immune cells: phagocytic cells 
(monocytes/macrophages, neutrophi1s and natural killer cells) that non-specifically 
would recognize and destroy pathogens by secreting cytotoxic components, which is 
fo11owed by their digestion (phagocytosis) [17]. 
Non-specific recognition of foreign substances (antigens) present in circulation 
corresponds to the outer part of the ce11 wall of microorganisms. More specifica1ly, it 
has been recognized that solely the existence of fragments of the bacterial cel1 
membrane within the host system was effective for the development of an 
inflammatory reaction . Indeed, it has been observed by Pfeiffer in the 19th century 
that insoluble part of bacterial cells was sufficient to trigger the activation of the 
innate inflammatory response and this substance was termed as "endotoxin" 
(endo=within, in Greek) [18]. Endotoxin refers to a component found on the outer 
part of the cell wall of Gram-negative bacteria. It has been shown that its structure 
contains lipid and polysaccharide and therefore it was termed as lipopolysaccharide 
(LPS) [19]. The notion that endotoxin has to be recognized in a host by a specific 
receptor led to the discovery of the 1ipopolysacharide receptor in C3H mice, derived 
by the mutation of a single locus and named as Lps [20]. In 1970, macrophages were 
recognized as the primary cells of the innate immune system responsible for the 
recognition of LPS [21]. Since then, LPS has been regarded as a poison and pyrogen. 
On the other hand, this endotoxin has been shown not to be detrimental in absence of 
its binding protein (low-density-lipoprotein), present in the blood [22]. 
Activated innate immune cells sensitize adaptive immune cells by activation of a 
complement system that leads to the release of cytokines and interleukins (IL). 
Cytokines represent a large family of signaling molecules that are secreted by the 
cells of the innate and adaptive immune systems exerting autocrine, paracrine and 
endocrine effects on distant organs [23]. Interleukins belong to the same group of 
cytokines, but were subdivided as it was thought that these signaling molecules are 
primarily produced by lymphocytes. 
The role of lymphocytes is in elimination of specific antigens through the activation 
of T lymphocytes, which is accomplished by the production of antibodies (the 
soluble form of antigen receptors) secreted by B lymphocytes. T lymphocytes are 
3 
divided into two groups based on the surface molecules expressed on their 
membrane: CD4 and CDS [24]. The CD4 group of T lymphocytes are recognized as 
a T helper cells and they are generally subdivided into Thl and Th2 cells, even 
though some more subtypes have been discovered (Thl 7, Th9) [24]. Thl cells are 
involved in stimulation and activation of other immune cells, mostly related with 
autoimmune diseases, whereas Th2 cells are involved in the activation of B 
lymphocytes and the production of anti-inflammatory interleukins. Production of 
Th2 cell types is important in the elimination of excessive proinflammatory action of 
Thl. Secreted by innate immune cells, cytokines promote clonal differentiation of 
previously activated lymphocytes into their cytotoxic form or stimulate the secretion 
of antibodies. At the same time, activated T lymphocytes are also a great source of 
cytokines, which have purpose of activating other immune cells. When inflammation 
subsides, some of these activated lymphocytes stay activated for a longer period of 
time to provide protection against the re-invasion of microorganisms. 
Inflammation that occurs in peripheral organs is characterized by mcrease m 
temperature, swelling, redness and pain. A hallmark of acute immune reaction is 
increased permeability of the vascular system and infiltration of the cytokine-
releasing phagocytic cells to the site of injury. In most cases, this event is self-
limiting and activated phagocytic cells undergo the process of apoptosis if the 
primary stimulus persists any longer. On the other hand, if the antigen is still present, 
this can lead to sustained macrophage activation, which is described as a hallmark of 
chronic inflammation [25]. 
1.1.3 Peripheral inflammation 
Microorganisms and other pathogens that reach circulation can be rapidly recognized 
by circulating monocytes and local macrophages such as Kupffer's cells in the liver 
[26]. This recognition process is accompanied by the activation of Toll-like receptors 
(TLR's) that reside on the external membrane of immune cells. TLR' s are known as 
pattern recognition receptors (PRRs) as they recognize specific patterns, also 
referred to as pathogen associated molecular patterns (PAMP 's) presented on the cell 
surface or inside it. There are many different types of TLR's [27], divided by their 
function to recognize specific type of P AMP' s and the most important one that will 
be described further in the text is TLR4 [28]. TLR4, expressed by innate immune 
cells, mediates recognition of LPS [28]. Recognition of LPS is followed by 
4 
recruitment of the nuclear transcription factor (NF-KB) and activation of the IL-1 
signaling pathway [29, 30]. As a result of TLR4 activation, certain proinflammatory 
cytokines such as IL-1, IL-6, tumor necrosis factor-a (TNF-a) are synthesized and 
released into circulation [28]. Cytokines are synthesized in a small amount (nano- to 
picomolar concentrations) and act in the autocrine manner, modulating the function 
of the same cell where they are produced, or in the paracrine manner, by interacting 
with adjacent cells [31]. They are also capable of inducing their own synthesis or 
release and the production of other cytokines ( e.g. TNF-a and IL-6). At the same 
time, proinflammatory cytokines antagonize their inflammatory effect by inducing 
the synthesis of anti-inflammatory cytokines such as IL-10, interleukin-I receptor 
antagonist (IL-lra) [32]. 
Although cytokines are not long-range signaling factors and are not able to penetrate 
the blood-brain barrier (BBB) passively, they are still able to signal the brain through 
brain areas that are devoid of BBB and indirectly through the synthesis of 
prostaglandins. Generally it is accepted that cytokines may signal the brain m 
humoral and neural ways. 
1.2 Communication between cytokines and the brain 
There have been recognized four main routes of cytokine-to~-brain communication: 
1) cytokines synthesized in the periphery bind to the receptors of the vagus nerve 
[33], 2) secreted by the circulating immune cells, cytokines induce their own 
production and the induction of liposoluble molecules such as nitric oxide (NO) and 
prostaglandin E2 (PGE2) by endothelial cells and resident immune cells that are in 
contact with the BBB [34] , . 3) transmission into the brain from the area of 
. . 
circumventricular organs (CVO's) [35] and 4) diffusion through the BBB by the 
mechanism of saturable transport [36]. 
1.2.1 'Cytokine-induced neural communication through the vagus nerve 
Neuronal communication betyveen cytokines and the brain parenchyma is established 
through afferent projections of vagus nerv~s. The vagus nerve .is connected to many 
diffe~ent organs in the periphery, conveying the information from and back to central 
nervous system (CNS). At the same time, information about the condition of 
peripheral organs is sent back to CNS via the vagus nerve [3 7]. 
5 
In rodent models of LPS-induced inflammation in peritoneal cavity, the ends of 
vagus nerves react by production of proinflammatory factors ( e.g. IL-1 ~), since their 
perineural sheaths contain macrophages and dendric cells [38]. Neurons of vagus 
nerves also express receptors for IL-1 ~' so in that way signals from the periphery are 
transmitted to the brain [39]. The IL-1 ~-induced neuronal transmission is followed 
by the activation of several brain areas such as hypothalamus, brainstem and limbic 
system [39]. The evidence that the vagus nerve is involved in the transmission of 
peripheral inflammation to the brain emerged from animal models in which the 
vagus nerve was surgically ablated [ 40]. In that experiment, vagotomized animals 
did not experience sickness behavior (social withdrawal) with peripheral 
administration of LPS or IL-1 ~ [ 40] but failed to show resistance upon 
intracerebroventricular (i .c.v.) IL-1~ injection, leading to the conclusion that 
vagotomy itself does not alter the sensitivity of the brain to immune system 
challenges [ 41]. Even though vagotomized animals showed decreased signs of 
sickness behavior (similar to depressive-like behavior) after peripheral inflammation, 
it has been noticed that these animals were still able to develop fever through 
synthesis of prostaglandins in one part of the brain ( organum vasculosum of the 
laminae terminalis) [ 42], which implies that there are other pathways besides neural 
ones that may propagate the immune reaction in the brain. 
1.2.2 Humoral communication between cytokines and the brain 
The humoral signaling pathway is another, yet slower way of transmission of 
peripheral inflammation to the CNS, characterized by the activation of the 
hypothalamic-pituitary-adrenal axis (HP A). It is considered that CNS recognizes 
peripheral inflammatory events by receiving information from secreted cytokines, 
through the activation of the HP A axis [ 43]. In connection with the previous 
statement it was previously demonstrated that hypophysectomized rats [ 44] and mice 
[ 45] failed to show IL-1 induced HP A activation [ 46]. Upon immune challenge in 
the periphery, cytokines are being synthesized by circulating immune cells. Released 
from the innate immune cells, cytokines such as IL-1, TNF-a and IL-6 stimulate the 
synthesis of PGE2 that is mediated by cyclooxygenase-2 (COX-2) and inducible 
nitric oxide synthase (iNOS), which catalyzes production of NO [ 4 7]. As a result, 
PGE2 and NO are synthesized and released into the brain parenchyma. More 
specifically, PGE2 diffuses into the hypothalamus and binds to its receptors (EP3 
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and EP4 receptors) that are located in neurons of paraventricular nucleus (PVN) 
[48]. 
Subsequently, the corticotropin-releasing hormone (CRH) is synthesized [ 46] and 
transported to the pituitary gland where it stimulates the release of the 
adrenocorticotropic hormone (ACTH) in the blood. Recognized by its receptors on 
adrenal gland, ACTH further stimulates the secretion of glucocorticoids ( e.g. 
cortisol). Circulating glucocorticoids act as a modulator of immune response by 
suppressing the further release of cytokines and by stimulating the anti-inflammatory 
action of Th2 cells [ 49]. Cytokines are also able to directly stimulate the HP A axis 
by binding to their receptors that are expressed in pituitary and adrenal gland, 
contributing to the elevated levels of glucocorticoids during chronic inflammation 
[50]. 
The neural and humoral pathways are two main routes of communication between 
peripheral inflammation and the brain. Even though these two pathways are 
connected in a manner that is still not fully understood, stimulation of both results in 
an expression of IL- I in brain parenchyma. Produced by the resident macrophages in 
the brain, IL- I is a proinflammatory cytokine that was shown to be implicated in 
many different neurodegenerative diseases [ 51]. 
1.3 Peripheral inflammation and activation of immune system in the BBB 
The CNS is known as an organ that is largely protected by the BBB that provides 
isolation and protection from pathogens, proteins and immune cells [52]. The BBB is 
a physical barrier separating the brain from the systemic blood and it is quite 
complex in its structure. This structure includes several components: endothelial 
cells, basal lamina, astrocytes, pericytes ( contractile cells) and perivascular 
macrophages [53]. Brain endothelial cells form tight junctions that regulate entry of 
endogenous compounds from the periphery. The tight junctions are enabled by the 
presence of integral membrane proteins such as claudin, occludin and junctional 
adhesion molecule-A (JAM-A) [54]. Endothelial cells are polarized cells and their 
cell membrane is quite unique in that one side is exposed to the blood and the inner 
side is connected to the brain parenchyma. This type of membrane expresses 
different kinds of transporters that allow communication between the brain and 
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circulating blood [55]. Endothelial cells are known to express the following types of 
TLR: TLR2, TLR4 [56], and TLR3, TLR6 [57]. 
Presence of the inflammatory factors in the peripheral circulation or produced by the 
brain endothelial cells may cause leakage of the BBB. Production of reactive oxigen 
species (ROS) from monocytes in in vitro studies, was suggested to contribute to 
increased BBB permeability [ 5 8] . Production of inflammatory cytokines ( e.g. IL-1, 
IL-6 and TNF-a) by resident macrophages, endothelilal cells or transported from the 
blood are shown to increase permeability of BBB [59] , but the exact mechanism is 
still unclear. More specifically, it has been shown that endothelial cells are more 
responsible as a source of circulating cytokines and sustainable inflammation in the 
brain, rather than microglial cells that reside next to the BBB [ 60]. Along with 
PGE2, IL-1 ~ may be synthesized by local macrophages [61] and then promote its 
own production by pericytes in the region of CVO's, choroid plexus [62] , endothelial 
cells of CVO's [63] and the BBB [64]. It has been shown that IL-1~ expression in 
the CNS induces reversible breakdown of the BBB [65]. Endothelial cells express 
also several adhesion molecules such as lymphocyte functional antigen-I (LFA-1 ), 
intercellular adhesion molecule- I (ICAM-1), very late antigen-4 (VLA-4) and 
vascular cell adhesion molecule- I (VCAM- I) that enable migration and adhesion of 
leukocytes to the site of injury [ 66]. Thus, stimulated by inflammatory factors ( e.g. 
TNF-a or IL-1) or LPS, adhesion molecules are shown to enable lymphocyte 
trafficking across the BBB [67]. Interestingly it has been shown that JA:t--.1-A acts as 
an adhesion molecule for the infiltrating leukocytes in inflammatory conditions [68] , 
contributing in that manner to higher permeability of the BBB. In in vitro studies 
conducted in primary cell culture of pericytes, TNF-a has been shown to induce the 
release of matrix metalloproteinase-9 (MMP-9) [69] a zinc-dependent 
endopeptidase, the increased level of which has been associated with BBB 
breakdown [70]. In post-mortem studies conducted on patients suffering from 
Parkinson' s disease, the BBB [71] has been observed to be disrupted with alteration 
of the blood vessels [72] , caused by the high levels of circulating vascular enothelial 
growth factor (VEGF) [73]. VEGF is a very important growth factor involved in 
angiogenesis, but it also has been shown to cause BBB leakage upon intravenous 
administration in rodents [7 4]. 
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Overall, mounting evidence suggests that peripheral inflammatory cytokines interact 
with brain endothelial cells of CVO's and choroid plexus. These afterwards induce 
the production of pro inflammatory cytokines ( e.g. IL-1) in brain parenchyma. These 
chains of events represent a general pathway of communication between the 
periphery and the brain in the inflammatory process (figure 1.1 ). 
- ~---- PGE2 
Figure 1.1: Schematic representation of signaling pathways between peripheral 
organs and the brain. 
1.4 Diffusion of peripheral cytokines and lymphocytes into brain 
parenchyma and activation of resident immune cells 
Even though the CNS has been considered as an "immune privileged" organ in the 
past because of the presence of the BBB [75] , upon immune challenge, cells such as 
leukocytes may still penetrate the BBB and secreted cytokines may enter the brain 
parenchyma. Since the first two routes of cytokines trafficking have already been 
described, the main focus of this section will be to describe the process of cytokines 
transmission into the brain via CVO' s and the mechanism of saturable transport. 
Pro inflammatory cytokines produced in the periphery such as TNF-a, IL-1 ~ and IL-
6 [76] can cross the BBB via specific saturable transporters in endothelial cells [77]. 
Cytokines are also able to diffuse into the brain in the areas that are less protected by 
the BBB (CVO's and choroid plexus) [78], as it has been shown that cytokines such 
as TNF-a and IL-1~ were expressed within CVO's [79, 80]. Diffused cytokines (e.g. 
IL-1 ~) propagate their own production by activation of TLR on innate immune cells 
in the CVO's [81]. TNF-a is then able to activate NF-kB of nearby microglial cells 
to synthesize inflammatory factors that can further spread across brain parenchyma. 
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In a rodent model of peripheral LPS-induced inflammation, it has been shown that 
few factors are elevated within brain parenchyma: COX-2, iNOS and IL-1~ mRNA 
[82]. More specifically, the expression of IL-1~ mRNA and iNOS mRNA was 
initially induced in the areas that are outside the BBB such as choroid plexus, 
meninges and vasculature after 2 hours of LPS injection [83]. Later at 6 hours from 
LPS injection, these inflammatory markers were increasingly expressed in areas that 
are outside of the BBB such as the median eminence [83]. Moreover, at 6 hours that 
expression was also noticeable in the areas inside the BBB, such as the PVN and 
arcuate nucleus [83] . This implies that peripheral proinflammatory factors such as 
NO and prostaglandins can trigger inflammatory cascade in the CNS through the 
activation of microglia and astrocytes [84]. Similarly, the expression of IL-1~ that 
has been observed in brain parenchyma next to the CVO's implies that IL-1~ may 
diffuse into the brain and propagate its synthesis in microglia [85] . It is believed that 
a key element responsible for neuroinflammatory process 1s IL-1 ~' a 
proinflammatory cytokine that is upregulated in most neurodegenerative disorders 
( e.g. Parkinson's disease, Alzheimer disease) [86-88]. 
Trafficking of immune cells through BBB is achieved by process of diapedesis. The 
passage that leukocytes use to penetrate into the brain is in the place of the 
postcapillary venules [89]. This process includes many steps that involve adhesion to 
the endothelial cells of BBB with their transportation across the wall of blood 
vessels. Infiltration of leukocytes includes activation of many adhesion molecules 
and signaling pathways. Leukocyte trafficking into the BBB is achieved in a two-
step process. The first involves expression of selectins on blood vessels that attract 
carbohydrate ligand on the leukocytes cell membrane. As a result of this cellular 
binding, leukocytes express integrins on their cellular membrane [90], which 
strengthens adhesion between the vascular surface and the leukocytes. At the very 
end of this two-step process, leukocytes are recruited through the BBB. In contrast to 
the peripheral inflammation, during brain inflammation there is only a small fraction 
of peripheral neutrophi !es crossing the BBB [91]. 
Along with peripheral organs being under protection by immune cells, the brain 
parenchyma is also under constant surveillance by resident immune cells situated at 
the walls of cerebral blood vesels and inside the parenchyma [92]. Activation of 
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resident immune cells in the brain as a response to threat is a process defined as a 
neuroinflammation. Macrophages and dendritic cells residing close to the blood 
vessels of meninges and choroid plexus, represent the first line of defense against 
invading pathogens. If the inflammatory insult eventually crosses the BBB then 
another set of cells will be activated, such as brain endothelial cells, macrophages 
and glial cells. These glial cells are divided into two groups: 1) macroglia, which are 
further divided into astrocytes and oligodendrocytes and 2) microglial cells. Glial 
cells are the initial responders to tissue insult. In concert with surrounding astrocytes 
(star-shaped glial cells), activated microglia produce the majority of chemokines that 
recruit other peripheral immune cells to the site of injury [93]. The action of 
microglial cells will be further described in detail in a separate chapter. 
Activation of the peripheral immune system, disruption of the BBB, leukocyte 
infiltration and production of proinflammatory cytokines by brain resident immnune 
cells are events that are decribed as hallmarks of neuronal degeneration [94] . 
1.5 Interaction between LPS-induced cytokines and BBB 
One of the most common stimuli that has been used for the investigation of the CNS 
response to inflammation is LPS [95], usually injected intravenously or 
intraperitoneally. The purpose of using systemic LPS injection is to mimic sepsis and 
infectious challenges. 
While peripheral inflammation usually starts m a specific organ, LPS-induced 
systemic inflammation rapidly activates TLR that are present on the vasculature and 
parenchyma of different organs [96]. It was shown that the half-life of intravenous 
injected LPS in blood is approximately 30 minutes and most of it is reabsorbed by 
abdominal organs (spleen and liver) and lungs [97] . More specifically, LPS has been 
found in lysosomes of Kupffer' s cells in the liver, and in macrophages and 
leukocytes of the spleen [97]. Remaining residue of LPS is cleared out from the 
system with a half-life of 12 hours [97]. In case of intraperitoneal injection, LPS 
reaches the blood within 15 minutes [98], but is not able to breach the BBB. Instead 
it was found to bind to endothelial cells of the brain [56]. Administrated directly into 
the primary culture of brain microvascular endothelial cells, LPS has been shown to 
dysregulate tight junctions between the cells suggesting that LPS might increase 
BBB permeability, allowing the entrance of external insults [99]. 
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Even though circulating LPS has a limited access to the BBB, it can still bind to 
TLR's present on microglia and macrophages from CVO's, choroid plexus and 
leptomeminges of the brain [ 100]. For instance, it has been shown that 
intraperitoneal injection of LPS (1 mg/kg) can cause activation of microglial cells in 
the brain with concomitant production of pro inflammatory cytokines [ 101]. 
Activation of microglia through TLR's depends on routes of LPS administration. If 
LPS is administrated directly into the brain, then microglia will be activated through 
TLR4-MyD88 pathway [102]. On the other hand, activation of microglia by 
systemic LPS depends on the proinflammatory cytokines such as IL-1 ~ [96, 103] 
and TNF-a [81]. Although it has been reported that TLR4 is expressed by astrocytes 
[104], endothelial cell [105] and neurons [106], the CNS immune response is mainly 
mediated by microglia [l 02]. 
Systemic LPS can also mediate its action on CNS by stimulation of the afferent 
projection of the vagus nerve [38]. Macrophages and dendritic cells that reside in 
perineural sheaths of vagus nerve produce IL-1 when stimulated by LPS [3 8]. As a 
result, IL-1 binds to its receptors located on the vagus nerve [3 9], resulting in 
activation of vagal afferent projections. In this manner, an inflammatory response 
from the periphery is delivered to the brain in very short period of time. 
Interaction between systemic LPS and CNS may also be established indirectly, 
through the cytokines that are synthesized in the periphery by local lymphocytes. 
Released from the peripheral immune cells upon LPS stimulation, IL-1 ~ is further 
synthesized from macrophage-like cells, located in CVO's and choroid plexus [85]. 
Produced in that way, IL-1 ~ may interact with its receptors and propagate its further 
action in the brain. 
During acute neuroinflammation, damaged neurons tend to recover over a short 
period of time, but the process of chronic neuroinflammation tends to persist long 
after an initial insult has begun [ 107]. For instance, in acute model performed on 
monkeys injected intramuscularly with l-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), loss of dopamine neurons were recorded in substantia 
nigra, stria tum and pallidum [ 108]. Despite having substantial loss of dopamine 
neurons, these animals recovered their locomotor activity due to increased number of 
dopaminergic and serotonergic fibers that compensated for the loss of neurons [ 108]. 
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In another study, single systemic LPS injection induced delayed and progressive loss 
of dopamine neurons in male mice that was accompanied by elevated level of 
proinflammatory cytokines, seven months after the initial insult [ 109] . Sustained 
inflammation leads to activation of peripheral or CNS resident immune cells and it is 
considered that this long-term self-perpetuating process has a detrimental effect on 
neuronal survival in different neurodegenerative diseases. 
1.6 Inflammatory signaling mediators in CNS 
During peripheral inflammation there are certain mediators that are expressed in 
peripheral organs and glial cells of the brain. Early response to immune activation is 
characterized at first by secretion of inflammatory markers such as cytokines ( e.g. 
IL-1, IL-6, IL-18 and TNF-a) and chemokines ( cytokines that enable 
chemoattraction between cells), followed by others, such as NO, eicosanoids and 
ROS. The interleukin-1 group of cytokines belongs to a large family of 
proinflammatory cytokines, produced during infection/inflammation by local 
lymphocytes [110]. Most notable cytokines from this family that will be discussed 
further in the text are: IL-~, IL-la, IL-lra, IL-18 and some others interleukins that 
do not belong to this group, such as IL-6. Caspase-1 is the enzyme that is involved in 
cleavage of inactive IL-1 ~, IL-18 and IL-3 3 into their matur~ bioactive form [ 111]. 
Below, there is a brief description of cytokines that are relevant factors to the IL-1 
pathway and some others, such as TNF-a and IL-6. 
1.6.1 Caspase-1 {Casp-1) 
Caspase-1 is an enzyme that cleaves proinflammatory cytokines IL-1~ (pro-IL-1~), 
IL-18 and possible IL-33 into their active form [111]. There are two types of caspase 
sub-families: inflammatory and apoptotic. It is considered that caspase-1 is part of 
inflammatory group. Besides having part in the activation of cytokines, caspase-1 is 
also a p_art of the programmed cell death signaling pathway named as pyroptosis, an 
intracellular process of mediated cell death of infected macrophages that contributes 
to the release ofIL-1~ [112]. 
Caspase-1 is synthesized as an inactiye precursor (pro-caspase-1) and it is cleaved in 
its active form by a mulitiprotein complex (inflammasome) [113]. Activation of the 
inflammasome is followed by the stimulation of TLR' s or purinergic receptors 
(P2X7) expressed on the cell membrane of cyrculating monocytes and macrophages. 
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Activation of purinergic receptors by adenosine triphosphate (ATP) or LPS causes 
caspase-1 dependent cell death of macrophages with concominant release of 
proinflammatory cytokines [114]. More specifically, ATP exposure causes only 
modest release of IL-1 ~, whereas LPS is necessary for maturation of this cytokine 
and cell death [ 115]. 
Inhibition of caspase-1 in inflammatory processes has a positive effect on neuronal 
survival. It was demonstrated that administration of caspase-1 inhibitor reduces brain 
injury followed by ischemia [ 116]. More specifically, caspase-1 knockout mice 
showed significant resistance to MPTP-induced loss of dopamine neurons [117]. The 
MPTP is neurotoxin that is often used in animal model of Parkinon' s disease due to 
its capability to selectively destroy dopaminergic neurons [117]. Therefore, caspase-
1 is considered as a valuable therapeutic target in the treatment of brain diseases 
since many neurodegenerative disorders are characterised by a high-level of 
neuroinflammation [ 118]. 
1.6.2 lnterleukin-1~ (IL-1~) 
IL-1 ~ is a pro inflammatory cytokine, released from immune cells in response to 
acute and chronic phases of systemic injury or disease~ Except for the caspase-1 
dependent process of IL-1 ~ activation, which represents the essential pathway of IL-
1 ~ maturation, this inteleukin can be also processed extracellularly into its active 
form by proteinase-3, elastase, matrix metalloprotease-9 ( degrades extracellular 
macromolecules) and granzyme A [119-122]. IL-1 exerts pleiotropic effects on 
surrounding cells of peripheral organs and the brain. 
IL-1 ~ is known to have several physiological functions within the CNS. Levels of 
IL-1 ~ during prenatal and postnatal periods of the brain development were shown to 
be elevated in the cortical part of the brain [ 123], while in adulthood IL-1 ~ is 
sustained at a very low level [ 124]. Relevance of IL-1 in brain development has been 
shown on a example of the development of the dopaminergic system where IL-1 
played a key role in proliferation and concomitant differentiation of mesencephalic 
dopaminergic progenitors [125]. In normal conditions low quantities of IL-1 are 
synthesized and its function in the CNS is to maintain long-term potentiation, sleep 
and memory [ 126]. IL-1 has a role in modulating cell membrane potential. It can 
increase neuronal activity through enhancement of N-methyl-D-aspartate (NMDA) 
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current [127] . On the other hand, it can trigger hyperpolarization by enhancing 
inhibition of gamma-aminobutyric acid (GABA) [128]. Therefore, physiological 
levels of IL-1 (pM range) are necessary for maintaining long-term potentiation on 
neuronal membranes [129] . Secreted in large quantities, IL-1 exerts endocrine 
function by increasing the secretion of corticotropin releasing factor (CRF), ACTH, 
cortisol and thyroid stimulating hormone (TSH) from the pituitary [130-132]. 
Interleukin-1 is a key mediator of inflammatory processes in the peripheral organs. 
In the periphery, the production of IL-1 ~ is regulated by monocytes, macrophages, B 
lymphocytes and natural killer cells. Secreted in a small amount, IL-1 functions as a 
mediator of local inflammation by stimulating endothelial cells to secret integrins 
that contribute to adhesion of circulating leukocytes [133]. Produced by peripheral 
limphocytes, IL-1 ~ stimulates the synthesis of PGE2 in blood vessels that can 
penetrate in the brain and activate neurons in substantia nigra [134]. IL-1~ that 
reaches the brain, produced from peripheral neutrophiles and monocytes, activates 
microgial cells to further increase its synthesis and release [135]. 
In the brain, action of IL-1 ~ is mediated through activation of glial cells (microglia, 
astrocytes and oligodendrocytes), where it contributes to their proliferation and 
production of inflammatory factors [ 13 6]. Produced and secreted in the brain, IL-1 ~ 
stimulates infiltration of peripheral immune cells into the brain by repressing the 
brain resistance to recruitment of leukocytes [137, 138]. Upon binding to its 
receptor, IL-1 receptor 1 (IL-lRl ), IL-1 orchestrates the synthesis and induces 
release of proinflammatory factors from glial cells and activates the NF-kB signaling 
pathway [ 13 9]. IL-1 also has a function of modifying the physiological function of 
local neurons through the activation of the sphingomyelinase (nSMase) signaling 
pathway [140, 141]. It has been reported that intranigral injection of a recombinant 
adenovirus that expressed IL-1 ~ caused progressive loss of dopamine neurons in 
substantia nigra pars compacta (SN pc), just three weeks after the exposure 
accompanied with motor disabilities and activation of microglia [142]. In a state of 
CNS inflammation, inhibition of IL-1 has been shown to ameliorate the 
inflammatory process and improve neuronal survival [143]. 
All these reported data suggest that infiltration of inflammatory markers into the 
brain parenchyma, especially IL-1 ~ as a result of peripheral inflammation, may 
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increase inflammation in substantia nigra and consequently have a deleterious effect 
on functionality of dopamine neurons. 
1.6.3 Interleukin-la (IL-la} 
Interleukin- I a has a function as an autocrine growth factor [ 144]. Even though the 
exact mechanism of its activation remains unknown, this cytokine may be activated 
by cal pain (Ca2+ activated cystein-protease) that is associated with cell membranes 
[145]. Nevertheless, its precursor form is biologically active and contributes to the 
cellular differentiation of endothelial and ectodermal cells [ 146]. IL-1 a and its 
precursor are expressed in the epithelial cell under normal conditions and their 
function is impaired by the intracellular form of interleukin-I receptor antagonist 
(icIL-lra) . Except for its intracellular form, IL-1 a is also found on the cell 
membrane of monocytes and B lymhocytes [147] where it plays a major role in the 
inflammatory process . IL-1 a was expressed by astrocytes in a variety of brain areas 
(striatum, substantia nigra and ventral tegmental area) during peripheral MPTP-
induced inflammation, and it was proposed to contribute to recovery of 
dopaminergic neurons by inducing axonal growth [148]. Peripheral injection of IL-
la was implicated in activation of the HPA axis and development of fever [149]. 
1.6.4 lnterleukin-1 receptor antagonist (IL-lra) 
IL-Ira is a cytokine that belongs to interleukin-I family. It has been recognized for 
its function of inhibiting IL-1 ~ [ 15 OJ action by binding to its receptor (IL-1 R 1) on 
the membrane cell surface, without eliciting second messenger signaling [ 151]. IL-
1 ra is secreted by a variety of cell types such as immune cells [152], endothelial cells 
[153], adipocytes [154]. 
Since IL-1 ra functions as an inhibitor, its production is correlated with the synthesis 
of IL-1 [155]. IL-1~ and IL-la signaling pathways are conducted through IL-lRl 
that resides on the cell membrane, and IL-lRl associates with IL-1 receptor 
accessory protein (IL-lRAcP). Under normal conditions the ratio between IL-1 ra 
and IL-1 is close to 1 [156]. In a state of inflammation it has been estimated that to 
effectively block the IL-I-induced activation, it is necessary that the ratio between 
IL-lra/IL-1 is approximately 25:1 [157]. It has been shown that systemic 
administration of IL-lra protected dopamine neurons in SNpc from exposure to 
polyinosinic:polycytidylic acid induced inflammation [158]. Also in in vivo studies 
16 
with rats, subcutaneous administration of IL- lra attenuated dopamine cell loss in 
experiment with single intranigral injection of LPS into substantia nigra [159]. Upon 
brain injury, IL-1, IL-lRl and caspase-1 are actively synthesized and produced by 
microglia [160], but during severe neuroinflammation an efficient blockade exerted 
by IL-lra might not occur. 
1.6.5 Tumor necrosis factor (TNF) 
TNF is one of the main mediators of acute phase of inflammatory response to 
bacterial infection. It is among the first cytokines detected in the circulation after 
systemic inflammation with LPS [ 161]. Except being mostly related with the 
activation of the inflammatory signaling pathway, it is also involved in the apoptotic 
process, cellular proliferation and differentiation [162]. There are many TNF-related 
cytokines, but the most known are TNF-a and TNF-~. TNF is synthesized as a 
transmembrane homotrimer and it may apear in soluble form once cleaved by TNF-
a converting enzyme. These two active forms exert their action on other surounding 
cells via their receptors: TNF receptor 1 (TNFRl) and TNF receptor 2 (TNFR2) 
[163]. Soluble form of TNF preferably binds to TNFRl and transduces 
proinflammatory stimuli [ 164]. Activation of TNFR2 is accomplished via the 
transmembrane form of TNF and it is considered to promote proinflammatory and 
pro-survival signaling pathways [165]. 
In connection with IL-1, TNF stimulates the endothelial cell of the BBB to express 
membrane adhesion molecules and chemokines. During an in vivo inflammatory 
process, it has been shown that in relation with IL-1 ~' TNF is capable of increasing 
BBB permeability by activation of local endothelial cells and astrocytes to produce 
chemokines, which enables localy circulating leukocytes to infiltrate into CNS 
parenchyma [166]. In endothelial cells, TNF induces activation of COX-2 that in 
turn synthesize PGE2 and also induces iNOS which increases the NO. Within the 
brain, _TNF meadiates activation of astrocytes and microglia to promote their 
differentiation [167]. Acting through TNF;Rl, cyrculating TNF mediates activation 
of the NF-KB inflammatory signaling pathway and ceramide/sphingomyelinase 
pathways, which leads to neuronal degeneration [168, 169]. Elevated plasma levels 
of TNF-a and its receptor are reported in Parkinson's diseased patients and were 
suggested to contribute to the pathogenesis of this disease [170, 171]. 
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1.6.6 Interleukin 6 {IL-6) 
The interleukin-6 is a cytokine secreted by macrophages and T cells [172, 173]. This 
cytokine acts both as proinflammatory and anti-inflammatory interleukin by exerting 
its function through two receptors : soluble form IL-6R and IL-6R-a. Upon binding 
to the receptors, signal transduction is followed by activation of the JAK-STAT3 
signaling pathway with concomitant expression of genes such as monocyte 
chemoattractant protein-1 (MCP-1 ) [174]. It also acts on the HPA axis and 
stimulates secretion of catecholamines with dysregulation of glucocorticoids [175]. 
Under normal conditions in the brain, this interleukin plays neurothophic and 
neuroprotective roles [176], acting as an inducer of brain-derived neurotrophic factor 
(BDNF) [ 177]. 
Following inflammatory challenge (e.g. LPS) and brain injury, the expression of IL-
6 is highly up-regulated [175, 178]. In the brain, IL-6 causes activation ofmicroglia 
and astrocytes [179]. Its production is mediated through several signaling pathways 
including one regulated by TNF-a [180]. More specifically, delayed activation of IL-
6 has been shown to be dependent on TNF-a activation via TNFRl [181]. 
Anti-inflammatory activity of IL-6 comes from its ability to control and decrease 
cytokines production in activated immune cells [182]. More specifically, IL-6 has 
been shown to deactivate the production of TNF-a and to induce of secretion of IL-
1 ra [179]. It has been demonstrated that increased levels of TNF-a and IL-6 showed 
protective effect against methamphetamine- induced cell death of microglia through 
activation of the JAK-STAT3 signaling pathway [183]. Similarly in in vitro studies, 
IL-6 has shown a protective role in the survival of midbrain dopaminergic neurons 
from l-methyl-4-phenylpyridinium (MPP (+)) induced neurodegeneration [184]. 
1.6.7 Interleukin 18 (IL-18) 
IL-18 is another proinflammatory cytokine released from immune cells after the 
recognition of certain pathogens. It has been first recognized as an inducer of 
interferon-y (IFN-y) [185]. IL-18 has been indentified as an important link between 
the innate and adaptive immune systems [ 186], as a potent stimulator in production 
of various chemokines and iNOS synthesis. Synthesized as an inactive precursor 
protein by varios cell types, IL-18 is cleaved in its active form by activation of 
caspase-1. Its precursor can be also be processed extracellularly by various enzymes, 
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such as serine protease, cathepsin G and elastase [ 187-189]. IL-18 exerts its action 
on adjacent cells via its receptor IL-18R that belongs to a family of TLR. Soluble 
protein IL-18 (IL-18BP) has been identified as a negative regulator of IL-18 action. 
Upon binding to its receptor, IL-18 mediates its action via recruitmet of adaptor 
myeloid differentiation factor (MyD88) with concominant activation of NF-KB 
[ 111]. In comparison to IL-1 and TNF-a, which are capable inducers of fever, IL-18 
has no role in activation of COX-2 and therefore there is no production of PGE2 
[190]. 
During the inflammatory process in the CNS, IL-18 is involved in microglia 
activation and infiltration of immune cells into the brain [ 191, 192]. In the brain, IL-
18 is produced by microglia [193], ependymal cells and neurons of medial 
habenular nucleus [194], hippocampus, hypotalamus, cerebellum, cortex and 
striatum [ 195]. IL-18 is also produced by the adrenal cortical cells and pituitary 
gland [196], which suggest that this interleukin mediates the comunication between 
the endocrine and nervous system. Microglia are activelly synthesizing IL-18 during 
inflammation and are also able to respond to this interleukin via IL-18R [ 196]. It has 
been shown that IL-18 deficient mice had impaired microglial activation [ 197] and 
therefore increased survival of dopamine neurons [191]. 
1.6.8 Chemokines 
Chemokines represent a group of small cytokines. Their main function is regulation 
of leukocyte trafficking to the inflammatory site. According to their molecular 
stucture that contains cysteine residue, this large protein family was divided into 
subgroups (C ( chemokines containing only one cysteine residue), CC ( cysteine 
. . 
residues are connected together with a disulfide bond), CXC ( disulfide bonds 
between cystein residues are separated with one amino acid (X)) and CX3C). They 
exert th~ir function by binding to G protein-coupled receptors. There are only two 
chemokines expressed in the brain by neurons and atrocytes under normal 
conditions: fractalkine (CX3CL1) and SDF-la (CXCL12) [198-200]. In a state of 
inflammation that occurs in the brain, chemokines are produced by resident immune 
cells such as microglia, astrocytes and endothelial cells of the BBB. Activated 
microglia by LPS secrete the following chemokines: chemokine IL-8 (CXCL8), 
interferon gamma-induced protein-10 (IP-10), macrophage inflammatory protein-la 
(MIP-la), MIP-f~, MCP-1 and regulated on activation, normal T cell expressed and 
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secreted (RANTES) [201]. In comparison with microglia, astrocytes exposed to LPS 
and other inflammatory insults produce the same group of chemokines except from 
MIP-1 and MIP-2 [202]. Chemokines expressed on the cell membrane of activated 
microglia stimulate their migration to the site of injury [203]. 
1.6.9 Eicosanoids 
Eicosanoids are derivates of arachidonic acid and are found to play a major role in 
the pathogenesis of the CNS. Most important ones are the prostaglandins (PGD2, 
PGE2, PGFla) converted from arachidonic acid by activation of COX-2. 
Prostaglandins are secreted at the site of injury, and it is reported that they might be 
synthesized by endothelial cells (PGE2) of CNS or transported though BBB from 
peripheral circulation [204]. It has been demonstrated that COX-2 and oxidative 
stress had a detrimental effect on survival of dopaminergic neurons, which was 
shown to be associated with high levels of PGE2 [205]. The main route of PGE2 to 
cause apoptosis of dopamine neurons has been shown to be via its receptor-
endogenous pyrogen 1 (EPl) [206]. 
1. 7 Dopaminergic neurons and their role in movement control 
The predominant function of dopaminergic system is in control the smooth execution 
of limb movements and body posture. Other functions of the dopamine system 
include the control over the various behaviors, such as the procedural learning, 
emotions and cognition. This is enabled by the neurotransmitter dopamine that is 
synthesized and released in dopamine neurons of substantia nigra [207, 208]. 
Dopaminergic neurons are the main source of dopamine in the midbrain. Dopamine 
is catecholamine neurotransmitter and its synthesis is regulated by rate-limiting 
enzyme tyrosine-hydroxylase (TH) [209]. Dopaminergic neurons correspond to 
approximately 1 % of total neurons. These neurons represent a heterogeneous group 
of cells, localized in three anatomical compartments: diencephalon, mesencephalon 
and olfactory bulb [21 O]. Approximately 90% reside in the ventral part of the 
mesencephalon. The mesencephalic dopaminergic system has been subdivided into 
three nominal systems as shown below (figure 1.2). 
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Figure 1.2: Schematic representation of the mesencephalic dopaminergic system 
[207]. 
1) The nigrostriatal system originates in SN pc and extends its fibers into the caudate-
putamen region (also known as the dorsal striatum). This pathway plays a key role in 
control of voluntary motor movement. 
2) The mesolimbic and 3) the mesocortical dopaminergic systems, anse from 
dopaminergic cells present in the ventral tegmental area (VTA). These two 
dopaminergic systems are involved in emotions such as motivation and reward. The 
neurons of the mesolimbic dopaminergic system originate i~ the VTA and project 
into the nucleus accumbens, the olfactory tubercle, the septum, amygdala and 
hippocampus. The dopamine neurons in the medial VTA, which have projections to 
the prefrontal, cingulated and perirhinal cortex constitute · the mesocortical 
dopaminergic system. Because there is certain overlap between mesocortical and 
mesolimbic dopaminergic neurons, the two systems are often referred as the 
mesocorticolimbic system [211]. 
The physiological actions of dopamine neurons are established via membrane 
dopamiJ?.ergic receptors. Dopamine receptors belong to the group of transmembrane 
G protein-coupled receptors and are divided according to their structure and 
function, into five subtypes: D1-like receptor subtype (Dl and D5) and D2- like 
receptors (D2, D3 and D4). D1- like receptors contain a Gs subunit that induces 
activation of adenylyl cyclase and therefore contributes to the increase of cAMP 
synthesis. On the other hand, D2- like receptors inhibit adenylyl cyclase and activate 
K+ channels since their activity is regulated by a Gi subunit [212]. 
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Other receptors expressed on dopamine neurons include GABA receptors [213], 
NMDA receptors [214], serotonergic receptors [215] etc. 
1.7.1 Function of basal ganglia 
The basal ganglia represents group of nuclei involved in the regulation of motor 
function [216]. It is situated in the white matter of the cerebral cortex and 
compromised of the following nuclei: striatum, globus pallidus (GP), subthalamic 
nucleus (STN) and substantia nigra. Anatomically striatum is divided into caudate 
and putamen. The globus pallidus is composed of external and internal parts (GPe 
and GPi). The substantia nigra contains dopaminergic neurons, and it is divided into 
SNpc and substantia nigra pars reticulata (SNpr). The main connections between 
described anatomical parts of the basal ganglia are schematically represented in 
figure 1.3. 
· Cortex 
Brainstem and spinal cord 
-excitatory 
-inhibitory 
Figure 1.3: Schematic representation of circuits in the basal ganglia. 
The basal ganglia is a part of a loop that transmits information from the cerebral 
cortex and back, via several major relay points: the striatum, the internal part of 
globus pallidus, the SNpr and the thalamus. In this process, the striatum receives 
information from the cortex, whereas GPi and SNpr send information back to the 
cortex. Input from the cortex is excitatory and it is established via g1utaminergic 
neurons, while output is inhibitory and transmitted via GABA neurons. On the other 
hand, dopamine is involved in the regulation of neuronal firing in the striatum, 
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through its receptors (Dl and D2) [217], and in that way contributes to execution of 
movement [218]. As a compensation to the dysfunction of basal ganglia, increase in 
dopamine receptors activity has been reported [219]. 
1.7.2 Movement control through action of basal ganglia 
Inputs related to motor coordination come from the motor cortical area and converge 
at the basal ganglia via the striatum. Basically, the cortical area, which is involved in 
the planning and execution of movements, projects to the striatum. Further on, the 
striatum ( caudate and putamen) that receives this input signals to the globus pallidus. 
Information collected in the basal ganglia is transferred to the globus pallidus and 
then to the ipsilateral motor thalamus. From the thalamus, output is sent to the motor 
cortex [220]. 
Information that reaches the globus pallidus from the striatum are divided into two 
pathways: direct and indirect [221]. These two pathways exert opposite effects on 
motor activity and their dysregulation may explain problems seen in dysfunction of 
the basal ganglia. 
In the direct pathway, information is gathered in the interior of the globus pallidus 
and then transduced to the thalamus and the motor cortex (figure 1.4). Signals from 
the motor cortex to the globus pallidus are sent via the glutamate neurotransmitter, 
which has the role of exerting an excitatory effect on striatal neurons. Neurons in the 
striatum then release a GABA that inhibits the cells of the globus pallidus and SN pc 
acting through the Dl receptor. Inhibition of GP cells leads to less inhibition of 
thalamic nuclei, which results in increased firing of neurons in the motor cortex. 
Eventually this will increase firing in the corticospinal tract and muscle movement 
[220]. 
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Figure 1.4: Representation of the direct pathway of the basal ganglia. 
The indirect pathway is followed by neural signal transmission from the cortex to 
extemal part of the globus pallidus (figure 1.5). Before reaching the thalamus, 
signals from the external part of the globus pallidus are projected to subthalamic 
nuclei and SNpc, then backwards to the internal part of the globus pallidus. Signal 
transduction on these neurons is accomplished via D2 receptors. Signals from the 
internal part of globus pallidus are transmited to the thalamus and motor cortex. 
Signaling pathways in subthalamic nuclei, cortex and thalamus are mediated through 
glutamate, whereas in the globus pallidus and striatum are operated by GABA. Thus, 
neuronal communication can be stimulated or inhibited depending on the 
neurotransmitter that is involved. In the case of the indirect pathway, signal 
transduction via subthalamic nuclei results in a decrease of excitatory drive in the 
cortex [220]. 
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Figure 1.5: Representation of the indirect pathway of the basal ganglia. 
Dopamine produced in SNpc is released in striatal neurons via nigrostriatal pathway, 
where it exerts its function by binding to Dl and D2 receptors. In the direct pathway, 
dopamine binds to D 1 receptors and in that way exerts an excitatory effect on striatal 
cells. In concert with D2 receptors that are associated with the indirect pathway, 
dopamine has inhibitory effects on signaling in the striatum. According to this, 
released dopamine promotes motor activity via activation of the direct pathway and 
at the same time inhibits the indirect pathway that is responsible for turning down 
motor activity [220]. 
Loss of dopaminergic neurons m SNpc leads to decreased activity m the direct 
pathway with concomitant increase in activity of indirect pathways, which results in 
inhibition of thalamic-cortical output. Decreased activity in the direct pathway 
comes from loss of dopamine input from SNpc to striatum, which leads to decreased 
excitation of striatal neurons via D 1 receptors. At the same time this decreased 
excitatory effect on striatum causes inhibition of GABA output to the internal globus 
pallidus .and SN pr. Chronologically, loss of dopamine leads to inhibition of D2 in the 
striatum, which causes increa~e of GABA activity in the external part of the globus 
pallidus in the indirect pathway. This increqsed GABA activity in the external globus 
pallidus leads to less GABA release to the subthalamic nucleus, resulting in the 
increase of glutamate in SNpr. In all, reduction of GABA activity in the direct 
pathway with the increase of glutamate in the indirect pathway results in overall 
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increased induction of GABA in the thalamus and the decrease of glutamate release 
from the motor cortex leading to a loss of motoric function [220]. 
1.8 Susceptibility of dopaminergic neurons to inflammation 
Neuroinflammation has been associated with development of various neurological 
disorders ( e.g. Parkinson's disease), described as the activation of microglial cells 
and depletion of certain neurons. Dopaminergic neurons are considered to be prone 
to oxidative stress [222] due to their high rate of oxygen metabolism, low levels of 
antioxidants and high levels of intracellular iron. Dopamine itself is capable of 
generating toxic ROS via both its enzymatic (involving monoamine oxidase (MAO)) 
and non-enzymatic catabolism involving free-transition metal ions like iron [223]. 
The oxidation of dopamine via MAO generates a wide range of toxic free radical 
species such as H20 2, semiquinones and quinones [224]. Free radical species have 
been shown to cause mitochondrial dysfunction by inhibiting complex I [225]. 
Presence of neuromelanin exerts a protective effect against oxidative damage of 
dopamine neurons [226]. Neuromelanin represents the accumulation of oxidative 
lipid derivates and altered proteins compiled in autophagic vacuoles [227]. In such a 
state, neuromelanin is further degraded by cellular lysosomes. In contrast, during the 
aging process these neuromelanin depositions may grow larger, as a consequence of 
limited clearance, and by interacting with other cellular components it may 
accumulate some of the toxic iron species which could exacerbate neuronal damage 
once neuromelanin is released from the cell [228]. 
Proinflammatory cytokines interfere with the synthesis of dopamine, its secretion 
and final reuptake into dopamine neurons [229]. Cytokines such as IL-6 and 
interferon-a (IFN-a) were shown to cause depletion of tetrahydrobiopterin (BH4) in 
CNS [230, 231], an essential enzyme co-factor that is important for the proper 
function of the tyrosine-hydroxy lase enzyme. Dopamine reuptake into the vesicles of 
pre-synaptic dopamine neurons is dependent upon vesicular monoamine transporter-
2 (VMAT-2). It has been shown that expression of VMAT-2 was decreased in 
isolated enterochromaffin-like cells that were pretreated with IL-1 and TNF-a [232]. 
Cytokines control dopamine release indirectly via stimulation of glutamate release 
from astrocytes [233]. In this manner, high levels of released glutamate from 
astrocytes stimulate production and release of dopamine that is by itself highly 
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susceptible to auto-oxidation, and these bio-products of dopamine oxidation lead to 
dopaminergic neuronal death [234]. 
A recent study of non-human primates has drawn attention to the fact that some 
midbrain dopamine neurons are not equally susceptible to CNS insults [235]. 
Dopamine neurons of SNpr are the most vulnerable one, whereas neurons of SNpc 
are less vulnerable and dopamine neurons of VT A are the most resistant to the 
neurodegenerative process [235] . 
Reactive microglial cells cause a negative impact on neuronal survival during 
inflammation. Upon treatment of isolated neuronal-glial cells with LPS, only 
mesencephalic ( dopaminergic) neurons are shown to be more sensitive to 
degradation in comparison to hippocampal and cortical neurons [236]. Susceptibility 
of dopamine neurons to inflammation was in correlation with number of present 
ramified microglia cells [236]. Taking into an account that there is unequal 
distribution of microglial cells in the brain, being most abundant in an area of 5% in 
the cortex and corpus callosum to 12% in the substantia nigra [237], in inflammatory 
process the number of activated microglia was in correlation with extent of neuronal 
damage [236]. Another study in rodents showed that chronic intracerebral low doses 
-
of LPS injections selectively caused the loss of dopamine neurons in substantia 
nigra, while cholinergic neurons in the basal nucleus of Meynert and serotonergic 
neurons in dorsal raphe were unaffected [23 8]. 
1.9 Toxin-mediated degeneration of dopamine neurons 
LPS has been recognized as a potent inducer of dopaminergic neurodegeneration and 
it exerts 'its neurotoxicity via activation of microglia cells [239]. In the CNS, LPS 
activates microglia cells as it binds to TLR4, which results in neuronal damage 
[240]. 
Besides LPS, there are several other toxins that have been described as potent 
inducers of dopamine neurons degenerati<?n, A 6-hydroxydopamine (6-OHDA) 1s 
neurotoxin that shares structural similarities to dopamine and norepinephrine. It 
exhibits a deleterious effect on dopamine neurons via reactive oxidative species and 
quinones [241]. 
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MPTP specifically induces dopamine cell death via its metabolite MPP ( +) that 
accumulates in the dopamine cells causing the inhibition of ATP production and also 
induces the formation of free radical species [242]. 
Rotenone, mostly used as an effective pesticide and insecticide, causes the dopamine 
neurodegeneration by impairing the oxidative phosphorylation in mitochondria. It 
also inhibits the formation of microtubules from tubulin [243]. Tubulin was shown to 
be deleterious for cell in excess [244]. 
N,N'-dimethyl-4-4'-bipiridinium (paraquat), 1s a potent herbicide that exerts its 
deleterious effect through oxidative stress. It has been demonstrated that systemic 
injection of paraquat in mice resulted in reduced locomotor activity and loss of 
striatal dopamine fibers and dopamine neurons in substantia nigra [245]. 
1.10 . Mechanisms of neuronal cell death of dopamine neurons 
1.10.1 Oxidative stress 
Oxidative stress is considered to be one maJor component associated with the 
development of neurodegenerative diseases. It occurs when free radical species 
( oxygen and nitrogen free radicals) are produced in excess and the anti-oxidative 
system is no longer capable of neutralizing these radicals . Free radical species 
originate from unpaired numbers of electrons presented on oxygen or nitrogen 
atoms. There are three major radicals generated from oxygen: superoxide anion (02-
), hydrogen peroxide (H20 2) and hydroxyl radical (OH). Radicals generated from 
nitrogen are NO, and peroxynitrite (NOr ). 
Free radical species are produced during many different metabolic processes but 
mainly in inflammatory states by infiltrating leukocytes at the site of the injury. Also 
their presence is relevant in processes such as cell proliferation, cell growth and 
glucose metabolism [246]. Besides the beneficial effect of free radical species, they 
also represent a constant danger to DNA, proteins and lipids of cell membrane. The 
free radical species interact with them in an unspecific manner, causing mutations, 
protein miss-folding, loss of enzymatic functionality and lipid peroxidations. 
As the brain is one of the organs with the highest metabolic rate (20 % of total 
amount of oxygen) [247] , it is more prone to oxidative stress. Neurons are shown to 
be more sensitive to oxidative damage due to high content of iron that can mediate 
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lipid oxidation of polyunsaturated fatty acids in the brain [247]. Moreover, neuronal 
cells are post-mitotic cells have higher lipid content and higher metabolic activity. At 
the same time the capacity of the antioxidative system is relatively low [248] . With 
aging, frequency of oxidative stress further increases as the process of antioxidant-
mediated damage repair gradually slows down. Aging is considered one of the major 
factors implicated in the loss of dopamine neurons as it has been shown that 5-10% 
of their loss is linearly correlated with each decade of aging [249]. 
Dopamine neurons are susceptible to damage caused by ROS that are generated by 
the metabolism of dopamine itself [250]. Dopamine as a molecule is relatively 
unstable and prone to auto-oxidation, producing a high amount of ROS [250]. Its 
degradation may be spontaneous or mediated by monoamine oxidase B (MAO-B). 
Byproducts of dopamine metabolism are 3, 4- dihydroxyphenylacetic acid 
(DOPAC), homovanillic acid (HV A) and small amounts of quinones, H20 2 and 0 2-
(251]. Secreted dopamine is restored back into the cell by dopamine active 
transporter (DAT) that is shown to be depleted with aging, which results in the 
higher production ofH2O2 and ·OH [252]. 
1.10.2 Mitochondrial dysfunction 
Mitochondria are vital organelles responsible for the production of cellular energy in 
the form of ATP that is accomplished in the process of oxidative phosphorylation. 
On the other hand, this process is accompanied with the high production of free 
radical species that may constitute a potential danger for mitochondria functionality 
and cell survival overall. Alterations in mitochondrial complex I are considered to be 
the main reason for production of ROS [253]. 
Dysfunction of mitochondria caused by the large production of ROS is related with 
neuronal cell death [254]. In clinical studies, it has been reported that mitochondrial 
DNA was highly deleted in dopamine neurons of older in comparison to younger 
human brain tissues [255] . Deletion in of DNA in older human brain was associated 
with dysfunction of cytochrome c oxydase (complex IV) [255]. 
Impaired function of the mitochondrial permeability transition pore that is located in 
between the inner and outer membrane of mitochondrial cell membrane results in the 
release of cytochrome c in the cytosol, which in tum activates the caspase signaling 
pathway leading to programmed cell death [256]. 
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1.10.3 Activation of the ceramide signaling pathway via TNF-a and IL-lP in dopamine 
cells 
The TNF-ceramide signaling pathway is another and yet more specific mechanism of 
programmed cell death of dopamine neurons [257]. Ceramide belongs to a group of 
sphingolipids that has one fatty acid attached to its sphingoid base. Attached to a 
cellular membrane, ceramide is a constitutive component that contributes to 
increased membrane permeability [258]. Ceramide is also involved in a signaling 
pathway that controls cell proliferation and differentiation and also cell death [257]. 
TNF-a-induced dopaminergic cell death is triggered via TNFRl [259] followed by 
the activation of the ceramide signaling pathway. TNFRl is expressed on the cell 
membrane of dopamine neurons and is involved in the transmission of cell death 
signaling [260]. Having established a connection to TNFRl, TNF-a activates 
membrane-bound sphingomyelinases resulting in the conversion of sphingomyelin 
into ceramide in vitro [257]. With the activation of these signaling pathways, 
ceramide-induced cell death follow several different routes of actions: increase in 
intracellular Ca2+ [261 ], mitochondrial dysfunction [262], oxidative stress in 
endoplasmic reticulum [263], inhibition of survival pathway (PI3K/Akt) [264] and 
promotion of caspase-3 dependent apopototic process [257]. Similarly, the 
sphingomyelinase death-signaling pathway has been triggered by activation of the 
IL-1 ~ pathway [ 140, 265]. · 
1.10.4 lnflammasome assembly and release of proinflammatory factors (activation of 
caspase-1 through the TLR4 signaling pathway) 
The inflammasome represents an intracellular multiprotein complex that mediates 
the acti ation of caspase-1 , which in turn cleaves pro inflammatory cytokines (IL-1 ~, 
IL-18 and possible IL-33) into their mature form [266]. A key component of the 
inflammasome is PYD domains-containing protein 3 (NALP3) also known as 
cryopmn or NLRP3, the name of which represents also the name of the protein 
complex. It belongs to the NLR (nucleotide-binding oligomerization domain-like 
receptor) family of proteins in olved in the regulation of the innate immune 
response, and it is expressed in microglia [267]. 
The structure of ALP3 is composed out of three different domains: P AMP/DAMP 
( 'pathogen-associated molecular patterns' / "danger-associated molecular pattems")-
sensing C-terminal leucine-rich repeat (LRR), a central nucleotide binding (NACHT) 
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domain and an N-terminal effector domain, namely pyrm domain (PYD) [113] 
(figure 1.6). Activation of NALP3 inflammasome may be induced by membrane 
damage in the presence of several insults: 1) extracellular ATP originating from 
dying and injured cells activates NALP3 through P2X7 receptors and subsequent 
release of 2) intracellular potassium [268] and 3) crystals such as uric acid and 
calcium pyrophosphatedihydrate. Along with the P2X7 receptor, another type of 
channel namely pannexin-1, has been reported to play a role in ATP-induced NALP3 
activation [269]. Other relevant danger signals that lead to the activation of the 
NALP3 inflammasome include the recognition of PAMPs through TLR4. Under 
basal conditions in the brain, TLR4 is found in the choroid plexus, leptomeninges 
and CVO' s in the membrane of resident immune cells [270]. 
Upon activation, the PYD domain, one of the NALP3 domains interacts with an 
adaptor molecule speck-like protein containing a caspase recruitment domain (ASC). 
After being translated, caspase-1 exists in the form of inactive zymogen (pro-caspase 
1 ). Pro-caspase-1 carries its activation through domain, namely caspase activation 
and recruitment domain (CARD), which binds with the CARD domain present on 
ASC. Pro-caspase-1 is then processed into its active form: caspase-1 [113] by 
proteolysis [271]. Activated caspase-1 cleaves the immature _forms of IL-1~ [272], 
and IL-18 [273], which are immediately released from the cells [274] (figure 1.6). 
Secretion of IL-1~ and IL-18 
Cell death 
Figure 1.6: Structural representation of the NALP3 inflammasome and the 
possible signals required for its activation. 
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1.10.4.1 TLR- mediated tolerance to the inflammatory process (tolerance to 
repeated administration of LPS) 
Upon LPS stimulation activated TLR4 mediates the production of various cytokines, 
chemokines, prostaglandins and NO from resident immune cells in the brain. 
Frequent exposures to LPS injections have been shown to significantly increase 
production of proinflammatory cytokines in comparison to only one injection [275]. 
Even though repeated systemic inflammation may subsides with increased tolerance 
to cytokine production, a similar outcome is not necessarily seen in the brain. For 
instance, during systemic LPS-induced inflammation, expression of cytokines in the 
brain was reported to be quite high while in the periphery the cytokines were no 
longer detected [276]. Similarly, it was concluded that resident immune cells in the 
brain are not tolerant of peripheral inflammation, instead these cells become primed, 
which may lead to prolonged production of cytokines and progression of disease 
[277]. 
1.10.5 Role of microglia activation in the degeneration of dopamine neurons 
In the 1930's, Pio del Hortega estimated that microglia cells accounts for 
approximately 12% of the brain [278]. Microglia are resident immune cells of the 
CNS that have major roles in monitoring the brain for any kind of insults and 
invading pathogens [279]. In the past, it was thought that microglia cells originated 
from circulating blood monocytes that reached the brain parenchyma [280]. 
Although previous evidence suggested that microglia progenitors were recruited 
from the periphery upon CNS damage [281 ], it has also been demonstrated that CNS 
resident microglia can undergo mitosis and self-renewal during different insults 
[282]. Microglia cells are mostly found in the grey matter of the CNS with 
predominance in the hippocampus and substantia nigra [283]. There are also two 
distinct populations of microglia: 1) a short-lived population, which is replaced by 
the circulating monocytes and are situated in perivascular regions; 2) a long-lived 
group of microglia residing in the whole CNS. In the adult brain, the majority of 
microglia remain in a "resting" state in which they exhibit a ramified morphology. 
Microglia cells in the "resting" state are characterized by small cell bodies and many 
small branches, containing up to 20 spines. On the other hand, activated microglia 
display ameboid cell shape with truncated branches. Resting microglia are not static, 
dormant cells . Rather, they are constantly monitoring the area in which they reside. 
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In other studies it has been suggested that microglia cell bodies do not move during 
normal surveillance, but rapidly and dynamically extend and retract their processes 
[284, 285]. 
There is also a third state of microglia activation, namely the hyper-ramified state, 
which represents an intermediate stage between the resting and the reactive forms 
(figure 1. 7). Hyper-ramification represents the beginning of microglial hypertrophy. 
Even though this state is rarely seen, it occurs during aging and under certain 
degenerative changes [286]. In late life, microglia hyperthrophy may become 
extreme; they tend to lose contact inhibition and begin to fuse with each other. Such 
fusion can result in the formation of small microglial clusters, which are suspected to 
be responsible for the formation of senile plaque [287]. 
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Figure l.7: Morphological presentation of microglial cells in different stage of 
activation (microglial plasticity) [288]. 
The morphology and degree of .microglia activation depends on the severity of 
injured neuronal cells. This is due to signals that are emitted by dying cells. In case 
of mild injury, microglia may undergo morphological changes turning into the 
hyper-ramified state. In most cases, microglia becomes activated to remove dying 
cells. However, if injured cells start to recover, then microglia might revert to the 
ramified state (resting microglia). If microglia have already undergone 
transformation into macrophages, then they are predestined for cell death [288]. 
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1.10.5.1 Microglia activation 
Microglia are capable of recognizing a vast variety of insults within the CNS . They 
display a battery of cell-surface receptors, including receptors for endotoxin, 
cytokines, chemokines, mis-folded proteins, serum factors and ATP. Microglia also 
act as antigen-presenting cells (APc) and present pathogenic material to T-cells to 
generate an adaptive immune response through expression of maJor 
histocompatibility complex (MHC) class II antigen [283, 289]. 
A widely used experimental approach for in vitro and in vivo activation of microglia 
is the administration of LPS. As it was mentioned earlier LPS activates microglia by 
interacting with TLR4 [60]. It has been reported that microglial cells display 9 of 12 
members of TLRs [290]. LPS-induced microglia activation results in the synthesis 
and release of a number of cytokines and chemokines such as IL-1~, IL-la, IL-Ira, 
IL-6, IL-8, IL-10, IL-12, IL-18, macrophage colony stimulating factor, MIP-1 a, 
MIP-1~, MCP-1, transforming growth factor-~ (TGF-~) and TNF-a [291]. In an 
autocrine manner, these cytokines potentiate microglia activation by binding to their 
receptors [291]. They control microglial motility, phagocytic functions and 
chemotactic movements through their receptors [291]. One of the potent activators of 
cytokine receptors on microglia cell membrane is IFN-y [292]. It activates the 
expression of proinflammatory cytokines and also enhances the responsiveness of 
microglia to the other inflammatory stimuli leading to the process tenned as 
"priming". The complete mechanism of microglia transition from activated to 
ramified is still unsolved [292] . 
Microglial cells, are also activated by IL-1, and under the influence of pathological 
concentrations (nM) can synthesize a variety of inflammatory mediators such as 
adhesion molecules [293], chemokines [294] and prostaglandins [295]. Two other 
potential activators of i:nicroglia are matrix metalloproteinase-3 (MMP-3), and 
neuromelanin [296, 297]. It is also been suggested that activation of microglia may 
occur due to a "switching-off' mechanism of the inhibitory effect that neurons exert 
on microglia during baseline conditions. In this case, expressed neuronal CD200, a 
cell-surface transmembrane glycoprotein, binds to microglial CD200R [298], 
maintaining the microglial cells in a quiescent state in the healthy brain [291]. There 
are multiple factors that may contribute to the transformation of microglia to the 
resting cell phenotype, such as TGF-~ and IL-10 [299]. Most recently a group of 
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nuclear receptors of transcription factors were discovered, which might suppress the 
microglial activated state: estrogen receptor-a (ER-a), peroxisome proliferator-
activated receptor-y (PP ARy), liver X receptor-a (LXRa) and LXR~ have been 
described fo attenuate the symptoms of Parkinson' s disease [300]. 
Activated microglia is considered to be vital for normal brain function because they 
have beneficial effects by acting as scavengers and by remodeling brain tissue. On 
the other hand, continuously activated or over-activated microglia can cause viable 
cell damage, particularly neurons. The activation of microglia caused by toxins, 
pathogens or endogenous protein, might persist for a long-term due to positive 
feedback of damaged neurons, even if the initial insult has ceased. During the aging 
process chronically primed microglia may release more proinflammatory cytokines 
and are suggested to become over-responsive [301, 302] . Thus, microglia activation, 
and hence neuroinflammation could be propagated and prolonged to amplify the 
destruction of neurons: a process called reactive microgliosis, which is a common 
characteristic of neurodegenerative diseases [303]. The ventral midbrain of patients 
with Parkinson' s disease consistently shows increased microglial reactivity and the 
presence of markers of inflammation [283 , 304, 305] and in animal models of 
Parkinson 's disease this microglial response has been shown to contribute to 
dopamine neurodegeneration [306, 307]. 
After phagocytosis of apoptotic cells or granulocytes, microglia undergo apoptosis 
[308-310] or return to the ramified state under the influence of anti-inflammatory 
factors secreted by monocytes [311 , 312]. Apoptosis is carried out by the caspase-
dependent pathway or by another caspase-independent programmed cell death [313]. 
1.10.5.2 NF-KB activation and cytokine expression in microglia 
The inflammatory response begins with recognition of LPS by TLR4 on microglia 
membrane. Apart from binding TLR4, LPS is also recognized by LPS-binding 
protein, CD14 (protein which mediates LPS recognition) and MD-2 (a soluble 
protein that can form a complex with LPS) [314, 315]. LPS may be also recognized 
by the presence of P2X7 receptors that reside on the cell membrane. 
Immediately after interacting with LPS, the intracellular domain of TLR4 namely, 
Toll-interleukin-I (TIR) associates with MyD88, a TIR domain-containing adaptor. 
By recruiting the TLR4 receptor and TIR assembly, the MyD88 downstream 
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signaling pathway continues in two different directions: 1) the MyD88-independent 
pathway, which mediates induction of the Type I interferon and 2) MyD88-
dependent pathway that is responsible for the expression of proinflammatory 
cytokines. The MyD88-independent signaling pathway is particularly associated 
with TLR4 signal transduction [316]. Upon activation of the MyD88, it recruits 
interleukin-1 receptor associated kinase 4 (IRAK 4 ), which in turns phosphorilates 
and activates IRAKl. Then, the activated IRAKl associates with tumor necrosis 
factor receptor-associated factor 6 (TRAF6). TRAF6 is responsible for further 
activation of transforming grow factor-~-activated protein kinase 1 (TAK 1) which 
undergoes ubiquitination and forms a complex with TABl, TAB2 and TAB3. Once 
activated, TAKl recruits the I kappa B kinase (IKK) complex and catalyzes the 
phosphorilation of two N-terminal serine residue on I-KB. These two phosphorylated 
serines constitute a target for the E3 ubiquitin ligase, which polyubiqutinates I-KB. 
Thereafter, I-KB undergoes degradation releasing NF-KB. Afterwards, NF-KB is 
translocated into the nucleus and binds to DNA on specific NF-KB binding sites that 
are present on the promoter of inflammatory cytokines. At the same time, TAKI also 
activates mitogen-activated protein kinase (MAPK) that in turn activates activator 
protein-1 (AP-1 ), one of the transcription factors that also controls the expression of 
proinflammatory cytokines (figure 1.8). 
Figure 1.8: TLR-4 mediated signaling pathway. 
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The MyD88-independent pathway is followed by the recruitment of TRAM and Trif, 
which interacts with TANK-binding kinase 1 (TBKl). TBKl and IKKi (IKB kinase) 
conduct the phosphorylation of interferon regulatory factor 3 (IRF3), which forms 
dimers and translocates into the nucleus to bind to the DNA (figure 1.8) [316]. 
1.11 Obesity and its effect on dopamine system 
1.11.1 High-fat diet-induced obesity 
Term obesity is referred to a state of the increased accumulation of lipids into the 
adipose tissue. The level of fat deposition depends not only on general food intake, 
but also on basal metabolic rate, body thermoregulation and physical activity. In 
particular, increased intake of food rich in fat has been associated with weight gain 
and development of obesity in humans [317]. Currently, the percentage of obesity in 
the global human population has reached epidemic scale. According to a report of 
WHO (World Health Organisation), 10% of the male and 14% of the female global 
population are obese [318] . Obesity increases the risk of the development of several 
metabolic disorders such as type-2 diabetes, glucose intolerance and insulin 
resistance, hypertension and dyslipidemia [319]. 
Diet-induced obesity in rodents is achieved by introducing food rich in carbohydrate 
and fat with the purpose of mimicking obesity in population of humans that are 
exposed to a Western diet on a daily basis. The first model of diet-induced obesity 
was introduced in 1955, where substantial weight gain reported in rats was due to the 
excess consumption of food rich in fat [320]. Feeding the animals with such high 
calorie diet results in significant weight gain with concomitant occurrence of various 
metabolic problems seen in obese human population. For instance, the first 
parameter observed in animals fed a high-fat diet is that these animals tend to 
consume more calories than the controlled group [321]. This condition is known as 
hyperphagia, the term that is described as the inability of an individual to regulate its 
own food intake. High-fat diet consumption also has a role in remodeling the fat 
tissue by increasing the number (hyperplasia) and the size (hypertrophy) of 
adipocytes [322]. Other metabolic alterations caused by high-fat diet induced obesity 
involves the occurrence of insulin resistance [323], increased lipogenesis, increased 
intestinal capacity for fat absorbtion [324] development of hepatic steatosis [325] 
etc. 
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1.11.2 Obesity and inflammation 
Obesity has been recognized as a state of a low-grade chronic inflammation [326]. 
Inflammation in obesity is caused by the excess intake of nutrients, which as a 
consequence leads to increased metabolic rate in adipocytes. Therefore, it has been 
hypothesized that nutrient overload in adipose tissue induces intracellular stress, 
which further contributes to the development of local inflammation [327]. 
Even though it was considered that the sole function of adipocytes is in storage of 
excess energy, discoveries made in past decade led to the conclusion that adipose 
tissue may operate as an endocrine organ as well [328]. The first hormone that was 
found in adipocytes is leptin, which functions to down-regulate food intake and 
increase energy expenditure [328, 329]. Adiponektin is another hormone secreted 
from adipocytes that was shown to negatively correlate with body weight and the 
dysregulation of which was associated with the development of metabolic syndrome 
[330]. The third hormone produced in adipocytes is resistin that was shown to down-
regulate insulin activity [3 31]. 
The condition of excessive food intake and fat accumulation triggers hyperactive 
adipocytes to release MCP-1 that further stimulates infiltration of macrophages into 
the adipose tissue [332]. There are two types of macrophages that may be found in 
adipocytes: 1) The Ml cell population is group of activated macrophages in their 
proinflammatory state and 2) The M2 is an anti-inflammatory cell population. In 
obese mice this Ml cell population was shown to be prevalent and had the negative 
impact of insulin sensitivity [333]. Infiltration of the immune cells in adipose tissue 
happens gradually forming aggregates known as Crown-like structures [334]. This 
macrophage infiltration is accomplished with the presence of not only MCP-1 but 
also of chemokine (C-C motif) receptor 2 (CCR2), as the knockout mice for these 
genes did not show macrophage infiltration [332]. Besides macrophages, in adipose 
tissues the presence of circulating lymphocytes [335], mast and natural killer T cells 
[336] was also reported. Activation of immune cells in adipose tissue is followed by 
the release of inflammatory markers such as IL-1 ~' IL-6 and TNF-a [337]. The 
prolonged inflammatory process then alters the proper function of immune cell into a 
proinflammatory environment. Such prolonged obesity-induced inflammation 
becomes chronic and unresolvable. 
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A diet rich in fat and carbohydrates may also influence the composition of gut 
microbiota and therefore contribute to greater weight gain [338] and enhance 
permeability of gut to inflammatory components, such as LPS. Microbes that are 
hosted in the gut of animals and humans are collectively named micro biota and their 
function is to improve digestion and in aid in the synthesis of some essential 
compounds (vitamins). Change in diet may profoundly influence the ratio between 
populations of different species of microbes which in turn stimulates weight gain as 
it was shown that microbita from obese animals had a higher capacity to harvest 
more energy in comparison to group of animals that were on a standard chow diet 
[339, 340]. Excessive food intake high in calories has been shown to induce an 
inflammatory state as mice that were chronically infused with lower dose of LPS had 
similar phenotypic characteristics with mice fed a high-fat diet (increased body 
weight, inflammation and hyperglycaemia) [341]. Moreover, it has been observed 
that gut micro biota in animals fed a high-fat diet produces substantial amount of LPS 
that is further transduced into circulation, which is considered to partially contribute 
to various metabolic complications seen in obesity [342]. 
1.11.3 Effect of high-fat diet and metabolic outcomes on the depletion of dopamine 
neurons 
Inflammation that originates from the adipose tissue may also influepce the 
functionality of the brain. Insulin resistance, induced by the consumption of high-fat 
diet is accompanied by weight gain, increased stress and hyperglycemia. These 
metabolic outcomes could make dopamine neurons more susceptible to the 
environmental insults. For example, adiposity [343] and type-2 diabetes [344] were 
alr~ady sµggested to be linked with Parkinson's disease, as it was reported that 50% 
of Parkinson's diseased patients had an abnormal glucose tolerance [345] or diabetes 
[346]. Also epidemiological studies have shown that there could be a connection 
between. consummation of animar meat rich in fat and development of Parkinson's 
disease . [347]. Brain fatty acid composition is also changed with high-fat 
consumption. Nine months of high-fat diet consumption causes alteration in brain 
fatty acids, such as a decreased ratio of n-3 and n-6 PUPA (omega-6 polyunsaturated 
fatty acids) [348]. One of the member of 6-PUFAs, arachidonic acid was noticed to 
be a contributor to the proinflammatory environment via cyclooxygenase and 
lypoxygenase action producing several bioactive eicosanoids [349]. Eicosanoids 
products were reported to be present in Parkinson's disease [350]. 
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In animal studies, a high-fat diet consumption leads to the development of systemic 
inflammation characterized by increased plasma level of leukocytes, granulocytes, B 
and T lymphocytes [351], and group of three cytokines: MCP-1, IL-la and MIP-la 
[3 51]. In addition, it has been shown that expression of inflammatory cytokines ( e.g. 
TNF-a, IL-6 and IL-1~) was increased in the hypothalamus of obese animals and 
were related with undergoing apoptotic process of the hypothalamic neurons [352]. 
In the presence of such high systematic inflammation, obese animals are shown to be 
more susceptible to a greater depletion of nigrostriatal dopamine neurons than the 
animals fed a chow diet, as observed through the intranigral infusion of MPTP [3 51] 
or 6-OHDA injection [353]. 
1.11.4 Effect of leptin on levels of dopamine and dopamine receptors 
Leptin is a l 6kDa peptide secreted by the adipose tissue. Its primary function is to 
control food intake. Its plasma levels are proportional to total body fat [354]. Leptin 
is transported through the BBB by binding to the leptin receptor, present in the 
cerebral capillaries [355]. Food intake causes an increase in leptin secretion, which 
in tum activates leptin receptors in the brain to inhibit appetite and stimulate thyroid-
regulated thermogenesis and oxidation of free fatty acids. More specifically this 
process of leptin signaling in the brain is established in arcuate nucleus of the 
hypothalamus [356]. It has been shown that leptin transport and function in CNS is 
impaired in obese patients and rodents [357]. This functional dysregulation of leptin 
has been shown to negatively affect bone formation, cause cardiovascular and 
reproductive problems [357] and weight gain. Leptin also has a role in 
immunomodulation by increasing the phagocytic function of immune cells and 
production of proinflammatory cytokines [358]. 
Leptin is positive regulator of dopamine release. Immunohistochemical analysis 
showed that leptin receptors are expressed within dopamine neurons of VTA and 
substantia nigra [359]. It has been suggested that the function of leptin and also the 
insulin receptor is in glucoregulation [360]. The function of dopamine neurons in the 
release of dopamine within SNpc to striatum has been observed to be dependent on 
ATP-sensitive K+ channels activity, which is directly related with the level of 
glucose [3 61]. In connection with the previous statement, leptin was shown to be 
involved in the regulation of potassium channels activity in the hypothalamus [362] 
and therefore it is believed that in a similar manner leptin may regulate dopamine 
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release in SNpc. In support of that notion is the finding that leptin receptors are co-
expressed with tyrosine-hydroxylase in areas of VTA and substantia nigra [363]. 
Leptin has been shown to be protective against the loss of dopamine neurons in 6-
OHDA of Parkinson's disease, both in vitro and in vivo [364]. For instance, treated 
dopaminergic cells with 6-OHDA had a greater survival rate in cases where leptin 
was present [364]. 
As leptin may be implicated in the control of dopamine release it is also suggested 
that it has a role in dopamine storage, since leptin-deficient (ob/ob) mice have been 
reported with decreased dopamine stores in dopamine neurons of the midbrain [ 11] . 
Studies conducted in rats showed that there might be direct correlation between the 
decrease of dopamine and high levels of leptin [365]. In regard to the previous 
statement, a study conducted on animals fed a high-fat diet showed that high levels 
of leptin might be implicated in down-regulation of TH enzyme expression [3 66]. 
Leptin also regulates the availability of the dopamine D2 receptor. In the cases of 
severe obesity, which is followed by leptin and insulin insensitivity, striatal 
dopaminergic activity may stay unchanged and in tum cause compensatory down-
regulation of D2 receptors [367]. It has been found that in obese individuals levels of 
-D2 receptors are decreased [367] . Similarly, the decline of D2 receptors was also 
observed in the striatum of leptin-deficient obese rodents [368]. Another study 
reported that administration of D2 receptor agonist decreased food intake, increased 
locomotor activity and D2 receptor binding in leptin-receptor deficient obese rats 
[369]. 
1.li.S Effect of insulin resistance on dopamine neurons 
The function of insulin is to mediate glucose clearance from peripheral circulation 
into skeletal muscles and adipose tissues [370]. This is accomplished by the presence 
of insulin receptor IRS (insulin receptor substrate). Upon insulin binding to its 
receptor, glucose transporter type 4 (GLUT-4) is translocated from intracelular 
storage to the cell membrane, which then enables glucose transport into the cell 
[371] .. The process of glucose transport may be disrupted if specific serine residue of 
IRS-1 is phosphorylated as this interferes with correct association to insulin receptor 
[372]. 
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Inflammatory cytokines released from infiltrating macrophages in adipose tissue 
negatively affect insulin sensitivity. It is shown that elevated TNF-a and free fatty 
acids may activate serine kinase, which in tum phosphorylates serine residue of IRS-
1 and hence blocks insulin signaling [373]. The inflammation created in the state of 
obesity is sensed by the activation of two stress sensors (serine kinases- JNK and 
IKK) that have been shown to be also linked with insulin resistance [374]. As an 
example of insulin sensitivity dysregulation in the presence of proinflammatory 
cytokines, adipocytes that were treated with TNF-a showed to have decreased 
glucose intake and insulin signaling [3 7 5]. Dysregulation in insulin signaling in 
animals fed a high-fat diet showed also to have a negative impact on dopamine 
release followed by a decrease in dopamine clearence [12]. 
Overall, the inflammatory state of obesity that develops as a consequence of high-fat 
consumption and metabolic disorders such as insulin resistance cumulatively elicts a 
negative effect on the functionality of dopamine neurons and their survival. 
1.12 Research questions 
The purpose of this project was to explore the possible connection between 
inflammation, elicited by repeated sublethal dose of LPS and increased caloric 
intake, on the onset and progression of dopaminegic neurodegeneration in a time-
and dose-dependent manner. Although mounting evidence suggests that 
neuroinflammation plays a pivotal role in neurodegenerative diseases, there is still 
little understanding about the key role that prototypic proinflammatory factors such 
as IL-1 ~ play in neurodegeneration. Moreover, it is not well understood weather 
environmental factors such as increased energy intake leading to excess weight 
and/or obesity could elicit neuroinflammation and/or neurodegeneration. Therefore, 
there are two questions to be answered: 
What is the possible role of the IL-I-related pathway m inflammation-induced 
dopaminergic neurodegeneration? 
Is there an exacerbation in inflammation-induced dopaminergic neurodegeneration 
caused by increased caloric intake? 
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1.13 Hypothesis 
LPS inflammatory challenge and increased caloric intake, caused by exposure to 
high-fat diet, will cause microglial activation and dopaminergic 
neurodegeneration through a process involving the IL-1 pathway. 
Experimental aims: 
Hypothesis 1) Systemic inflammation induces dopaminergic degeneration 
followed by activation of the IL-1 pathway in resident microglial cells of CNS. 
AIM 1: To study the long-term effect of systemic LPS challenge on behavioral, 
metabolic and inflammatory outcomes, exerted through the IL-1 pathway. 
Hypothesis 2) LPS inflammatory challenge may be exacerbated by the high-fat 
diet exposure. 
AIM 2: To study the long-term effects of high-fat diet consumption and systemic 
LPS challenge on behavioral, metabolic and inflammatory outcomes. 
To inv~stigate these two major hypothesis, the experiments were designed based on 
the previous work reported by a research team from North Carolina [376] with the 
addition of Casp-1-/-, IL-lra-/- and WT mice fed a high-fat diet and with the 
implementation of the other behavioral tests to explore more thoroughly long-term 
effect of LPS inflammatory challenge. 
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2. Materials and methods 
2.1 Experimental Plan and Methodology 
All animal experiments were performed according to the rules and regulations of the 
"Australian code of practice for the care and use of animals for scientific purposes"; 
therefore, all the experimental protocols were approved by the Australian National 
University-Animal Ethics Committee. 
Mice were housed in groups of up to five individuals per cage and maintained under 
standard living conditions (22 +/- 2°C, 12/12 hour light I dark cycle, food and water 
ad libitum). These conditions remained consistent throughout the experiment unless 
indicated otherwise. In this thesis, three different strains of mice were bred in the 
C57bl/6 background and those employed groups were: WT (n=60), Casp-1-/- (n=30) 
and IL-lra-/- (n=30) mice. All mice were randomly assigned to the different 
experimental groups. The WT mice were divided into two groups (n=30) and were 
fed either a regular chow diet (RD) or a high-fat diet (HFD). The Casp-1-/- and IL-
lra-/- mice that were used in this thesis were previously described by Li, P et al 
[377] and Hirsch, E et al [378], respectively. All knockout mice were fed a regular 
chow diet. Mice from each group (genotype and diet) were divjded into 3 groups: 
- Group 1: injected five times with saline - one injection per month [ 10 mice from 
WT (fed either a RD or HFD), Casp-1-/- and IL-Ira-/- genotype]. 
- Group 2: injected only once with LPS and 4 times with saline - one injection per 
month [10 mice from WT (fed either a RD or HFD), Casp-1-/- and IL-lra-/-
genotype]. 
- Group 3: injected five times with LPS - one injection per month [10 mice from WT 
(fed eith_er a RD or HFD), Casp-1-/- and IL-Ira-/- genotype] (table 2.1 ). 
Casp-1 -/- and IL-Ira-/- mice were not subjected to high-fat diet since the workload 
with the current mice groups was extensive and it involved long-term behavioral 
assessment over thirteen months period. Due to these factors, the preference was 
drawn to high-fat diet-fed WT mice in order to expand the research based on the 
previous published study [376]. 
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Diet Treatment WT Casp-1-/- IL-lra-/-
Saline ( control) 10 10 10 
Regular diet LPS ( 1 time) 10 10 10 
LPS (5 t imes) 10 10 10 
Sa line (control) 10 
LPS ( 1 time) 10 
LPS (5 times) 10 
Table 2.1: Schematic representation of the experimental groups employed in 
this thesis: Mice were 47 days old when they received their first saline/LPS injection. All 
mice were injected 5-times per month. Mice from the control group received 5 injections of 
saline. Mice from the LPS I -time groups received the first LPS injection when they were 47 days old, and 4 saline injections per month. Mice from LPS 5-times group received five LPS injections per month. 
2.2.1 Genotyping of mice 
Casp-1-/- mice were bred in a homozygous state, whereas IL-lra-/- mice were bred 
in a heterozygous state. Thus, the genotype of IL-lra-/- mice was determined by 
PCR. For this purpose, DNA was extracted from ear punches at weaning with DNA 
extraction kit (Life Technologies) . The concentration and quality of purified DNA 
was determined by spectrophotometry by using a NanoDrop apparatus 
(Spectrophotometers, Thermoscientific). In the IL-lra-/- mice, all four isoforms of 
IL-lra were disrupted [378]. Since IL- lra-/- mice were generated by inserting 
neomycin resistance gene (NEO) within the IL-Ira gene, primers were synthesized 
as one set specific for Tl4/Tl6 loci (Tl4/Tl6 OX) and another set specific for NEO 
to differentiate homozygous and heterozygous [378]. 
T14/Tl6 OX primers: 
Primer F (OX)- 5' -TGGAGCTCTGGTTCACTGTA-3' 
Primer R (OX)- 5' - ATCCTGGACAGGCAGCTGACTC-3' 
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The PCR reaction was performed as follows: 1) 94°C for 3 minutes, 2) 94°C for 30 
seconds, 3) 64°C for 30 seconds, 4) 68°C for 2.5 minutes; steps 2 to 4 were repeated 
in 34 cycles, 5) 68°C for 7minutes and 6) 10°C oo. 
NEO primers: 
Primer F (OX)-5'-AGACAATCGGCTGCTCGAT-3' 
Primer R (OX)-5 ' - CAA T AGCAGCCAGTCCCTTC-3' 
The PCR reaction was performed as follows: 1) 94°C for 3 minutes, 2) 94°C for 30 
seconds, 3) 58°C for 30 seconds, 4) 68°C for 1 minute; steps 2 to 4 were repeated in 
34 cycles, 5) 68°C for 7minutes and 6) 4°C oo. 
The PCR reactions were performed in an EppendorfTermocycler and the products of 
amplification were analyzed by agarose gel electrophoresis. 
2.2.2 lntraperitoneal injection of LPS 
Animals were injected intraperitoneally with 0.9% NaCl (saline), or 5 mg/kg of 
lipopolysaccharide from Escherichia coli (strain 0111 :B4, Sigma-Aldrich), 
previously dissolved in saline. The dissolved drug was filtered, aliquoted and stored 
at -20°C until usage. Mice were injected with the first saline/LPS injection when they 
reached 4 7 days of age. 
2.3 Behavioral tests 
Two behavioral tests namely, rotarod and open-field were performed to ascertain 
locomotor skills throughout a period of nine months starting before (baseline) and 
after (nine months) from the first saline/LPS injection: 
1) Rotarod test: it was conducted twice a month [the first week (seven days after 
saline/LPS injection) and in the last week]. 
2) Open-field test: it was performed the third and last week after saline/LPS 
injection. 
This time period was chosen due to previous research results that showed that the 
first significant difference in behavioral tests, between control group and five 
monthly LPS-injected WT female mice, was observed after 7 months (in rotarod 
test) and 9 months (in open-field test) [376]. 
47 
2.3.1 Rotarod test 
This test is used to measure locomotor ability (balance and coordination) of mice to 
stay on the rotating drum of the rotarod apparatus (Panlab, Harvard apparatus, Spain, 
Barcelona) (figure 2.1 ). The rotarod starts at a baseline speed of 4 revolutions per 
minute (rpm) and accelerates to 40 rpm within the timeframe of 2 minutes. Mice 
were given 3 trials with 2 minutes break between trials. Prior to starting data 
collection, mice were trained for 4-6 days to achieve optimal performance in the 
rotarod test. The training started when mice reached the age of 43 days . During the 
training period all mice were fed a regular chow diet and were not injected. The 
latency to fall from the rotating drum was measured in seconds. Mice that show 
better balance and coordinative skills are able to remain for a longer period of time 
on the rotating drum. The final result was calculated as the mean of the latency to 
fall from the rotarod apparatus after 3 trials. In the infrequent event when mouse did 
not fall from the rotating drum after 2 minutes, it was removed from the apparatus 
and returned to its home cage [376]. As it was previously shown, five LPS injections 
(i.p.) induced the locomotor impairment in female mice that was observed in the 
rotarod test, seven months post initial LPS injection [376]. 
Figure 2.1: Rotarod apparatus. Five mice were individually placed on the rotating 
drum of the rotarod apparatus at initial speed of 4 rpm. Afterwards, accelerator mode ( 4-40 
rpm within 2 minutes) on the apparatus was initiated and latency of each mouse to fall from 
the rotating drum was recorded in seconds. 
2.3.2 Open-field test 
The open-field test was used for measurmg locomotor activity, explorative and 
anxiety/depressive-like behavior. This test was conducted by placing the mice 
separately in individual arenas (figure 2.2). The locomotor activity was recorded by 
camera in time frame of.32 minutes. The baseline performance of mice in the open-
field test was recorder when they reached age of 42 days. The data were collected 
and processed by the software "Viewer 3" (Biobserve, Germany 
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www.biobserve.com). The aim of this test was to measure the total distance travelled 
in the area of the arena where the mice moved. Rodents tend to avoid open bright 
areas. Consequently, those that move more in the centre of the arena are considered 
to display less anxiety/depressive-like behavior. Thus, two key end-points were 
determined in this behavioral test: 1) Total traveled distance (measured in ems), 
which reflected their locomotor activity [376] and 2) The ratio between central 
distance over total distance (CD/TD), which was used as an index of anxiety-like 
behavior in the final analysis. As mentioned above, the more time each mouse 
spends in the center of the arena, the less anxious they are. In the figure 2.2 a picture 
of 4 arenas are shown. Each arena has a red square in the center depicting the central 
area considered for the calculus of the center distance travelled by the time. 
Figure 2.2: Open-field arena. Each mouse is individually placed in the comer of the 
open-field box and animal behavior is recorder in next 32 minutes by the software ("Viewer 
3'1. 
. 
Since dysregulation in dopamine system may be accompanied by others, non-motor 
symptoms such as anxiety, depression and cognitive impairment, at the end of the 
nine months, following tests were conducted: 
- Tests for evaluation of anxiety/depressive-like behavior: 1) Elevated plus maze test, 
2) Forced swimming test and 3) Novelty suppressed feeding test. 
- Tests for evaluation of cognitive function: 1) Prepulse inhibition test and 2) Morris 
water maze test. 
Locomotor abilities in mice were further evaluated in the following tests: 1) Grid 
test, 2) Pole test, 3) Stepping test and 4) Hind limb clasping test. 
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All the tests listed above were conducted over a period of 9 to 13 months post first 
saline/LPS injection. This time frame was chosen since it was previously reported 
that significant LPS-induced coordinative and locomotor disabilities in mice 
observed in a period of 7 to 9 months, were related with dopaminergic 
neurodegeneration [376]. 
2.3.3 Elevated plus maze test 
The elevated plus maze apparatus was used to assess anxiety-like behavior. The 
maze was elevated 100 cm above the floor and has closed and an open arm ( 40 cm 
length x 8 cm width). The wall of the closed arm is 18 cm high and the open arm is 
surrounded with the rim (0.5 cm high) to prevent animals from falling (figure 2.3). 
Figure 2.3: Elevated plus maze apparatus 
The test is performed by placing the animal in the intersection of two arms, facing it 
towards the open arm (figure 2.3). The animal activity is recorded over a period of 5 
minutes with a camera coupled with software "Viewer 3" (Biobserve, Germany 
www.biobserve.com). The proportion of time (in seconds) that each mouse spends in 
the open and closed arm is used as the parameters in the final analysis. Less anxious 
animals will spend more time in an open arm and conversely less in a closed arm. In 
contrast, more anxious animals will spend less time in an open and more in a closed 
arm. As mentioned before, the experiment is conducted during the dark phase, as the 
animals are more active during nocturnal hours [379]. 
2.3.4 Prepulse inhibition test 
The prepulse inhibition test aims at measuring a neurological outcome in which a 
weaker acoustic stimulus (prepulse: few decibels above the background noise) 
inhibits the reaction of an organism to "startle" after being exposed to a subsequent 
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very loud noise (pulse). The reduction of the startle response reflects the ability of 
the nervous system to filter out the unnecessary information. Disruptions in prepulse 
inhibition response have been reported in psychiatric disorders associated with 
dopamine pathway dysregulation [380]. 
Prepulse inhibition test was conducted in four startle chambers (SR-LAB; San Diego 
Instruments, San Diego, CA). Each chamber consists of a clear nonrestrictive 
Plexiglas cylinder resting on a platform inside a ventilated box (figure 2.4). A high-
frequency loudspeaker inside the chamber produces both a continuous background 
noise of 72 decibel ( dB) and the various acoustic stimuli. Vibrations of the Plexiglas 
cylinder caused by the whole body startle response of the animals are transduced into 
analog signals by a piezoelectric unit attached to the platform. These signals are then 
digitized and stored in a computer. 
Figure 2.4: Prepulse inhibition apparatus. Each mouse was placed into a restrainer of 
prepulse inhibition chamber. Underneath the restrainer, there is a piezoelectric unit that 
quantifies the startle response of the mouse immediately after being exposed to acoustic 
stimulus such as prepulses ( 4, 8 and 16 db above the background noise) or pulses of loud 
noise (120 db). The presentation, of the prepulses prior to the pulse usually diminishes the 
startle response. In normal ( control) mice, louder prepulses cause greater degree of inhibition 
of the startle response. 
All prel?ulse inhibition test sessions consisted of startle trials (PULSE ALONE), 
prepulse trials (PREPULSE), and no-stimulus trials (NOSTIM). The PULSE 
ALONE trial consisted of a 120 dB pulse and lasted for 40 msec. The PREPULSE 
trials consisted of a 20 msec long prepulse, an interval of 100 msec of background 
noise and followed by a pulse of 120 dB lasting 40 msec. Prepulse intensities were 4, 
8, and 16 dB above the 72 dB background noise. The NOSTIM trial consists of 
background noise only. Test session started and finished with five presentations of 
the PULSE ALONE trial. Moreover, in between the PULSE ALONE trials, each 
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trial type (PULSE ALONE, PREPULSE and NOS TIM) was presented 10 times in a 
pseudorandom order. There was an average of 15 sec (range, 12- 30 sec) break 
presented in between the trials (inter trial interval). The test was conducted by 
placing mice individually in the startle chambers, with a presentation of a 72 dB 
white noise as background for 10 minutes, as an acclimation period [380, 381]. 
The percentage of inhibition in prepulse inhibition test was calculated by using the 
following formula : [ mean of startle response (PULSE ALONE) - mean of startle 
response (PREPULSE)]/ mean of startle response (PULSE ALONE) x 100. 
2.3.5 Forced swimming test 
The forced swimming test was used to assess depressive-like behavior. The test was 
performed in glass cylinders ( 40 cm height and 18 cm in diameter) filled with water 
to a level of 18 cm at temperature of 23±1 °C (figure 2.5). Mice were individually 
placed into the cylinders and their behavior was recorder with a camera that was 
connected to a computer for behavioral analysis. The duration of the test was 5 
minutes. During this time frame the animal activity was processed by software (FST 
High throughput Forced Swim Test Analysis, Biobserve, Germany 
www.biobserve.com). Three types of behaviors were analyzed: 1) Floating: defined 
as the minimal amount of movements to remain afloat, 2) Struggling: defined as 
energetic vertical paddling against the container wall and elevating the head above 
the water level, 3) Swimming: energetic movements inside the container in a 
horizontal- manner. After this test, mice were taken back to their cages and dried 
with paper towels. The total time that each mouse spent struggling, swimming or 
floating was used in the final analysis. This test considers that an animal displays 
depressive-like behavior when it tends to float more and spend less time swimming 
and/or struggling. 
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Figure 2.5: Forced swimming test. This picture depicts the different types of recorded 
behavior. For instance the Animal 1 is swimming, Animal 2 is floating and Animal 3 is 
struggling. 
2.3.6 Morris water maze test 
The Morris water maze is a method used to assess spatial memory in rodents. This 
methodology is based on the animal's ability to memorize the position of a 
-
submerged platform. In that process rodents rely on distal cues that are placed on the 
rim of water tank to navigate from their starting point towards the platform. The test 
was performed in a water tank (lm in diameter) (figure 2.6) that was divided into 4 
quadrants and designated as following: east (E), west (W), south (S) and north (N). 
The water inside the tank was colored ( opaque white paint, by adding non-toxic 
water-soluble paint). The temperature was set at constant 23±1 °C. Above the water 
tank, a camera was attached to the roof and connected to a computer operated by 
Biobsetve software (Morris water maze, www.biobserve.com). Prior to testing, mice 
were placed into water to swim for 1 · min without the escaping platform. On the 
second day, mice were given 1 min period to find a platform that was slightly 
elevated above the water level and with a bright flag attached to it as a cue. Mice 
were placed in the water facing the rim of the tank and they are given 4 trials. After 
each trial the platform was randomly placed in different quadrants. This initial test 
was used for the assessment of habitual learning [382]. During the next three days 
mice were exposed to the same test with few additional changes. The platform was 
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kept in a middle of only one quadrant and submerged 0.5 cm below the water 
surface; mice were given 4 trials with inter-trial interval of 5 minutes starting each 
time from a different side of the pool in pseudorandom order. Mice that failed to find 
the platform in a period of 1 minute were guided towards the platform and left there 
for 15 seconds. On the last day, mice were given again 4 trials, but after the fourth 
trial the platform was removed and their swimming tracks were recorded over 1 
minute. In that last trial, the number of crossings mice made by swimming across the 
place where the previous platform was located and the number of their visits to the 
right quadrant where the platform was previously placed were used in the final 
analysis [3 82, 3 83]. 
Figure 2.6: Morris water maze test. Presented pictures depict the four quadrants that 
were detennined in a computer with the software. Mice swimming tracks to the platform 
were recorded as shown. Four navigational cues were attached on the rim of water tank. 
2.3.7 Grid test (the four limb hang test) 
The grid test is used to evaluate the strength of mouse limbs [384, 385]. In this 
thesis, the grid test was used as a control test to determine if the observed differences 
in motor coordination displayed by different mice in the rotorod test could be due to 
reduced muscle strength. The test aims at determining the ability of the animal to 
grasp the wire mesh with both forelimbs and hind limbs and to remain clinging in the 
inverted positions for a period of time. The latency to fall was recorded in seconds 
and analysed. Mice were given three trials, separated by intertribal intervals of 5 
minutes. The height of the apparatus is between 20-50 cm to prevent that the animal 
climbs down easily (figure 2.7). 
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Figure 2.7: Grid test apparatus. Animal was placed on the wire mesh of the grid 
apparatus and then mesh was inverted. Mice were left clinging on the wire mesh till they fall 
on the bedding of home cage. 
2.3.8 Novelty suppressed feeding test 
This test is performed in order to assess anxiety/depressive-like behavior in animals 
[386]. It is a behavioral paradigm where a food-deprived animal has to overcome its 
natural fear of a novel environment and approach to food pallet in the centre of the 
arena in order to feed. The faster they do it, the less anxious they are. Prior to the 
experiment, mice were weighed and their food was removed from their cages, but 
the animals were not water deprived. Sixteen hours later, mice were transferred to a 
testing room and allowed to acclimate to the new environment by placing them in a 
new clean cage for a period of 30 minutes. The testing arena consisted of a plexiglass 
cage that was covered by bedding of 2 cm (figure 2.8). The bedding in the testing 
arena was changed after each tested animal and the cage cleaned in order to prevent 
the following animal being distracted by the odour of the previous one. In the centre 
of the testing arena, a small piece of previously weighted food was placed on circular 
filter paper (9.5 cm in diameter). Light in the testing room is dimmed and the testing 
arena was isolated from any noise: Each mouse was individually placed in the comer 
of the testing cage and time was recorded until the first moment an animal started to 
bite the food pellet. Afterwards each mous_e was put back in its original home cage 
with the food pallet and left there to feed for another 5 minutes. Once this session 
was over, leftover food was weighed and the animal was placed back in another 
clean cage, supplied with water and food. At the end of the experiment, the elapsed 
time from initiation to feed and food weight was analysed. The measured elapsed 
55 
time represents the index on anxiety-like behavior. Longer latency to approach to the 
food in the centre of arena represents anxiety-like behavior. The measurement of 
food intake in the home cage was used as a control test to verify the anxious 
behavior that mice might have potentially displayed in new environment. The home 
cage is a familiar environment and therefore this second part of the experiment is 
used to determine mouse food intake in a non-stressful environment. 
Figure 2.8: Novelty suppressed feeding test arena. The picture depicts the arena 
where mice are tested. In the centre of the arena, food pallet is placed on the circular filter paper. Latency for each animal to start feeding is measured in seconds. 
2.3.9 Pole test 
This test represents one of the possible methods used to assess the agility of the 
animals. It is mostly used as a measurement of bradykinesia (slowness of movement) 
[387], a locomotor disability most frequently seen in Parkinson's diseased patients. 
The test requires the usage of pole, 50 to 55 cm in height and 8 to 10 mm in diameter 
with rough surface that stands vertically in a home cage (figure 2.9). The test was 
conducted by placing an animal close to the top of the pole and leaving the animal's 
head up. The period of time that animal spent in turning around (the first 
measurement) and climbing down (the second measurement) the pole was recorded. 
This task is very sensitive to nigrostriatal dysfunction as it involves skilled forelimb 
grasping and maneuvering, which would require an intact basal ganglia [388]. 
Therefore, both parameters (time to tum around and climb down) were used for 
assessment of bradykinesia in mice. 
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Figure 2.9: Pole test. Mice are individually placed on the top of the pole and time to tum 
around and climb down the pole are recorded in seconds. 
2.3.10 Stepping test 
The stepping test is another reliable method to assess forelimb akinesia caused by 
bilateral dopaminergic neuron lesion in a parkinsonian mouse model [389]. It is 
performed on a table and the animal is placed on one edge of it. Afterwards, hind 
legs are lifted by pulling animal ' s tail upwards and in that position the animal is 
pulled back, toward the other edge of the table. The number of animal ' s adjusting 
steps from both forepaws are counted (figure 2.10) [389]. 
Figure 2.10: Stepping test. The picture depicts the method used in stepping test. Mice 
hind limbs are lifted by pulling animal ' s tail upwards and thereafter mice are pulled back 
towards the other edge of the table. Number of adjusted steps are recorded. 
2.3.11 Hind limb clasping test 
This test is used for an assessment of dyskinesia ( diminished voluntary movements) 
in mice [390]. Mice are suspended in the air by the tail for a period of ten seconds 
(figure 2.11 ). The position of hind limbs are observed and scored. Based on the 
position of the limbs mice are scored as: 
0- hind limbs are splayed outwards, 
1- one hind limb is retracted towards abdomen, 
2- both hind limbs are partially retracted towards abdomen and 
3- hind limbs are completely retracted and touching the abdomen [391]. 
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Figure 2.11: Hind limb clasping test. The picture depicts the three examples of mice 
hind limb positions. Mouse on the very left side is scored O; mouse in the middle is scored 2 
and mouse on the right hand side is scored 3. 
2.4 L-DOPA/carbidopa test 
L-DOPA/carbidopa was prepared in concentration of 30mg/ 3mg/kg [376]. L-3,4-
dihydroxyphenylalanine (L-DOPA) was purchased from Sigma-Aldrich and was 
dissolved in distilled water for 20 minutes before injection. Carbidopa (Sigma-
Aldrich) was mixed in a drop of Tween-20 and distilled water, and added to the 
already prepared L-DOPA solution. The mixture of L-DOPA/carbidopa was briefly 
sonicated in order to completely dissolve these mentioned drugs. 
Twelve months after the first saline/LPS injection, WT µ1ice were subjected to L-
DOP A/carbidopa test. Prior to testing, mice were pre-trained for four days in order to 
establish stable baseline performance on the rotarod apparatus. On the day of the 
experiment, mice were tested on the rotarod apparatus and the results were recorded 
as initial baseline perfonnance. Afterwards, mice were injected intraperitoneally 
with the L-DOPA/carbidopa solution and their locomotor activity was tested on a 
rotarod apparatus after two hours. In order to show that potential positive effect of L-
DOP A/carbidopa injection on locomotor activity was only due to replacement of 
missing dopamine, mice were subjected to another rotarod test a week later. It is 
considered that complete effect of L-DOPA/carbidopa wears out during that period 
of time [376]. 
2.5 Metabolic studies 
2.5.1 Dexa scan 
Dual-emission X-ray absorptiometry (DEXA) scan is used primarily to evaluate 
bone mineral density (BMD), body composition and fat content [392]. Prior to 
testing, animals are deeply anesthetized with 2-3% isofluorane-oxygen gas for an 
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entire period of test (5-10 minutes) and then placed in a PIXImus apparatus 
(PIXImus Mouse Densitometer). The whole body of each mouse was scanned and 
analyzed with PIXImus software (LUNAR PIXImus 2) (figure 2.12). The mouse 
head was excluded from the scan by using the ROI (region of interest) that was 
placed manually surrounding the whole body. The data that were used for further 
analysis were: percentage of fat mass, weight of lean tissue, BMD and bone mineral 
content (BMC). 
!JI LUNAR PIXlmu,1 1.10 Subject File: C:\PIXIMUS\dala\517 Ol-13-11 10-35"41.img 
SubjectlO : 
Description: 
Comments: 
Weight 31._17 grams 
SUBJECT RESULTS 
Bone ROI TOTAL 
BMO 0.0705 0.0/05 g/cm' 
BMC 0.627 0.627 grams 
Area 8.89 8.89 cm' 
Tissue ROI TOTAL 
Lean 23.0 13.0 grams 
Fat 7.3 7.3 grams 
'Total 30.3 30.3 grams 
%Fat 24.1' 24.1 
INCLUSION ROI (In pixels) 
Width : 445 PosX: 256 ' 
Length : 358 PosY: 228 
Angle : O (deg.) . 
Press one ot the function Keys, or use the Mouse to cliclc on the desired 
function ' 
Fl F2 Fl F4 F5 F6 Fl F8 or Esc 
Help Edtt Subject AA!just ROI Print Log Results AA!just Cancel 
Threshold 
Figure 2.12: PIXImus software. The picture depicts the scan of mouse whole body and 
parameters such as: BMD, BMC, percentage of fat mass and weight of lean tissue. 
2.5.2 lntraperitoneal glucose tolerance test (IPGTT) 
The IPGTT test is used to assess how fast the glucose is cleared out from the blood 
upon glucose (i.p.) injection. Prior to testing, mice were transferred to clean cages 
and fasted for a period of 6 hours, but they were provided with water ad libitum. 
Mice 'Yere weighed and their baseline blood glucose levels were checked by 
collecting one small drop of blood from animal's tail vein at O minute (baseline). 
Afterwards, mice were injected with D-glucose (2 g/kg, i.p.) solution [393], which 
was previously dissolved in phosphate buffered saline (PBS).· The glucose levels 
were measured by a glucometer "(Accu Chek®, Roche, Australia) at 30, 60, 90 and 
120 minutes after the injection. 
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2.6 lmmunoassays 
2.6.1 lmmunohistochemistry of dopamine neurons and microglia cells 
Mice were anesthetized with intraperitoneal injection of ketamine/xylasine (100+ 10 
mg/kg, ratio 2:1) and transcardially perfused with solution of cold PBS and heparine 
(5 U/ml) within 3 minutes. The mouse brain was removed and frozen in chilled 
isopentanol and stored at -80°C. The brain blocks were dissected in a cryostat (set at 
- l 2°C) in 15 µm thick coronal sections that encompassed the entire substantia nigra. 
The sections were collected on gelatin-coated slides, air-dried and post-fixed in 4% 
paraformaldehyde (pH~7.4 in PBS) for 8 tol0 minutes. After a PBS wash (3 times 
within 5 minutes), the sections were incubated for 20 minutes in 3% peroxide mixed 
in methanol in order to inactivate the endogenous peroxidase. Afterwards, the 
sections were incubated with 5% normal goat serum and 0.015% Triton X-100 in 
PBS. After 30 minutes incubation, the sections were immunoreacted with rabbit anti-
tyrosine hydroxy lase antibody (1: 1000 dilution, Life Technology) and rat anti-mouse 
CD68 monoclonal antibody (1:700, AbD Serotec) in 0.015% Triton X-100 for 24 
hours at 4°C. The next day, the slides were washed in PBS and incubated with 
biotinylated goat anti-rabbit or goat anti-rat secondary antibody (Vector 
Laboratories) for 1 hour. After a PBS wash, the slides were reacted with avidin-
biotin complex (ABC, Vector Laboratories) for 30 minutes. In the final step, the 
slides were washed with PBS and incubated with 3,3'-diaminobenzidine (DAB, 
Sigma) and 30% peroxide until the color was developed (5-7 minutes). The slides 
were counterstained with hematoxylin (30 seconds), dehydrated in alcohol gradient 
(80%, 90%, 100%, 100%), immersed in xylene, mounted with DPX and finally 
coverslipped. 
2.6.1.1 Quantification of dopamine neurons and microglia 
In order to assess the loss of dopamine neurons, thirty-two consecutive slides were 
collected in duplicates. Thickness of slides was 15 µm and the region of substantia 
nigra (rostral to caudal: -2.65 to -3.61 mm posterior from bregma) was sampled. 
Eight evenly spaced slides were used for counting the dopamine neurons or 
microglia. The borders of substantia nigra were defined in order to exclude the VTA 
area from counting [394]. The area defined for counting covered an entire area from 
rostral part of SNpc to the caudal end of SN pr. The images of the slides were taken 
on an Olympus camera (20 x magnification) and analyzed by Image] software (from 
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NIH). Positive CD68 microglia cells in substantia nigra were counted manually on a 
Nikon Eclipse 50i microscope ( 40 x magnification). 
2.6.2 The enzyme-linked immunosorbent assay (ELISA) 
Blood was collected transcardialy in ethylenediaminetetraacetic acid (EDTA)-coated 
tubes. Blood samples were centrifuged at 2000g for 15 minutes at 4°C and plasma 
was separated from blood cloth and stored at -20°C until used. The samples for 
insulin measurement were diluted in ratio of 1/8 for HFD-fed mice, 1/4 for Casp-1-/-
mice, while samples of RD and IL-lra-/- were not diluted. Plasma insulin was 
measured with ALPCO ELISA kit (Mouse Ultrasensitive Insulin ELISA, catalog 
number: 80-INSMSU-E0l, El0). Leptin levels were measured with mouse Leptin 
ELISA kit (Duo Set R&D Systems, catalog number: DY 498). Samples for leptin 
measurements were diluted in ratio 1/3 for Casp-1-/- and RD-fed mice and 1/8 for 
HFD-fed mice. MCP-1 plasma level analyzed with Mouse/Rat CCL2/JE/MCP-l 
ELISA kit (Quantikine ELISA, catalog number: MJE00, SMJE00, PMJE00), 
according to the manufacturer' s instructions. Samples for MCP-1 measurements 
were diluted in ratio of 1/2 for RD and HFD-fed mice, Casp-1-/- and IL-lra-/-. 
2. 7 Statistics 
Data were analyzed by Graph-Pad (Prism 5) software and expressed as means ± 
S.E.M. Time-dependent differences (between baseline and final performance) in 
behavioral and metabolic outcomes were analyzed within each treated group (WT, 
Casp-1-/- and IL-lra-/-) by paired Student's T-test. Unpaired Student's T-test was 
used to analyze the differences between RD and HFD-fed mice. One-way ANOVA 
followed by Tukey's post-hoc test was used to analyze the differences among the 
three genotypes (WT, Casp-1-/- and IL-lra-/-). Values of p<0.05 were considered 
signific'.1nt. 
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3. Effect of peripheral inflammatory 
challenge and high-fat diet on 
behavioral outcomes. 
3.1 Introduction 
As it was previously described in the general introduction ( chapter 1.2), LPS-
induced activation of the innate immune system increases inflammatory factors such 
as IL-1~ and TNF-a that are able to propagate the inflammatory cascade within the 
CNS by activated microglial cells. Proinflammatory factors produced by local 
microglial cells might interfere with normal synthesis of dopamine, its secretion and 
reuptake (chapter 1.10.5.1). Moreover, IL-1 has been directly implicated in 
programmed cell death of dopamine neurons (chapter 1.10.3). Furthermore, 
emerging evidence suggests that high-fat diet-induced obesity causes low-grade 
chronic inflammation that, in concert with metabolic disorders such as leptin and 
insulin resistance, may further dysregulate the function of the dopamine system 
( chapter 1.11 ). Thus, dysregulation of the innate and adaptive immune system could 
lead to the alteration of locomotor skills . 
Impairment of the dopamine system may be effectively assessed by performing 
behavioral paradigms, such as open-field and rotarod tests . Evaluation of 
neurological/motor capabilities in rodents, through the implementation of various 
behavioral tests, is a helpful tool to define the phenotype of mice with neurological 
impairment due to the dysfunction of the basal ganglia. The open-field and rotarod 
test offer the opportunity to examine the extent of locomotor disabilities caused by 
the alteration of the dopaminergic system, which is usually manifested by reduced 
locomotion, impaired coordination and postural instability, occurrence of tremors, 
rigidity and bradykinesia (slowness of movement). Other behavioral tests such as the 
stepping test and the pole test also represent noninvasive methods for the assessment 
of motor skills [395]. 
Dysregulation of the nigrostriatal system may also be accompanied by the 
occurrence of other, non-motor signs of behavioral impairment, such as anxiety, 
depression [396] and cognitive decline [397]. The reported prevalence of cognitive 
decline in the form of dementia in Parkinson's disease patients was estimated around 
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31 % [398] and the prevalence of depression was estimated to occur in 35% of 
Parkinson ' s diseased patients [399, 400]. Evaluation of anxiety-like behavior in 
rodents can be ascertained with tests such as the elevated plus maze, novelty 
suppressed feeding and open-field. Depressive-like behavior can be assessed by the 
forced swimming test. Cognitive decline in mice may be measured by tests such as 
the Morris water maze, which is designed for an assessment of spatial learning and 
memory, and the prepulse inhibition test, which is used for the evaluation of animal 
attention once exposed to silent stimuli from the environment [ 401]. 
3.1.1 Evaluation of neurological/motor skills 
General control over locomotor activity is highly dependent on normal functionality 
of basal ganglia and sufficient production of dopamine by its neurons. Dysfunction 
in basal ganglia in Parkinson's diseased patients results in impairment to initiate 
voluntary movements, maintenance of gait posture and inability to suppress 
involuntary movements [ 402]. 
The inflammatory process may dysregulate the normal function of the dopamine 
system via proinflammatory cytokines that originate from peripheral organs and/or 
brain resident immune cells. For instance, a single intraperitoneal injection of LPS 
into male WT mice (5 mg/kg) was sufficient to cause 23% depletion of dopamine 
neurons in substantia nigra over a period of seven months [109, 376]. In the same 
study, loss of dopamine neurons (37%) after nine months in five monthly LPS-
injected female mice was accompanied with decreased locomotor skills, as it was 
ascertained in the rotarod apparatus and in the open-field arena [376]. Histological 
analysis of the brains showed pronounced activation of microglia and increased 
immunostaining of IL-6 [376]. In another similar mouse study, as the serum level of 
TNF-a declined to baseline, examination of the brain extracts showed that protein 
levels of TNF-a [109] and IL-18 [403] were still elevated even ten months after the 
first LPS (5 mg/kg, i.p.) injection. Collectively, these studies show that a long-term 
activation of the CNS inflammatory cascade after a peripheral LPS inflammatory 
challenge [109, 376, 403] was associated with nigrostriatal dopamine degeneration 
and locomotor disabilities [376]. Human study has shown that frequent exposures to 
pesticides, which is mostly observed in agricultural communities makes people more 
susceptible to develop Parkinson ' s disease [ 404]. Pesticides are known for their 
ability to induce brain inflammation and have been related to occurrence of 
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Parkinson's disease [ 405]. Therefore, inflammation induced by endotoxins may 
cause deleterious effects on the survival of dopamine neurons, which ultimately will 
result in impaired locomotor skills. 
Even though the exact cause of dopamine cell loss in Parkinson's disease is 
unknown, factors such as genetics, age, diet, exposure to environmental pollutants 
and various toxins are thought to be implicated in the development of this disease 
[ 406]. Since there are many factors that may contribute to the onset or progression of 
Parkinson's disease, it was proposed that these factors , or "hits" may "prime" the 
neuroiflammatory cascade in the brain in additive or synergistic manner [ 407]. 
According to this hypothesis of "multiple hits", obesity might be considered as one 
of the factors that along with inflammation may lead to dopamine neuronal 
degeneration [ 406, 408]. Obesity and high-fat diet-induced insulin resistance may 
favor an increase of the susceptibility to dopaminergic neurodegeneration [ 408] . 
High-fat diet-induced insulin resistance may interfere with normal release and 
reuptake of dopamine into presynaptic vesicles [12]. Data from previous study 
suggest that rodents fed a high-fat diet have decreased availability of D2 receptors in 
striatum accompanied with increased levels of ROS [367]. Feeding mice a high-fat 
diet has been shown to exacerbate the depletion of striatal dopamine under treatment 
with the neurotoxin MPTP [ 409] followed by the depletion of dopaminergic 
terminals [3 51]. The insulin resistance in high-fat diet-fed rats was suggested to 
lower the threshold for the depletion of nigrostriatal dopamine content with 
unilateral infusion of 6-OHDA in medial forebrain bundle [353]. Overall, these 
studies s1+ggest that high-fat diet consumption and obesity exacerbated the depletion 
of nigrostriatal dopamine [351, 353, 409]. Thus, a high-fat diet may elicit metabolic 
and inflammatory dysregulations leading to dopaminergic neurodegeneration. 
In sectio·n 3 .4.1 the putative role of the IL-1 pathway was assessed on motor ability 
in mice of different genotypes (WT, Casp-1-/- and IL-lra-/-) that were injected with 
saline and/or LPS (single or five monthly injections). In the same section, the effect 
of long-term exposure to HFD on locomotor skills of WT mice was ascertained. 
3.1.2 Evaluation of an anxiety/depressive-like behavior 
Chronic activation of the immune system has also been related to depressive 
behavior in animals and humans, since it is well known that animals injected with 
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LPS develop sickness behavior [ 41 OJ and depressed patients frequently have 
increased serum concentration of proinflammatory factors [ 411-415]. In particular, 
an increasing body of evidence suggests that patients suffering from rheumatoid 
arthritis, an example of chronic inflammatory disorder, are twice as likely to suffer 
from depression [ 416, 417]. Therefore, it has been thought that immune challenges 
and secretion of cytokines may play a role in the development of depression. For 
example, several cytokines have been found to be elevated in the plasma of 
depressed patients, such as IL-1 [412], IL-6 [413], IFN-y [414] and TNF-a [415]. 
Emerging new evidence suggests that dopamine neurons from the VT A zone 
modulate a neuronal circuit that is involved with the control of depressive-like 
behavior in rodents [ 418]. It was demonstrated that selective inhibition of dopamine 
neurons m the VTA zone induces depressive-like of behavior in mice [418] 
suggesting that neuroinflammation may interfere with dopaminergic 
neurotransmission and consequently cause depressive-like of behavior in rodents. 
Endotoxin-induced inflammation may regulate depressive-like behavior in rodents. 
Symptoms seen in sickness behavior induced by the acute administration of LPS 
(hypomotility, hypophagia, decreased exploratory activity, anhedonia) are mostly 
observed in depression. One of the elements that reflect depressive behavior is 
anhedonia (inability to experience pleasure). As such, it has been recently reported 
that LPS induces the release of cytokines in the brain that in tum activate 
monoamine transporters to metabolize monoamines leading to anhedonia [ 419]. 
Likewise, the same research team reported that a LPS-induced anhedonia over-
activates serotonin transporters and consequently increases serotonin reuptake [ 420]. 
This relation between LPS and serotonin receptors is connected through LPS 
activation ofTLR4, which stimulates the activation of the p38 MAPK pathway [421] 
that results in activation of serotonin reuptake [ 422]. 
As it was previously described in chapter 1.11, obesity causes a low-grade 
inflammatory state [6]. Human studies have shown that obesity increases the risk of 
depression [ 423]. In regard to the concept of low-grade chronic inflammation caused 
by obesity, it has been shown that high-fat diet consumption for ten weeks 
exacerbated the depressive-like behavior in the Flinders Sensitive and Resistant Line 
(FSL/FRL) rats, a genetic rat model of depression [ 424]. 
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Depressive-like behavior in rodents may be evaluated with the behavioral paradigm 
such as forced swimming test [ 425]. As it was explained in the methods section, this 
test evaluates the latency to "give up" as measure of depressive-like behavior. For 
example, VMAT-2 heterozygous mutant mice displayed depressive-like behavior, 
measured as increased floating time in the forced swimming test [ 426]. Therefore, 
the effect of single and/or repeated LPS injection in absence or presence of a high-fat 
diet on depressive-like behavior will be shown in chapter 3.4.2. 
There is evidence suggesting that anxiety-like behavior in rodents may be influenced 
by neuroinflammatory process in the brain [427]. High levels of IL-6 and TNF-a 
expression has been reported to be associated with anxiety in a mouse model of 
autoimmune lupus [ 428]. Likewise, animals exposed to polymicrobial sepsis showed 
signs of anxiety in elevated plus maze without locomotor impairment and had 
increased levels of inflammatory markers in the brain (IL-1~, IL-6, TNF-a, IFN-y) 
[ 429]. Similarly, inflammatory markers have been correlated with anxiety behavior 
in humans [ 430]. Deficiency of IL-lRl in mice had a positive effect on decrease of 
anxiety without altering locomotor activity, suggesting that IL-1 plays a role as an 
anxiogenic factor [ 431]. Anxiety behavior in rodents is regulated via the CRH 
signaling pathway and its receptors CRHRl are expressed in- the anterior pituitary 
gland. It was recently suggested that the dopamine system could have a role in 
emotional disorders [ 432]. In particular it was proposed that CRH/CRHRl mediate 
the control over glutaminergic and dopaminergic neurons in an antagonistic manner, 
modulating anxiety behavior [ 433]. In conjunction with the previous statement, it 
was demonstrated that activation of glutamate releasing neurons in the limbic system 
by CRH elicits anxiety behavior, whereas release of dopamine in mid-brain induced 
by CRH evokes a behavioral outcome that reduces fear [ 43 3]. 
Anxiety behavior in rodents is ev.aluated with several methods, such as the open-
field test, the elevated plus maze [379] and the novelty suppressed feeding [ 434]. 
The effect of single and/or repeated LPS challenges and the possible effects of high-
fat diet on anxiety behavior in mice will be described in chapter 3 .4.2. 
3.1.3 Evaluation of memory and cognition 
The relevance of hippocampal function m learning and memory is very well 
demonstrated [ 435 , 436]. Leaming is a process that involves formation of new 
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synaptic connections between neurons that was hypothesized by Ramon y Cajal in 
1893 [ 43 7] . Therefore, synaptic plasticity has been explained as a connection 
between two neurons being active at the same time in a process determined as long-
term potentiation (LTP) followed by the dysregulation of this synaptic activity- long-
term depression (LTD). Synaptic signal trafficking through LTP or LTD is enabled 
through a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) [ 438]. 
The amplitude of L TP or LTD induced synaptic firing is further modified by the 
number of NMDA receptors in a process of synaptic scaling [ 439]. Physiological 
levels of IL-1 are shown to be important for the maintenance of LTP [ 129] and also 
in the expression of AMPA receptors [440]. Similarly, impaired IL-I signaling in IL-
IR-/- mice was associated with a deficit in the hippocampal memory [441]. On the 
other hand, pathological conditions accompanied with increased levels of 
proinflammatory cytokines within the brain resulted in learning and memory 
impairment [442] . For instance, an excess of IL-I was shown to induce memory 
impairment in mice by affecting cholinergic neurotransmission [443], nerve growth 
factor (NGF) [444] and impaired BDNF expression in the hippocampus [445]. 
High-fat diet consumption has been shown to impair memory and cognition [ 446]. 
As obesity is associated with elevated proinflammatory factors, it has been observed 
that cytokines might cause memory impairment [ 44 7]. Comparative studies in 
humans and rodents suggest that high-fat diet-induced insulin resistance is associated 
with the development of memory deficit and dementia [ 448]. It has been 
demonstrated that four weeks exposure to a high-fat diet impaired hippocampal 
neurogenesis in male rats before causing obesity, which was associated with high 
serum levels of corticosterone [ 449]. These data collectively suggest that chronic 
high-fat diet consumption and obesity-induced metabolic perturbations may lead to 
memory impairment [ 446-448]. 
In rodents, impaired dopaminergic neurotransmission in the prefrontal cortex was 
reported to impair working memory function [ 450]. Stimulation of dopamine release 
in the prefrontal cortex of Parkinson's diseased patients with antidepressants [ 451] 
improved the memory deficit [ 452]. In regards to the effect of diet-induced obesity, 
it has been demonstrated that electrically evoked dopamine release in prefrontal 
cortex of obesity-prone rats was attenuated [ 453], which might suggest possible link 
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between obesity-induced dysregulation of the dopamine system and memory 
impairment. 
Memory deficit in rodents can be evaluated by several behavioral paradigms such as 
the Morris water maze [454] and the prepulse inhibition test [455]. The role of IL-1 
signaling and high-fat diet consumption on memory impairment will be addressed in 
chapter 3.4.3. 
3.2 Objectives 
Single and/or repeated LPS inflammatory challenges and high-fat diet consumption 
may potentially interfere with normal functionality of the basal ganglia. Therefore, 
the aims are to ascertain the putative role of the IL-1 pathway and high-fat diet-
induced obesity on: 
1) Locomotor skills; 
2) Anxiety/depressive-like behavior and; 
3) Memory and cognitive function in mice. 
3.3 Brief methodology 
Different mouse genotypes such as WT, Casp-1-/-, and IL-1 ra-/- were tested m 
batteries of behavioral tests in order to assess: 
1) Locomotor capabilities: Possible alteration in motor abilities m mice was 
tested twice a month in the open-field and rotarod paradigms. These two tests 
were performed over a period of nine months starting from the first 
saline/LPS injection. This time frame was chosen as it was previously shown 
that repeated systemic LPS injections in female mice were sufficient to 
induce motor disabilities in the rotarod and open-field arena in a period of 
seven to nine months, respectively [376]. After nine months, another set of 
tests was employed to assess locomotor functions in mice: The grid test (was 
used as a control test for assessment of muscle strength in high-fat diet-fed 
mice), the pole test ( to assess bradykinesia ), the stepping test ( to assess 
akinesia) and the hind limb clasping test (to assess dyskinesia). 
2) Anxiety/depressive-like behavior in mice was assessed with behavioral tests 
such as the open-field ( central/total distance), the elevated plus maze, the 
novelty suppressed feeding and the forced swimming test. Except for the 
open-field test, the other tests were performed between 10 and 13 months 
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after the first saline/LPS injection. Tests were organized and performed in an 
orderly manner by exposing the mice from the least to the most stressful test. 
3) Memory and cognitive function: Mice were tested after a period of 10 to 13 
months starting from the first saline/LPS injection in the Morris water maze 
for an assessment of memory and in the prepulse inhibition test for cognitive 
evaluation. 
3.4 Results 
3.4.1 Evaluation of neurological/motor skills 
In order to better understand the long-term effects elicited by single or repeated LPS 
inflammatory challenges and in particular the role of IL-1 on dysregulation of the 
nigrostriatal system, several behavioral tests were performed to assess locomotor 
skills in mice. 
The open-field test is used as one of the methods for an assessment of voluntary 
movements in rodents. In this test total traveled distance is recorded and used as a 
measure of mouse general motor activity. For instance, a decrease in dopamine level, 
as it was shown on the example of VMAT-2 deficient mice, was accompanied by a 
reduction in locomotor activity in the open-field test that was later rescued with L-
DOP A treatment [252]. As it was previously described, a loss of dopamine neurons 
(37%) led to significant decline in traveled total distance [376]. Therefore, the open-
field test has been used as a reliable indicator of the loss of dopamine neurons and/or 
level of dopamine [3 7 6]. 
Figure 3 .1 (A, C and E) displays the total distance travelled (measured in ems) in the 
open-field arena of mice of the three studied genotypes (WT, Casp-1-/- and IL-Ira-/-, 
respectively). Data collected at the baseline point (0 month) and after 9 months from 
the first saline/LPS injection are presented for the three experimental conditions (Sal, 
LPS-1 T and LPS-5T). The main purpose of these three figures is to evaluate the 
putative time-dependent differences in locomotor activity between time 9 months 
and O month for each treatment within each genotype. 
Figures 3 .1 B, D and F were constructed to evaluate the possible differences among 
the three experimental conditions for each genotype (WT, Casp-1 -/- and IL-Ira-/-, 
respectively). The baseline point (0 months) is considered in each experimental 
condition to be 100%. The absolute difference (travelled distance at 9 months -
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travelled distance at 0 month) was expressed as a percentage of change from time 0 
month for each experimental condition. 
The total ciistance travelled in the open-field arena did not change significantly 
within the WT or Casp-1-/- groups neither within the treatment group (difference 
between 0 and 9 month) (figure 3.1 A and C, respectively) nor among treated groups 
(Sal, LPS-1 T and LPS-5T) (figure 3.1 B and D). 
With regards to the IL-Ira-/- mice, the total travelled distance largely decreased at 9 
months for each experimental condition (Sal, LPS-lT and LPS 5-T) (figure 3.1 E). 
The percentages of decreases versus their time 0 month were 53% for saline 
(p<0.001), 31% for LPS-lT (p<0.01) and 37% for LPS-5T (p<0.01) (figure 3.1 F). 
The comparison among experimental groups yielded no significant differences 
(figure 3.1 F). 
Figure 3.1 G and H were constructed to evaluate the genotype differences for each 
experimental group at baseline (time 0 month) (figure 3.1 G) and after 9 months (by 
considering the percentage of the difference between 0 and 9 months calculated in 
figures 3.1 B, D and F and sorting the data per experimental condition (figure 3.1 
H)). 
As it is shown in figure 3 .1 G there were significant differences among the three 
genotypes at the baseline level. Casp-1-/- mice were 39% more active than WT mice 
(p<0.001) and 58% more active in comparison to IL-Ira-/- mice (p<0.001). In regard 
to the differences in motor activity that was already shown with Casp-1-/- mice, IL-
lra-(- mice were also 32% less active in comparison to WT mice (p<0.001). 
As it was already described in the figure 3 .1 G, there were significant differences in 
the locomotor activity at the baseline among the three genotypes. In order to 
understand if the final reported traveled distance in the open-field test is different 
among three different strains of mice, percentages of changes that were previously 
calculated for the individual genotype (figure 3 .1 B, D and F) were gathered in figure 
3 .1 H and compared among genotypes within same treated group. 
In figure 3.1 H, among saline treated groups, locomotor activity of IL-Ira-/- mice 
was significantly reduced by 60% in comparison to WT (p<0.001) mice and 40% 
versus Casp-1-/- mice (p<0.01). The similar situation was observed in a group 
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treated with one LPS injection, while this trend did not persist in a group injected 
five times with LPS. 
Overall, presented data from the open-field test suggest that there were not obvious 
LPS effects observed among the three genotypes. However, the locomotor activity of 
IL-lra-/- mice significantly reduced during nine months period, suggesting that the 
absence of IL-Ira could have impaired nigrostriatal activity. 
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Figure 3.1: Long-term effect of peripheral LPS inflammatory challenge on total 
distance travelled during open-field test: Comparison within each treated group: The 
total distance travelled by A) WT, C) Casp-1-/- and E) IL-Ira-/- mice during 32 minutes 
before Sal or LPS injection (month 0) and after nine months starting from the first Sal/LPS 
injection (month 9) . Data were presented as values of baseline points and session after nine 
months. Results were analyzed by paired T-test. Treatment comparison: Percentage of 
difference between month 0 (first session) and month 9 (last session) in B) WT, D) Casp-1-/-
and F) IL-Ira-/- mice was calculated by formula [(9 month-0 month)/0 month* 100] and 
expressed as delta. Data were analyzed by one-way ANOVA followed by Tukey ' s post-hoc 
test unless otherwise indicated on the graph. G) Data of baseline performance of all three 
genotypes were collapsed from figures A), C) and E) and compared by one-way ANOVA 
followed by Tukey's post-hoc test. H) Genotype and treatment comparison of motor activity 
was performed by collapsing the data displayed in figures B), D) and F) according to each 
experimental group (Sal, LPS-1 T and LPS-5T). Results were analyzed by one-way ANOV A (Tukey's multiple comparison test). Numbers in brackets refer to the total number of mice 
per each experimental group. Error bars represent standard errors. **p<0.01 , ***p<0.001 vs. 
0 month; /\p<0.05 , /\/\/\p< 0.001 vs. WT; ++p<0.0l ,+++p<0.001 vs. Casp-1-/-. 
The rotarod test is largely used to test motor skills such as coordination and balance 
in rodents. The latency for mice to fall from the rotating drum is recorded and used 
to assess their coordination. 
Figure 3.2 (A, C and E) represent the latency (measured in seconds) of mice of 
different genotypes (WT, Casp-1-/- and IL-Ira-/-, respectively) to fall down from the 
rotating drum of the rotarod apparatus. As it was described previously for the figure 
3.1 , data collected from O month and 9 months, starting from the first saline/LPS 
injection, are presented for the three experimental conditions (Sal, LPS-1 T and LPS-
ST) in order to assess changes in animal's coordination in a time-dependent manner. 
Figures 3 .2 B, D and F were constructed to evaluate the effect of single and repeated 
LPS injections on animal coordination within each genotype (WT, Casp-1-/- and IL-
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lra-/-, respectively). As it was described in figure 3.1 (B, D and F), baseline points 
collected at 0 month are considered for each experimental condition as 100% and 
percentage of difference for each treatment was calculated. 
Collectively, the data shown across the three genotypes (WT, Casp-1-/- and IL-lra-/-
) suggest that their ability to keep their balance on the rotarod apparatus declined 
after nine months (figure 3.2 A, C and E). The percentage of decline within the 
individual mice genotypes ( difference between 0 and 9 month) was not significantly 
affected by single or repeated LPS injections (figure 3.2 B, D and F). 
Similar to the analysis performed in figure 3 .1 ( G and H), figure 3 .2 G was 
constructed in order to compare the genotype's differences for each experimental 
group at baseline point. Figure 3 .2 H presents the genotypes difference in rotarod test 
after 9 months (percentage of differences between 0 and 9 months previously 
calculated in the figures 3 .2 B, D and F and sorting the data by experimental 
condition). 
As it may be observed in figure 3.2 G, baseline assessment of mice from three 
genotypes showed that their ability to keep their balance on the rotarod apparatus 
was significantly different. In particular, coordination skills of IL-Ira-/- mice were 
20% better in comparison to WT mice (p<0.05). 
The genotype comparison (figure 3.2 H) among saline-treated groups showed that 
rotarod performance of IL-lra-/- mice declined by 37% in comparison to WT mice 
(p<0.01). Coordination among the three genotypes, treated with single and repeated 
LPS injections, was reduced in similar manner, suggesting that mice's ability to keep 
their balance on the rotarod was not decreased by LPS treatment. 
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Figure 3.2: Long-term effect of peripheral LPS inflammatory challenge on 
rotarod performance: Comparison within each treated group: Average latency 
(measured in seconds) for A) WT, C) Casp-1-/- and E) IL-lra-/- mice to fall down from the 
rotating drum. Data collected at O month and after 9 months were compared within each 
treated group by paired T-test. Treatment comparison: Percentage of difference between 
month O (first session) and month 9 (last session) in B) WT, D) Casp-1-/- and F) IL-lra-/-
mice was calculated for each experimental group according to the previously described 
formula (in the legend to figure 3.1) and analyzed by one-way ANOVA followed by 
Tu.key's post-hoc test. G) Data of baseline performance in rotarod test of three genotypes 
were gathered from figures A), C) and E) and differences among genotypes were compared 
by one-way ANOVA followed by Tu.key's post-hoc test. H) Genotype and treatment 
comparison was performed by co11apsing the data displayed in figures B), D) and F) 
according to each experimental group (Sal, LPS-1 T and LPS-5T) and analyzed by one-way 
ANOVA followed by Tu.key's post-hoc test. Numbers in brackets refer to the total number 
of mice per each experimental group. Error bars represent the standard errors. *p<0.05 , 
**p<0.01, ***p<0.001 vs . 0 month; /\p<0.05, /\/\p<0.001 vs. WT. 
After nine months mice were subjected to the stepping test in order to assess other 
features of locomotor impairment such as forelimb akinesia, represented by the 
prolonged time needed to initiate a step, which can be caused by dysregulation of the 
dopamine system [ 456] and/or dopamine depletion [ 457]. The number of adjusted 
steps mice make with forepaws when lightly suspended by the tail and dragged 
across table surface for a length of one meter is used as an indication of akinesia. 
In the figure 3.3 (A, B and C), the effect of single and repeated LPS injections was 
assessed on total number of adjusted steps within three genotypes (WT, Casp-1-/-
and IL-Ira-/-, respectively). 
As it may be observed in figure 3.3 A, single and repeated LPS injections decreased 
the number of adjusted steps, but not significantly, in WT mice. A similar trend was 
77 
also observed in five LPS-inj ected IL-Ira-/- mice (figure 3.3 C). However, single 
LPS injection did not induce any significant change in IL-Ira-/- mice (figure 3.3 C). 
In contrast, the abi lity of Casp-I-/- mice to initiate steps was not affected by single or 
repeated LPS inflammatory challenges (figure 3.3 B). 
Treatment comparison among three different genotypes indicated that the ability of 
Casp-I-/- and IL-Ira-/- mice to adjust steps was significantly better versus WT mice 
(Sal, LPS-I T and LPS-5T) (figure 3.3 D). This difference was not due to the fact that 
WT mice displayed reduced ability to adjust steps as these animals had already 
shown to have similar performance at the age of eight months [45 7]. Therefore, the 
data suggests that better performance observed in Casp-I-/- and IL-Ira-/- was due to 
the inherent characteristics of these mouse strains. 
A WT mice 
:g_ 40 
Q) 
en 
] 30 
<I) 
:, 
~20 
0 
_gj 10 
E 
:, 
C 0 
ec,?r 0 ~ 
q_0 
v 
Q.c, ' 
'v 
treatment 
Stepping test 
B 
:g_ 40 
* al 30 
en 
:, 
~ 20 
0 
_gj 10 
E 
:, 
C 0 
Casp-1 -/- mice 
treatment 
Genotype comparison Q (within each treatment) 
40 
Cl) 
Cl. 
(]) 
t, 
-o 30 
(]) 
t, 
:::J 
'g 20 
0 
~ 10 
E 
:::J 
C 
Sal LPS - 1T 
AAA 
genotype and treatment 
C 
:g_ 40 
.'!l 
<I) 
-o 30 
* :, 
~20 
0 
1l 10 
E 
:, 
C 0 
LPS -5T 
IL-1 ra -/- mice 
4 0 ~ 
Q.0' Q.0' 
v 'v 
treatment 
Figure 3.3: Long-term effect of LPS inflammatory challenge on mice stepping 
test ability: The number of adjusted steps was recorded as mean of three trials per animal 
and presented in seconds . The effect of LPS treatment was individualy assessed in A) WT, 
B) Casp- 1-/- and C) IL-lr~-/- mice and analyzed by one-way ANOVA followed by Tuk:ey's 
post-hoc test. D) Data that were summarized from figures A), B) and C) were compared 
among different genotypes within same treatment. Results were analysed by one-way 
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ANOVA (Tukey's multiple comparison test). # #p<0.001 vs LPS-lT; +p<0.05 vs. Casp-1-/-; 
1\/\p<0.001, /\/\/\p<0.0001 vs. WT. 
To determine the effect of LPS inflammatory challenge and its possible exacerbation 
by diet-induced obesity, the motor performance of single and five monthly LPS-
injected WT mice fed a high-fat diet was assessed in the open-field and rotarod tests 
and compared with their controls (WT mice fed a regular diet). 
As it is shown in figure 3 .4 (A and C), there has not been observed significant 
decline in the open-field performance in neither RD no HFD-fed mice. Moreover, 
treatment comparison indicated that neither one nor repeated LPS injections altered 
the general performance of treated groups in comparison to their baseline ( figure 3 .4 
B and D). Baseline data gathered at O month showed no differences in activity 
between RD and HFD-fed mice (figure 3.4 E). Overall comparisons between diets 
and treatments did not reveal any significant difference (figure 3.4 F). 
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Figure 3.4: Effects of high-fat diet and LPS inflammatory challenge on total 
traveled distance during open-field test: Comparison within each treated group: The 
total distance travelled by A) RD and C) HFD-fed mice during 32 minutes before Sal or LPS 
injection (month 0) and after nine months starting from the first Sal/LPS injection (month 9). 
Data were presented as values of baseline points and session after nine months and analyzed 
by paired T-test. Treatment comparison: Percentage of di fference between O month (first 
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session) and 9 month (last session) in B) RD and D) HFD-fed mice was calculated and 
expressed as delta. Results were analyzed by one-way ANOVA (Tuk:ey's multiple 
comparison test) E) Data of baseline performances in the open-field test of two groups of 
mice fed with different diets were gathered from figures A) and C) and differences among 
them were compared by unpaired T-test. F) Diet comparison within each treatment: 
Comparison of motor activity between two groups of WT mice fed a different diet. Collected 
data were analyzed by unpaired T-test. Error bars represent standard errors. 
Along with the open-field test, mice were also tested on the rotarod apparatus in 
order to investigate the long-term effects of high-fat consumption and LPS 
treatments on animal coordination. 
As it was shown previously, mice fed a RD had experienced reduced ability to keep 
their balance on the rotarod apparatus. In saline-treated group of RD-fed mice, 
coordination declined by 19% (p<0.05) and in the single LPS-injected group, 
balance was reduced by 34% (p<0.05) (figure 3.5 A and B). A similar trend was 
observed in the five LPS-injected group of RD-fed mice, where decline in 
coordination was 22% but not statistically different versus baseline point (figure 3 .5 
A and B). 
The reduced coordination in HFD-fed mice was not particularly affected by LPS 
treatment (figure 3.5 C and D). After nine months, the balance of saline-treated HFD 
mice on the rotarod was reduced by 62% (p<0.01) and a similar decline was 
observed with one LPS [68% (p<0.05)] and five LPS injections [60% (p<0.0001)] 
(figure 3.5 C and D). 
Baseline performance of RD and HFD-fed mice in the rotarod test was not different 
(figure 3.5 E). 
Overall, diet comparison within each treated group showed that the extent of 
coordination impairment observed in HFD-fed mice was markedly higher m 
comparison to RD-fed mice (figure 3.5 F). 
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Figure 3.5: Effects of high-fat diet and peripheral LPS challenge on rotarod test 
performance: Comparison within each treated group: Average latency (measured in 
seconds) for A) RD and C) HFD-fed mice to fall down from the rotating drum was analyzed 
by paired T-test. Treatment comparison: Percentage of difference in the rotarod performance 
for time O and 9 months of B) RD and D) HFD-fed mice was calculated for each 
experimental group according to the previously described formula (figure 3.1) and compared 
by one-way ANOVA (Tuk:ey's multiple comparison test). E) Data of baseline performances 
of two groups of mice fed with different diets were gathered from figures A) and C) and 
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differences between them were analyzed by unpaired T-test F) Diet comparison within each 
treatment: Data displayed in figures B) and D) were collapsed according to each 
experimental group (Sal, LPS-1 T and LPS-5T) and compared by unpaired T-test. Error bars 
represent the standard errors. *p<0.05, **p<0.01, ***p<0.0001 vs . 0 month; Ap<0.05, 
A/\p<0.01, AA/\p<0.001 vs. RD. 
One of the first experiments performed after the open-field and rotarod test was the 
grid test, which gives reliable indications on the general condition of limb muscle 
strength [ 458]. The test was performed in order to exclude the possible effects of 
muscle strength disability that might occur in mice fed a HFD, which would have in 
tum affected their rotarod performance. General observation of the amount of time 
that animals spent hanging on the horizontally positioned grid indicated that muscle 
strength was not impaired with peripheral LPS treatment in the group of mice fed 
either RD (figure 3.6 A), or HFD (figure 3.6 B). Assessment of treatment effect 
between different diet-fed mice indicated that long-term consumption of high-fat diet 
did not impair muscle strength in mice (figure 3.6 C). 
A 
150 
u 100 
Q) 
!:E., 
Q) 
E 
~ 50 
0 
~ 0 
WT mice (regular diet) 
(' 4' 
q_0 
V 
q_0 
V 
treatment 
Grid test 
B 
150 
u 100 
Q) 
!:E., 
Q) 
E 
~ 50 
0 
Diet comparison 
C (within each treatment) 
150 Sal LPS-1T 
------· ------· 
/\/\ 
u 100 
Q) 
!:E., 
Q) 
E 
~ 50 
0 
«-Q r,,_Q ~ «-<:) r,,_Q ~ 
diet and treatment 
WT mice (high-fat diet) 
4 (' 4' 
q_0 
V 
q_0 
V 
treatment 
LPS-5T 
------· 
«-Q r,,_Q ~ 
Figure 3.6: Mice performance in the grid test: Limb muscle strength of WT mice that 
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were injected with saline or LPS on grid apparatus . Latency for animal to fall from grid of 
the apparatus was recorded in seconds. Time that mice fed with either A) RD, or B) HFD 
spent hanging on the horizontally positioned metal grid was analyzed by one-way ANOV A (Tukey' s multiple comparison test) . C) Gathered data from figures A) and B) were divided 
into two groups according to the treatment and compared by unpaired T-test. Error bars 
represent standard errors. J\/\p<0.01 vs. RD . 
In order to understand if the loss of locomotor activity observed in the rotarod test 
after nine months from the first saline/LPS injection was related to impairment in 
nigrostriatal dopamine activity, mice were subjected to L-DOP A/carbidopa test. L-
DOP A/carbidopa is a combination of drugs given to Parkinson's diseased patients 
[ 459, 460], as a replacement for the lack of dopamine. L-DOPA is a precursor of 
neurotransmitter dopamine and therefore it is used to increase dopamine 
concentration in the treatment of Parkinson's disease. Carbidopa is a drug given in 
combination with L-DOPA in order to inhibit peripheral metabolism of L-DOPA to 
dopamine since dopamine itself is not able to cross BBB. The effect of this drug is 
short and it is effective for a couple of hours after administration. It is shown that 2 
hours post-injected animals with L-DOPA/carbidopa (30mg/ 3mg/kg, i.p.) had 
improved motor ability when tested on the rotarod apparatus [376]. Therefore, this 
test is a useful method to assess if the locomotor impairment is related to depletion 
of dopamine in the system. 
Twelve months after the first saline/LPS injection baseline performance of mice was 
tested on the rotarod apparatus and recorded as time O hour (0 h). Afterwards, mice 
were injected with L-DOPA/carbidopa (30 mg/ 3mg/kg, i.p.) [376]. Two hours (2 
hrs) after injection mice were subjected to the rotarod test and this test was repeated 
after one week (1 wk) in order to evaluate if the putative short-term recovery in 
rotarod performance elicited by L-DOP A/carbidopa injection was cleared out after 
the retrieval of the drug. 
As it may be observed in figure 3.7 A, WT mice injected with one or repeated LPS 
injections had reduced, but not significantly, coordinative ability to keep their 
balance on the rotarod apparatus at O h. Reduced locomotor activity was recovered to 
the level of saline-injected RD mice 2 hours after the L-DOP A/carbidopa injection. 
One week (1 wk) after the L-DOP A/carbidopa test, mice coordinative ability on the 
rotarod apparatus was reduced again, which confirms that increased mice activity 
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after 2 hours post injection was due to the lack of dopamine in the nigrostriatal 
system. 
High-fat diet-fed mice had heterogenous response to L-DOPA/carbidopa test. As it is 
presented in figure 3.7 B reduced activity in HFD-fed mice that received one or five 
LPS injections was not recovered to the same extent as it was observed in RD-fed 
mice two hours after L-DOPA/carbidopa injection. Single LPS-injected HFD-fed 
mice did not respond to a L-DOPA/carbidopa test, whereas there was positive 
response in five LPS-injected mice, but the drug effect was not completely cleared 
out after one week. 
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Figure 3.7: L-DOP A/carbidopa test: Test was conducted 12 months after the first 
saline/LPS injection. Mice were tested on rotarod apparatus before administration of drug at 
time Oh. Afterwards, mice received L-DOPA/carbidopa (30 mg/ 3mg/kg, i.p.) injection and 
their ability to keep their balance on the rotating drum was tested in next 2 hrs and one week 
after injection. Data were analyzed by one-way ANOV A (Tukey' s multiple companson 
test). Error bars represent standard errors. 
The pole . test is a useful method for assessment of bradykinesia, which describes 
slowness of a performed movement and it has been shown to correlate with levels of 
striatal dopamine [388]. 
There was a tendency for animals treated with single or repeated LPS injections in 
RD and HFD group to take more time to tum around on .the pole (figure 3.8 A and 
C), while there was no change in time for treated mice to climb down (figure 3.8 B 
and D). Treatment comparison between two different diet-fed groups indicated that 
HFD-fed mice tended to spend more time to tum around on the pole accompanied 
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with significant delay to climb down (figure 3.8 E and F). These data provided from 
the pole test suggest that the level of dopaminergic neurotransmission might be 
impaired in HFD-fed mice that could have finally resulted in slowness of 
movements. 
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Figure 3.8: Effects of high-fat diet and LPS inflammatory challenge on pole test 
performance: Latency for WT mice to tum around and climb down the pole was recorded 
in seconds. Time that mice fed either A) RD, or C) HFD spent to tum around the pole was 
analyzed by one-way ANOVA followed by Tukey's post-hoc test. Latency of B) RD or D) 
HFD-fed mice to climb down the pole was analyzed by one-way ANOVA followed by 
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Tukey' s post-hoc test. E) Effects of diet and LPS treatment on mice ability to tum around 
and F) to climb down the pole was analyzed by unpaired T-test. Error bars represent 
standard errors . /\p<0.05 , Mp< 0.01 , (\/\/\p<0.001 vs. RD. 
As it was previously described, the stepping test is a reliable test used to determine 
forelimb akinesia, a movement disorder that has been related with nigrostriatal loss 
of dopamine [ 461]. 
The stepping test conducted in RD-fed mice showed that single and repeated LPS 
injections tended to decrease animal ability to adjust the steps (figure 3.9 A). On the 
other hand, there was no response to LPS treatment in HFD-fed group (figure 3.9 B). 
Collectively, HFD-fed mice had significantly decreased ability to adjust forelimbs 
steps [41% in Sal (p<0.001), 41% in LPS-lT (p<0.001) and 25% in LPS-5T treated-
group (p<0.05)] in comparison to RD-fed mice that could have been as a result of 
impaired dopamine level and/or dopaminergic neurotransmission in striatum (figure 
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Figure 3.9: Mice performance in the stepping test: Effect of single or repeated LPS 
injections on number of adjusted step in mice fed either A) RD or B) HFD was analyzed by 
one-way ANOVA followed by Tukey's post-hoc test. C) Number of adjusted steps was 
compared within each treated groups that were fed with different diets. Data were analyzed 
by unpaired T-test. Error bars represent standard errors. t\p<0.05 , t\t\t\p<0.001 vs . RD. 
Evaluation of dyskinesia ( diminished voluntary and prevalence of involuntary 
movements) may be conducted by performing a hind limb clasping test. It has been 
shown that poor motor ability reported in BH4-deficient mice assessed in hind limb 
clasping test was correlated with a lack of dopamine in the brain [ 462]. In the current 
study the hind limb clasping test is performed by suspending. mice in the air by the 
tail and the position of hind limbs are ob.served. Based on the position of the limbs 
mice are scored a O (hind limbs are splayed outwards), 1 ( one hind limb is retracted 
towards abdomen), 2 (both hind limbs are partially retracted towards abdomen) and 
3 (hind limbs are completely retracted and touching the abdomen). Results gathered 
from hind limb clasping test indicate that neuromuscular function in RD ( figure 3 .10 
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A) and in HFD (figure 3.10 B) mice was not significantly impaired by single or 
repeated LPS challenges. However, HFD mice have shown signs of dyskinesia in 
comparison to RD mice regardless of different treatments (figure 3 .10 C). These 
observations suggest that long-term exposure to HFD might have impaired 
dopaminergic neurotransmission. 
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Figure 3.10: Hind limb clasping test: Wild type mice were suspended in the air for 10 
seconds by the tail and their performance to clasp hind limbs was scored. Score for hind 
limb clasping test of WT mice fed either A) RD or B) HFD was analyzed by one-way 
ANOVA (Tukey ' s post-hoc test). C) Diet comparison within each treatment: Data were 
analyzed by unpaired T-test. Error bars represent standard error. "p< 0.05, "/'\/'\p<0.001 vs. 
RD. 
3.4.2 Evaluation of an anxiety/depressive-like behavior 
As it was described previously, inflammation induced dysregulation in nigrostriatal 
signaling pathways may also lead to anxiety/depressive-like behavior. One of the 
parameters used for the assessment of anxiety-like behavior is the ratio between 
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traveled distance in the central area of the open-field arena and total distance mice 
traveled in 32 min (CD/TD), as rodents tend to avoid open areas. 
Figure 3 .1.1 (A, C and E) displays the ratio CD/TD in the open-field arena of mice of 
the three genotypes (WT, Casp-1-/- and IL-Ira-/-, respectively). As it was described 
previously in the legend to figure 3 .1, data were collected at baseline (0 month) and 
after 9 months starting from the first saline/LPS injection. These figures show the 
time-dependent and treatment effect on the development of anxiety-like behavior. 
In order to evaluate the possible effect of single and repeated LPS injections for each 
genotype, the absolute differences between 0 and 9 months were expressed as 
percentage of change for each experimental condition (figure 3.11 B, D and F). 
The WT group did not show anxiety-like behavior (figure 3.11 A and B). There was 
neither time-dependent difference observed in CD/TD within the treatment group 
(difference between 0 and 9 months) (figure 3.11 A) nor among treated groups 
(figure 3.11 B). 
With regards to the Casp-1-/- and IL-Ira-/- mice, the CD/TD largely decreased after 
9 months for each experimental condition (Sal, LPS-lT and LPS 5-T) (figure 3.11 C 
and E). The percentages of decreases versus their time 0 month were 39% in saline 
(p<0.01), 57% in LPS-lT (p<0.01) and 42% in LPS-5T (p<0.01) treated Casp-1-/-
mice (figure 3.11 C). The comparison among experimental groups did not reveal any 
significant differences (figure 3.11 D). In a similar manner, the percentages of 
difference after 9 months in IL~lra-/- mice was 72% in saline (p<0.001), 52% in 
L~S-lT. (p<0.14) and 73% in LPS-5T (p<0.001) (figure 3.11 E) with no evident 
differences among experimental groups ( figure 3 .11 F). These data suggest that 
Casp-1-/- and IL-Ira-/- mice displayed anxiety-like behavior that was not 
additionally exacerbated by LPS ·administration. 
Figures 3 .11 G and H were constructed to evaluate the genotype differences for each 
experimental group at baseline (time 0, rrionth) (figure .3.11 G) and after 9 months 
(figure 3 .11 H) as it was previously c;lescribed in figure 3 .1. 
Figure 3 .11 G shows that there were significant differences among the three 
genotypes at baseline. The CD/TD ratio of IL-Ira-/- mice was significantly lower by 
53% versus WT (p<0.001) and 52% lower in comparison to Casp-1-/- mice 
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(p<0.001), suggesting that IL-lra-/- mice displayed anxiety-like behavior when mice 
were very young, 42 days old. 
The percentages of changes that were previously calculated for the individual strains 
(figure 3.11 B, D and F) were gathered in figure 3.1 H and compared among 
genotypes within each treatment. Despite the fact that IL-Ira-/- mice displayed 
nearly 2-fold lower CD/TD than both WT and Casp-1 -/- mice at 0 month (figure 
3 .11 G ), their CD/TD significantly decreased at 9 months in the three treated groups 
(Sal, LPS-1 T and LPS-5T) by approximately 60% (figure 3.11 H). Casp-1-/- mice 
showed a trend to be more anxious than WT mice and it reached significance in one 
and 5-times LPS-injected groups. However, the level of anxiety-like behavior in IL-
lra-/- mice was higher, but not statistically different, in comparison to Casp-l -/-
m1ce. 
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Figure 3.11: Effect of LPS inflammatory challenge on anxiety-like behavior in 
the open-field test: Ratio of central over total distance traveled in the open-field arena 
was used as an index of anxiety-like behavior. Comparison within each treated group: 
Average values of CD/TD collected at O month and after 9 months of A) WT, C) Casp-1-/-
and E) IL-1 ra-/- mice were compared within each treated group by paired T-test. Treatment 
comparison: Data collected from first and last open-field test of B) WT, D) Casp-1-/- and F) 
IL-1 ra-/- mice were transformed into percentage [Delta=(9 month- 0 month)/(0 month)* 100] 
and analyzed by one-way AN OVA (Tukey' s post-hoc test). G) Data of baseline 
performance in open-field test of the three genotypes were gathered from figures A), C) and 
E) and differences among genotypes were compared by one-way ANOVA followed by 
Tukey's post-hoc test. H) Genotype and treatment comparison was performed by collapsing 
the data displayed in figures B), D) and F) according to each experimental group (Sal, LPS-
1 T and LPS-5T) and were analyzed by one-way ANOVA followed by Tukey's post-hoc test. 
Error bars represent standard errors. **p<0.01, ***p<0.001 vs. 0 month; /\p<0.05 , 
/\/\/\p<0.001 vs. WT; + p<0.05, +++ p<0.001 vs. Casp-1-/-. 
Elevated plus maze is another test used for assessment of anxiety-like behavior in 
rodents. The aim of the test is to challenge the animal to choose between its desire to 
explore a new environment and the fear of exploring a bright illuminated area. When 
mice are anxious, they prefer to stay in the closed arm of the maze. After 5 minutes 
of testing, the proportion of the time that mice spent in the open or closed arm is 
used as an index of anxiety-like behavior. 
Figure 3.12 (A, C and E) displays the time that mice of all three genotypes (WT, 
Casp-1-/- and IL-Ira-/-, respectively) spent in the open arm. Figure 3.12 (B, D and F) 
shows the time that mice spent in the closed arm. Assessment of the three genotypes 
in the elevated plus maze test has shown that single and repeated LPS injections did 
not further exacerbate the anxiety-like behavior in comparison to their own saline-
treated group of mice. 
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On the other hand, genotype comparison has revealed that IL-Ira-/- mice were the 
group that showed clear signs of increased anxiety since these animals had spent 
significantly less time in the open arm (figures 3 .12 G) and concomitantly preferred 
to stay in the closed arm most of the time ( figure 3 .12 H) in comparison to WT and 
Casp-1-/- mice. In contrast, Casp-1-/- mice tend to be the least stressed group and the 
time these mice spent in the open and closed arm was significantly different from IL-
lra-/- mice (figure 3.12 G and H). These observations are related to the previous 
study where IL-lRl-/- mice had shown decreased anxiety behavior [431]. 
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Figure 3.12: Effect of the LPS inflammatory challenge on anxiety-like behavior 
m the elevated plus maze test: The proportion of time (5 min in total) that mice spent in 
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open or closed arm of elevated plus maze apparatus was measured in seconds. Treatment 
comparison: Time that A) WT, C) Casp-1-/- and E) IL-Ira-/- mice spent in open arm and B) 
WT, D) Casp-1-/- and F) IL-lra-/- in closed arm, respectively. Differences within each 
genotype were analyzed by one-way ANOVA followed by Tukey ' s post-hoc test. Genotype 
comparison within each treatment in open G) and closed arm H) was analyzed by one-way 
ANOVA (Tukey's multiple comparison test). Error bars represent standard errors. 
/\/\p<0.001, l\/\l\p<0.0001 vs. WT, +++p<0.0001 vs. Casp-1-/-. 
The forced swimming test is frequently used to assess depressive-like behavior in 
rodents [ 463 , 464]. Mice are placed individually in a cylinder half-filled with water 
to prevent them from escape during the test. Therefore, mice are forced to stay for 
five minutes in the water. The time that mice spend active (swimming and 
struggling) or passive (floating) is measured in seconds. The proportion of time that 
mice spend passive (floating) is considered to reflect the behavioral despair in 
animal, which results from the animal's sense of hopelessness to persist in its attempt 
to find an escape. 
The role of IL-1 signaling pathway and LPS inflammatory challenge on depressive-
like behavior in WT, Casp-1-/- and IL-Ira-/- mice was analyzed and presented in the 
figure 3.13 . The group of single-injected IL-lra-/- mice was not tested since there 
was no significant difference between saline and LPS-5T treated groups. 
As it is shown in figure 3.13 (A, Band C), the total time that WT mice, injected with 
five LPS injections, spent struggling (figure 3.13 A), and swimming (figure 3.13 B) 
was reduced but not significantly, whereas floating time tended to increase (figure 
3.13 C). Single LPS injection did not alter the performance of WT mice in the forced 
swimming test (figure 3.13 A, B and C). These results suggest that repeated LPS 
ch_alleng;es showed a trend to induce depressive-like behavior in WT mice, but the 
results were not significant. 
In regard to Casp-1-/- mice, single and 5-times LPS-injected mice had increased 
swimm°ing time and reduced floating time (figure 3.13 E and F). Struggling time was 
not affected by LPS challenge (figure 3.13 D). These observations imply that LPS 
inflammatory challenge did not induce or ·exacerbate the depressive-like behavior in 
Casp-1-/- mice. 
Similarly to the Casp-1-/- mice, repeated LPS inflammatory challenges did not alter 
the time that IL-1 ra-/- spent struggling, swimming and floating ( figure 3 .13 G, H and 
I). 
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Genotype comparison (WT, Casp-I-/- and IL-I-ra -/-) and within each treatment 
revealed that IL-Ira-/- mice spent significantly less time struggling in comparison to 
WT mice (figure 3. I3 J). On the other hand, there was no difference among 
genotypes in swimming and floating (figure 3.I3 Kand L). Although struggling was 
significantly lower in IL-Ira-/- mice, floating time was similar to other two 
genotypes, so it might be suggested that IL-Ira-/- mice did not show depressive-like 
behavior. 
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Figure 3.13: Effect of LPS inflammatory challenge on depressive-like behavior 
in the forced swimming test: Mice were placed in the beaker filled with water and their 
behavior was monitored for five minutes. Treatment comparison: Time that A) WT, D) 
Casp-1-/- and G) IL-lra-/- mice spent struggling; B) WT, E) Casp-1-/- and H) IL-1 ra-/-
swimming and C) WT, F) Casp-1-/- and I) IL-lra-/- floating was analyzed by one-way 
ANOVA (Tukey ' s multiple comparison test). J), K) and L) Genotype comparison within 
each treatment was analyzed by one-way ANOVA (Tukey's multiple comparison test). 
Error bars represent standard errors. **p<0.01 vs. Sal, l\/\/\p<0.001 vs. WT. 
In order to ascertain the possible negative effect of diet-induced obesity and LPS 
treatment on anxiety/depressive-like behavior, the same batteries of tests were 
performed as described before and with the addition of one more test (novelty 
suppressed feeding test). 
Ratio of central over total distance obtained from open-field test was used to assess 
the anxiety-like behavior in WT mice that were fed either a RD or HFD. 
Figure 3.14 (A, and C) displays the ratio of CD/TD in the open-field arena of mice of 
RD and HFD-fed mice. As it was described previously in the figure 3.11 , data were 
collected at baseline point (0 month) and after 9 months starting from the first 
saline/LPS injection. The analysis of anxiety-like behavior within each treatment did 
not reveal significant differences within the RD or HFD-fed mice ( figure 3 _ 14 A and 
C). 
As it was previously described in the figure 3 .11 , absolute differences between O and 
9 months were expressed as percentage of change for each experimental condition in 
order to assess the effect of single and repeated LPS inflammatory challenges on 
anxiety-like behavior (figure 3.14 B and D). As it is presented in figures 3.14 B and 
D, there was no treatment effect in RD and HFD-fed mice, suggesting the LPS 
treatment did not induce or exacerbate anxiety-like behavior in both groups of mice. 
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Differences between the two diet-fed groups are evaluated in figure 3 .14 (E and F). 
Figure 3.14 E indicates that there were not significant differences between RD and 
HFD-fed mice at baseline. Percentages of change that were previously calculated 
individuaily for RD and HFD group (figure 3.14 B and D) were gathered in figure 
3.14 F and compared between two diet-fed groups within each treatment. The 
comparison indicated that CD/TD was not different between RD and HFD-fed mice, 
suggesting that long-term exposure to high-fat diet did not induce anxiety-like 
behavior. 
101 
Open-field test {central/total distance) 
A WT mice (regular diet) 
(comparison within each treated group) 
0.25 
0.20 
~ 0.15 
0 
U 0.10 
0.05 
LPS - 1T 
() ~ 
months 
C WT mice (high-fat diet) 
(comparison within each treated group) 
0.25 Sal 
0.20 
0 0.15 t:: 
0 
u 0 .10 
0.05 
0.00 
() ~ 
E 
0.25 
0.20 
0 0.15 t:: 
0 
u 0.10 
0.05 
0.00 
~<::) 
LPS - 1T 
() ~ 
months 
Month 0 
diet comparison 
diet 
LPS - 5T 
~<::) ~ 
B 
WT mice (regular diet) 
ti (9- 0 month) treatment comparison 
90 
60 
..r::. 
c 
o 30 
E 
0 
-0 
c -3o 
<] 
-60 
-90-'---------------
D 
90 
60 
..r::. 
c 
o 30 
E 
0 
0 
c -3o 
<] 
-60 
treatment 
WT mice (high-fat diet) 
ti (9- 0 month) treatment comparison 
treatment 
ti (9- 0 month) F diet comparison within each treatment 
90 Sal LPS-1T LPS - 5T 
-------
60 
..r::. 
c 30 0 
E 
0 0 0 
c -3o 
<] 
-60 
-90 
~<::) rP ~ 
diet and treatment 
Figure 3.14: Effects of LPS inflammatory challenge and high-fat diet on 
anxiety-like behavior in the open-field test: Ratio of central over total distance 
traveled in open-fie ld arena was used as an index of anxiety-like behavior. Comparison 
within each treated group: Average values of CD/rD collected at O month and after 9 
months in A) RD and C) HFD-fed mice were compared by paired T-test. Treatment 
comparison: Data collected from first and last open-fie ld test in B) RD and D) HFD-fe d 
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mice were transformed into percentages [Delta=(9 month- 0 month)/(0 month)* 100] and 
analyzed by one-way ANOVA (Tukey's multiple comparison test) E) Data of baseline 
performances of two groups of mice were gathered from figures A) and C) and differences 
between them were compared by unpaired T-test F) Diet comparison within each treatment 
was performed by collapsing the data displayed in figures B) and D) according to each 
experimental group (Sal, LPS-1 T and LPS-5T) and analyzed by unpaired T-test. Error bars 
represent standard errors. 
Anxiety-like behavior was also assessed in the elevated plus maze test. Figure 3 .15 
(A and C) displays the time that RD and HFD-fed mice spent in the open arm. In 
figure 3.15 (Band D) the time mice spent in the closed arm is shown. Assessment of 
both RD and HFD-fed mice revealed that single and repeated LPS injections did not 
induce or exacerbate anxiety-like behavior in these mice. 
Comparison between the two different diet-fed groups (RD and HFD) within same 
treatment indicated that long-term consumption of HFD did not induce anxiety-like 
behavior (figure 3.15 E and F). 
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Figure 3.15: Effects of LPS inflammatory challenge and high-fat diet on 
anxiety-like behavior in the elevated plus maze test: The proportion of time (5 min 
in total) that mice spent in open or closed ann of elevated plus maze apparatus was measured 
in seconds. Treatment comparison: Time that A) RD and C) HFD-fed mice spent in open 
ann, or B) RD and D) HFD in closed ann were analyzed by one-way OVA (Tukey's 
multiple comparison test). Diet comparison: Time mice spent in E) open arm or F) closed 
ann was compared between two diet-fed groups within same treatment and analyzed by 
unpaired T-te t. Error bars represent standard errors. 
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In order to assess the effects of high-fat diet and LPS treatment on depressive-like 
behavior, mice were subjected to forced swimming test. 
As it was described before, 5-times LPS-injected RD-fed mice displayed a tendency 
to struggle (figure 3.16 A) and swim (figure 3.16 B) less, whereas floating time 
tended to be increased ( figure 3 .16 C). Overall, these results suggest that repeated 
LPS challenges tended to induce depressive-like behavior in RD mice, but the results 
were not significant. 
As shown in figure 3.16 (D, E and F) neither high-fat diet nor single and repeated 
LPS inflammatory challenge altered the time that HFD-fed mice spent struggling, 
swimming and floating. 
Comparison between two diet-fed groups (figure 3.16 G, Hand I) and within each 
treatment suggested that HFD-fed mice showed a tendency to struggle less, swim 
more and spend less time floating. These data suggest that long-term high-fat diet 
consumption did not induce depressive-like behavior. 
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Figure 3.16: Effects of LPS inflammatory challenge and high-fat diet on 
depressive-like behavior in the forced swimming test: Treatment comparison: Time 
that A) RD and D) HFD-fed mice spent struggling; B) RD and E) HFD swimming and C) 
RD and F) HFD floating was measured in seconds and analyzed by one-way ANOV A 
(Tukey ' s multiple comparison test). Diet comparison: Time that mice spent G) struggling, 
H) swimming and I) floating was analyzed between RD and HFD-fed mice within the same 
treatment by unpaired T-test. Error bars represent standard errors. /\p<0.05 , /\/\p<0.01 vs . 
RD . 
The novelty suppressed feeding test is used to ascertain anxiety-like behavior in 
rodents. Mice are food-deprived for 16 hours and then exposed to a new environment 
with a food pallet placed in the centre of arena. Since mice are hungry but also afraid 
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of open areas, they have to overcome their fear to approach the open area in order to 
eat. The faster they do it, the less anxious they are. This anxiogenic environment 
tests the fear to approach the food pallet in the centre of arena in order to feed. Thus, 
latency to eat is the main measure taken to assess the anxiety. It represents the total 
time the animal spent in arena until the moment the mouse took the first bite of food 
pallet. Afterwards the mice are transported to their home cage and total food intake 
is measured for a certain period of time (5 minutes). The home cage is a familiar 
environment and therefore this second part of the experiment is used to determine 
mouse food intake in a non-stressful environment. 
As it may be observed in figure 3 .17 A and C, latency to eat was not affected by 
single and repeated LPS injections, suggesting that LPS challenge did not elicit 
anxiety-like behavior in RD and HFD-fed mice. 
Similarly, food intake in the home cage was not affected by single and repeated LPS 
injections in RD and HFD-fed mice (figure 3.17 Band D). 
Comparison between RD and HFD-fed mice within each treatment revealed that the 
latency to eat of the HFD group was significantly higher suggesting that these mice 
were anxious to approach to the food pallet (figure 3.17 E). _ 
The measurements of final food intake did not reveal significant difference between 
the RD and HFD groups. The food intake is the parameter that is used as verification 
that HFD-fed mice were in fact hungry, but were too anxious to approach to the food 
in open arena ( figure 3. I 7 F). 
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Figure 3.17: Effects of high-fat diet and LPS inflammatory challenge on 
anxiety-like behavior in the novelty suppressed feeding test: After sixteen hours 
fasting, mice were individually placed in a novel arena. Treatment comparison: Latency of 
A) RD and C) HFD-fed mice to take first bite of food pallet was measured in seconds. Food 
intake of B) RD and D) HFD-fed mice was measured in kcal/g. Data were analyzed by one-
way ANOVA fo llowed by Tukey's post-hoc test. Diet comparison : E) Latency to eat and F) 
food consumption were compared between two diet-fed groups and within each treatment by 
unpaired T-test. Error bars represent the standard errors . /\p<0.05, /\/\p<0.01 , /\/\/\p<0.001 vs. 
RD. 
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3.4.3 Evaluation of memory and cognition 
The prepulse inhibition test was used as an assessment of pre-attentive functioning in 
rodents [ 465, 466]. Evaluation of cognitive performance in this test is based on the 
animal's ability to focus its attention on most silent information and exclude the 
disturbing effects of loud noise in the background [ 467]. Animal inability to canalize 
the information properly from the surrounding noise is thought to be related to over-
activation of sensorimotor gating and cognitive defragmentation [ 468]. The prepulse 
inhibition test is an auditory test and its methodology is based on the principle that 
weak stimulus above background noise will reduce the magnitude of startle response 
in rodents and humans when it is followed with subsequent stronger sound stimulus. 
In this test a prepulse of 4, 8 and 16 dB above the background noise of 72 dB is 
presented prior to exposure to the stronger stimulus of 120 dB. Exposure to the 
prepulse stimuli prior to the stronger stimulus reduces the magnitude of the startle 
response. Therefore, it is expected that the percentage of inhibition of the startle 
response will be higher when the intensity of prepulse stimulus increases [469] . 
Previous studies have shown the relation between dopamine and its receptors in 
modulation of prepulse inhibition in rodents [3 81]. In particular, there is evidence 
suggesting that D 1 and D2 receptors may be involved in regulation of prepulse 
inhibition [3 81]. Stimulation of either D 1 or D2 receptors by their specific 
pharmacological agonist led to a reduction of prepulse inhibition in mice [ 470]. The 
percentage of startle response inhibition in the prepulse inhibition test has been 
related with the level of dopamine, as the dysregulation in DAT in mice led to an 
"overflow" of dopamine, which was associated with deficit in prepulse inhibition 
[380]. 
Mice of three genotypes (WT, Casp-1-/- and IL-1 ra-/-) were exposed to prepulse 
stimulus of 4, 8 and 16 dB above background noise of 72 dB (i.e. 76, 80 and 88 dB). 
In the figure 3 .18 (A, B and C) · is presented the percentage of inhibition of startle 
response of three genotypes .(WT, Casp-1-/- and IL-Ira-/-, respectively) in order to 
assess the effect of single and repeated LPS inflammatory challenges on cognitive 
funct.ion within each genotype. Data collected from prepulse inhibition test have 
indicated that single and repeated LPS iiiflammatory challenges did not decrease or 
additionally exacerbate the attentive function in all three genotypes (figure 3.18 A, B 
and C). 
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In figure 3 .18 (D, E and F) the percentages of inhibition of the startle responses 
among three different genotypes (WT, Casp-1-/- and IL-Ira-/-), within the same 
treated group, are presented in order to assess the role of IL-1 pathway in 
sensorimotor gating. Based on the results shown in figure 3 .18 (D, E and F), the 
percentages of inhibition of the startle response in IL-1 ra-/- mice were lower, but not 
significantly, than those observed in the control group (WT mice). Similarly, startle 
response inhibition in Casp-1-/- mice tended to be lower than in WT mice and 
reached significance in the saline-treated group (figure 3 .18 D). 
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Figure 3.18: Effect of LPS inflammatory challenge on startle response in the 
prepulse inhibition test: Mice were placed in prepulse inhibition apparatus and exposed 
to the pulse alone (120 dB) and prepulse stimuli that were 4, 8 and 16 dB above the 
background noise of 72 dB, as described in chapter 2. Treatment comparison: Effect of 
single and repeated LPS injections in A) WT, B) Casp-1-/- and C) IL-lra-/- mice on 
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magnitude of startle response inhibition was analyzed within each genotypes by one-way 
ANOVA (Tukey's multiple comparison test). Genotype comparison: Percentage of startle 
response inhibition in C) Saline, D) LPS-1 T and F) LPS-5T treated mice was compared 
among genotypes within each treatment and analyzed by one-way ANOVA (Tukey's 
multiple comparison test). Error bars represent standard errors. 1\/\p< 0.01 vs. WT. 
In order to assess the additional effects of high-fat diet consumption on memory and 
cognition capabilities in mice, two tests were performed: The Morris water maze and 
the prepulse inhibition test. 
In figure 3.19 (A and B) mice fed either RD or HFD were exposed to prepulse 
inhibition test in order to evaluate the possible exacerbation of single and repeated 
LPS inflammatory challenges on sensorimotor gating in mice fed a high-fat diet. 
Single or repeated LPS inflammatory challenges did not induce or exacerbate the 
attentive dysfunction in both RD and HFD-fed group of mice. 
In figure 3.19 (C, D and E) the effect of long-term exposure to a high-fat diet was 
assessed between RD and HFD groups within the same treatment. Comparison 
between the two diet-fed groups revealed that HFD-fed mice displayed cognitive 
decline that was similar in three treated groups. 
Prolonged high-fat diet consumption may lead to diet-induced obesity and alter the 
synaptic plasticity in CNS. As it was demonstrated, long-term consumption of high-
calorie food may reduce the availability of DAT in the striatum and consequently 
decrease the rate of dopamine reuptake [ 4 71]. Since it was shown that DAT 
knockout mice demonstrated cognitive deficit in the prepulse inhibition test [380], it 
is suggested that dopamine "overflow" may lead to cognitive deficit in HFD-fed 
mice. 
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Figure 3.19: Effects of long-term exposure to high-fat diet and LPS treatment 
on startle response in the prepulse inhibition test: Mice were placed in prepulse 
inhibition apparatus and exposed to the pulse alone (120 dB) and prepulse stimuli that were 
4, 8 and 16 dB above the background noise of 72 dB, as described in chapter 2. Treatment 
comparison: Effect of single and repeated LPS injections in A) RD and B) HFD-fed mice on 
magnitude of startle response inhibition was analyzed within each diet by one-way ANOV A 
(Tukey' s multiple comparison test). Diet comparison: Percentage of startle response 
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inhibition in C) Saline, D) LPS-1 T and E) LPS-ST treated mice was compared between RD 
and HFD-fed mice by unpaired T-test. Error bars represent standard errors. /\p<0.05, 
/\/\p<0.01 vs. RD. 
The Morris water maze test is a behavioral paradigm aimed to test the capability of 
rodents to learn to find a hidden (i.e. non-visible) platform that is situated 0.5 cm 
below the water surface in order to stop swimming. This learning process represent a 
form of spatial memory and it is considered to be dependent on the proper function 
of hippocampal-cortical pathways [ 472]. With regard to the dopamine system, it has 
been shown that the D 1 class of dopamine receptors D 1 and D5 are necessary 
regulators of L TP in the hippocampus and therefore associated with hippocampus-
mediated learning [473,474]. Long-term exposure to a high-fat diet in rats decreased 
the expression of Dl receptors in nucleus accumbens [475], suggesting that 
expression of this receptor could have been altered in the hippocampus. 
As it was described in detail in chapter 2, the water tank is divided into four 
quadrants and one of them is designated as the main quadrant where the platform is 
placed and kept throughout testing. Mice were trained daily over a period of four 
days and were given four trials per day in order to locate and memorize the position 
of the platform. On the fourth day after the fourth given trial, the platform was 
removed from the tank and the mice were given a fifth trial where the total number 
of visits to the quadrant and the exact location of hidden platform was recorded and 
used as an index of memory. 
As it is presented in the figure 3.20, single and/or repeated LPS injections did not 
alter the spatial memory of RD and HFD-fed mice since number of visits to the right 
quadrant (figure 3.20 A and C) and to the exact location of previously removed 
platform (figure 3.20 Band D) were not reduced. 
Comparison between two different diet-fed groups and within each treatment 
indicated that single LPS-injected HFD-fed mice showed a reduced number of visits 
to the right quadrant (figure 3.20 E) and to exact location of the removed platform 
( figure 3 .20 F). These data suggest that there was a tendency for HFD-fed mice to 
display spatial memory impairment. 
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Figure 3.20: Effects of high-fat diet and LPS inflammatory challenge on 
memory performance in the Morris water maze test: After four days of training 
mice' s ability to memorize the right location of hidden platform was tested in Morris water 
maze test Treatment comparison: Number of quadrant entry of A) RD and C) HFD-fed 
mice and target zone crossing of B) RD and D) HFD-fed mice were analyzed by one-way 
ANOVA (Tukey's multiple comparison test). Diet comparison: E) Number of quadrant entry 
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and F) target zone crossing were analyzed between two different diet-fed groups and within 
each treatment by unpaired T-test. Error bars represent standard errors. /\p<0.05 vs . RD. 
3.5 Discussion 
Motor disability in the form of reduced locomotor activity is a late onset symptom 
that occurs as a consequence of degenerated dopamine neurons. Loss of dopamine 
neurons leads to a depletion of dopamine in striatum resulting in loss of control over 
voluntary movements. For example, severe symptoms of motor disability in 
Parkinson's disease patients occurs when 80% of striatal dopamine innervations are 
lost; this is mostly observed in old age. In a mouse model these symptoms vary in 
dependence of dose and routes of exposure to LPS. Intranigral injections or chronic 
infusion of LPS into substantia nigra has been shown to cause very rapid and 
progressive loss of dopamine neurons, up to 60% [476, 477]. In mouse study, one 
intraperitoneal injection of LPS (5 mg/kg) in male mice induced loss of 23% of 
dopamine neurons after seven months [ 109]. In a similar experiment by the same 
research team, five monthly injections of LPS (5 mg/kg, i.p.) in female mice induced 
depletion of 3 7% in dopamine neurons after nine months, which was sufficient to 
reduce mice coordination in rotarod test after seven months and lately locomotor 
activity in the open-field test [376]. Female mice were shown to be more resilient to 
LPS inflammatory challenge than male mice, and therefore four to five monthly 
doses of LPS (5 mg/kg) were needed to produce similar progressive loss of 
dopamine neurons [376]. As it was previously described in chapter 3 .1, 
neuroinflammation may also lead to cognitive/memory declines and 
anxiety/depressive-like behavior. Therefore, one of the aims shown in this chapter 
was to assess the three behavioral disorders (motor, memory/cognitive decline and 
anxiety/depressive behavior), and their possible connection with impaired 
nigrostriatal function. 
AIM 1: Long-term effect of systemic LPS challenge on behavioral outcomes, 
exerted through IL-1 signaling pathway. 
Major differences in behavioral outcomes were observed among the three genotypes 
(WT, Casp-1-/- and IL-Ira-/-): 
• Casp-1-/- mice showed increased baseline locomotor activity in the open-
field test and these mice remained hyperactive after nine months from 
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rece1vmg first saline/LPS injection. Although Casp-1-/- mice had similar 
baseline coordinative abilities as WT mice, there was a trend for these mice 
to have lower ability to keep their balance on rotarod apparatus after nine 
months. However, this was only a trend and Casp-1-/- mice did not show 
signs of akinesia, suggesting that the time-dependent decrease in coordinative 
abilities was not related with the depletion of dopamine. Casp-1-/- mice 
showed a time-dependent increase in anxiety-like behavior in the open-field 
test, which was not reproduced in the elevated plus maze test. According to 
the results obtained from the forced swimming test, Casp-1-/- mice did not 
show depressive-like behavior. The results from the prepulse inhibition test 
indicated that Casp-1-/- mice had impaired cognitive function. 
• IL-lra-/- mice showed better baseline coordinative skills on the rotarod 
apparatus than WT mice but initial locomotor activity in the open-field test 
was lower. Nine months after receiving the first saline/LPS injection, IL-lra-
/- mice showed a time-dependent decrease in both locomotor activities and 
coordinative skills, but did not show signs of akinesia. The results from 
elevated plus maze and open-field test (CD/TD) indicated that IL-lra-/- mice 
showed initial and time-dependent increases in anxiety-like behavior, but did 
-
not display signs of depressive-like behavior in the forced swimming test. 
The results from the prepulse inhibition test indicated that there was not 
significant decline in cognitive function. 
Effects of single and repeated LPS injections on behavioral outcomes were modest 
or undetectable. 
• Neither single nor repeated LPS injections induced or significantly 
· exacerbated the locomotor and coordinative skills in WT, Casp-1-/- and IL-
.lra-/- mice. There was a trend for five monthly LPS-injected WT and IL-lra-
/- mice to have lower ability to adjust their steps (forelimb akinesia). LPS 
treatment did not induce or exacerbate anxiety-like behavior of the three 
genotypes either in the open-field test (CD/TD) or in the elevated plus maze 
test. Five monthly LPS injections tended to induce depressive-like behavior 
in WT mice, whereas LPS effect was not observed in Casp-1-/- and IL-1-ra -
/- mice. Results obtained from the prepulse inhibition test showed that single 
117 
and repeated LPS injections did not induce or exacerbate the cognitive 
impairment in the three genotypes. 
1) Long-term effect of single and repeated LPS inflammatory challenges on 
locomotor abilities in mice. 
Mice of three different genotypes (WT, Casp-1-/- and IL-lra-/-) were used to 
evaluate the role of IL-1 on locomotor activity. Initial exploratory activities were 
significantly different among the three genotypes in the open-field test. Casp-1-/-
mice had higher locomotor activity in open-field arena and conversely, IL-lra-/-
mice were the least active group. These observations are in the agreement with the 
previous study where systemic IL-1 ~ administration in mice reduced their locomotor 
activities [ 4 78]. In contrast, mice lacking IL-lRl -/- signalling displayed increased 
locomotor activities [ 4 79] . Collectively, these observations suggest that motor 
activities in IL-lra-/- and Casp-1-/- mice are inversely related with IL-1 ~ signalling 
pathway. 
The effect of single and repeated LPS inflammatory challenges on locomotor activity 
in the open-field test was then monitored nine months after the first saline/LPS 
injection. Direct comparison within each genotype and treatment indicated that 
locomotor activity in IL-lra-/- mice significantly decreased after nine months 
regardless of treatment, while activity in WT and Casp-1-/- mice remained relatively 
unchanged. Percentages of differences in locomotor activity calculated between 0 
and 9 months revealed that single and repeated LPS injections did not reduce the 
motor performance in any of the three genotypes. As it was shown previously that 
five LPS injections in female WT mice reduced locomotor activity after nine months 
[376] , similar results could not be observed with single or repeated LPS injections. 
In another similar experiment conducted in two and half months old rats, single 
systemic LPS (5 mg/kg, i.p.) injection reduced locomotor activity in the open-field 
arena after seven days, but further exacerbation in motor hypoactivity was not 
observed after ten months [ 403]. The comparison among the three different 
genotypes and within the same treatment indicated that the decrease in locomotor 
activity in IL-lra-/- mice was higher than in WT and Casp-1-/- mice. Long-term 
reduction in locomotor activity of IL-lra-/- mice could be attributed to the excess of 
IL-1 ~ signaling in the brain, as it was shown that in rats with chronic over-
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expression of IL-lf3 by the adenoviral-mediated gene in the brain, open-field activity 
decreased [ 480]. Overall, it might be suggested that prolonged central rather than 
peripheral activation of IL-1 f3 signaling may produce more significant decline in a 
motor activities. 
Motor coordination was further evaluated in the rotarod test. Baseline assessment of 
coordination of all three genotypes on the rotating drum showed that IL-lra-/- mice 
had better coordinative skills than WT mice. Evaluation of rotarod performance over 
a period of nine months indicated that coordination of all three genotypes decreased 
and it was not further exacerbated by the LPS treatment. Age related decline in 
rotarod performance in WT (saline) control group has been observed in other long-
term studies even after eight months [ 481]. Comparison among the three genotypes 
and within same treatment showed that decrease in motor balance was pronounced in 
IL-Ira-/- mice in comparison to WT mice. Since chronic over-expression of IL-lf3 
by the adenoviral-mediated gene in rat brains decreased locomotor activity in the 
open-field test [ 480], similarly it could be assumed that central overstimulation of 
IL-1 f3 signaling in IL- lra-/- mice led to decreased coordination. 
Forelimb akinesia (loss or impairment of voluntary movements) 1s one of the 
-parameters used to assess dysregulation of the dopamine system. It has been 
demonstrated that intranigral injection of LPS in rats produced forelimb akinesia 
[ 482]. In that regard, single and repeated LPS injections tended to reduce the number 
of adjusted steps in WT mice. Non-significant decrease has been observed in five 
LPS-injected IL-lra-/- mice, while single and repeated LPS injections did not alter 
ability of Casp-1-/- mice to adjust steps. Comparison among genotypes revealed that 
the ability of Casp-1-/- and IL-lra-/- mice was significantly better than in WT mice, 
which could have been due to the strain differences. Collectively, data suggest that 
repeated LPS injections tend to induce ·decline over voluntary movements in WT and 
IL-lra-/- mice, which could be related to IL-lf3 signaling pathways, since Casp-1-/-
mice were protected against LPS inflammatory challenge. 
Overall, the effect of single and repeated LPS injections on locomotor impairment in 
all three genotypes was modest or undetectable. Although it was previously shown 
that five LPS injections (i.p.) induced reduction in locomotor and coordinative 
behavior in female mice over a period of 7 to 9 months [376], in the current study 
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neither single nor repeated LPS injections produced similar results in male mice. 
Significant time-dependent reduction of the locomotor ability and coordinative skills 
in IL-1 ra-/- mice could have been attributed to a decreased level of dopamine and/or 
dopaminergic neurons. 
2) Long-term effect of single and repeated LPS iriflammatory challenges zn 
anxiety/depressive-like behavior. 
One of the parameters used in the assessment of anxiety-like behavior in mice is the 
ratio of central to total distance travelled in open-field arena [ 483]. Mice are by 
nature afraid of open areas and mostly prefer darker and enclosed environments. 
Therefore, the central area of the open-field arena may evoke anxiogenic behavior in 
rodents. Behavioral evaluation of the three genotypes at the baseline showed that IL-
lra-/- mice were prominently anxious in comparison to WT and Casp-1-/- mice. This 
anxiogenic behavior in IL-Ira-/- mice could have been related to the over-activated 
IL-1 signaling as it was shown that i.c.v administration of IL-1~ induces anxiety-like 
behavior [483]. In a time frame of Oto 9 months both Casp-1-/- and IL-Ira-/- mice 
became significantly more anxious and this behavior was not exacerbated by single 
or repeated LPS treatments. In regard to a caspase-1 signaling, inhibition of caspase-
1 activity by the appropriate inhibitor (z-YV AD-FMK) has been shown to increase 
the NMDA receptor-mediated current in hippocampa1 slices in vitro [ 484, 485]. In 
connection with the previous statement, inhibition of NMDA signaling in dorsal 
hippocampus induced anxiolytic-like behavior in mice [ 486], suggesting that time-
related increase in activity of NMDA signaling in Casp-1-/- mice could have resulted 
in anxiety-like behavior in the open-field test. On the other hand, WT mice did not 
show any signs of anxiety-like behavior after nine months, nor it was altered by 
single and repeated LPS injections. 
Similar to the open-field test, the aim of the elevated plus maze paradigm is to 
evaluate the anxiety-like behavior in rodents. In this test mice ' s innate fear for the 
open, unprotected and brightly illuminated arm of the maze is challenged against 
their desire to explore a new environment. Therefore, more anxious animals tend to 
spend more time in the closed am1. Acute LPS-induced synthesis and secretion of 
IL-1 ~ has been suggested to be associated with the development of anxiety-like 
behavior in rodents [ 487]. In the present study, the long-term effect of single and 
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repeated LPS injections was not observed in any of the three genotypes . Comparison 
among genotypes indicated that IL-Ira-/- mice were the most anxious group of mice 
as they spent the least amount of time in the open-arm and consequently more time 
in the closed arm. On the other hand, Casp-1-/- mice seemed to display less anxious 
behavior, since these animals tended to spend more time in the open and 
consequently less time in closed arm in comparison to WT mice. The involvement of 
IL-1 in anxiety-like behavior is partially in agreement with previous studies where 
IL-IRI-/- deficient mice, were shown to display anxiolytic behavior in the elevated 
plus maze test [479]. 
The forced swimming test is used to assess depressive-like a behavior in rodents. 
The proportions of time that each animal spends in an immobile state (floating) or 
otherwise not struggling are used as indicators of depressive-like of behavior. 
Peripheral administration of LPS in mice has been shown to increase the duration of 
immobility in the forced swimming test [ 488]. The role of IL-1 in depression was 
demonstrated on an example of transgenic mice with deletion in IL-lRl, where 
chronic mild stress failed to induce depressive-like behavior in these mice [ 489]. 
Repeated LPS injections in WT mice seem to partially induce depressive-like 
behavior since there was a trend for these mice to struggle less and float more. In 
contrast, single and repeated LPS injections tended to even increase swimming and 
reduce floating in Casp-1-/- mice, suggesting that IL-1~-mediated inflammation was 
necessary to induce depressive-like behavior. These results are in agreement with 
recent published data in mice where it has been shown that the caspase-1 converting 
enzyme was necessary for the development of depressive-like of behavior following 
administration of LPS (i.c.v.) in mice [490]. Repeated LPS injections in IL-lra-/-
mice did not alter the time mice spent struggling or floating. Comparison among the 
three genotypes indicated that the only significant difference was that IL-lra-/- mice 
spent significantly less time struggling than WT mice. Since the final outcome in IL-
lra-/- mice was not accompanied by increased immobility in the forced swimming 
test, it might be concluded that there was no significant difference among the three 
genotypes with regards to changes in depressive-like behavior. 
Overall, observations suggest that IL-lra-/- mice have shown baseline and time-
dependent increases in anxiety-like behavior in open-field and elevated plus maze 
test that was not further exacerbated by single and repeated LPS injections. These 
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data imply that overstimulation of IL-1 might have contributed to anxiety-like 
behavior. In support of the previous statement, it was previously shown that i.c.v 
administration of IL-1~ caused anxiety-like behavior in mice measured in the open-
field and elevated plus maze test [ 483] . In particular, anxiety-like behavior caused by 
IL-1 ~ was associated with abrogated sensitivity of cannabinoid CB 1 receptors that 
control GABA synapses in the striatum [ 483]. On the other hand, time-dependent 
increases in anxiety-like behavior were observed in Casp-1-/- mice, despite 
tendencies to show anxiolytic behavior in elevated plus maze test. More studies are 
needed to clarify if Casp-1-/- mice become anxious in a time-dependent manner. 
3) Long-term effect of single and repeated LPS inflammatory challenges on cognitive 
function. 
It has been hypothesized that perturbations in the level of dopamine ( excess or 
deficit) may impair cognitive function [ 491, 492]. The role of IL-1 signaling in 
attentive cognitive performance was assessed by prepulse inhibition test in three 
genotypes (WT, Casp-1-/- and IL-Ira-/-) of mice. Single and repeated LPS injections 
did not alter cognitive function in all three genotypes. It has been demonstrated that 
acute LPS injection in mice reduced prepulse inhibition startle response 24 hours 
post-injection [ 493]. Similarly, in another study acute LPS injections (i.p.) reduced 
the prepulse inhibition startle response in a dose-dependent manner [ 494]. It is 
plausible that the long-lasting effect of LPS on prepulse inhibition startle response 
was not longer present. Comparison among genotypes indicated that Casp-1-/- mice 
had lower startle response in comparison to WT mice and this was in particular 
significant in saline-treated group. As it was described earlier, inhibition of caspase-
1 activity by the appropriate inhibitor (z-YV AD-FMK) increased the NMDA 
receptor-mediated current [ 484, 485]. Activation of NMDA receptors in primary 
hippocampal cultures isolated from fetal Wistar rats are shown to recruit more D 1 
receptors to the plasma membrane [495] . On the other hand, stimulation of DI 
receptors by specific agonists disrupted the prepulse inhibition startle response in 
C57bl/6 mice [3 81]. Collectively, these observations suggest that possible over-
activation of D 1 receptors within the hippocampus of Casp-1-/- mice could have 
resulted in reduced inhibition of the prepulse inhibition startle response. 
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Data from the current study suggest that cognitive function in Casp-1-/- mice was 
partially affected by altered dopamine receptor signaling. On the other hand, no 
significant alterations have been induced by LPS inflammatory challenges. There 
was no similar significant impairment in cognitive function of IL-lra-/- mice. 
AIM 2: Long-term effects of high-fat diet consumption and systemic LPS 
challenge on behavioral outcomes. 
Major differences in behavioral outcomes have been observed between RD and 
HFD-fed mice, whereas effects of single and repeated LPS injections were modest or 
undetectable: 
• The long-term high-fat diet feeding in WT mice did not induce locomotor 
disabilities, nor was it exacerbated with single or repeated LPS injections. On 
the other hand, coordinative skills in HFD mice declined with time, but this 
decrease was not exacerbated by LPS treatments. HFD-fed mice showed 
signs of akinesia, bradykinesia and dyskinesia that were not exacerbated by 
single and/or multiple LPS injections. Despite the decline in coordinative 
abilities observed in rotarod test, HFD mice did not respond to the L-
DOP A/carbidopa test. HFD-fed mice did not show a_nxiety-like behavior in 
open-field and elevated plus maze test, but they showed anxiety after 
overnight fasting in the novelty suppressed feeding test that was not 
exacerbated with LPS treatment. No effect of high-fat diet or LPS treatment 
on depressive-like behavior was observed in the forced swimming test. The 
results obtained from prepulse inhibition test indicated that overall saline and 
LPS-injected HFD mice showed cognitive impairment, and tended to have 
memory loss in the Morris water maze test. 
1) Long-term effect of single and repeated LPS inflammatory challenges and high-fat 
diet consumption on locomotor abilities in mice. 
Locomotor activity of mice fed with either regular or high-fat diet and subjected to 
treatments (Sal, LPS-1 T and LPS-5T) was tested in the open-field test as an 
indication of possible motor dysfunction due to dysregulation of the nigrostriatal 
dopamine system. 
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Initial assessment of voluntary movements between HFD and RD-fed mice showed 
no difference. Similarly, nine months after the first saline/LPS injection, locomotor 
activity was not significantly changed within each treated group (Sal, LPS-1 T and 
LPS-5T). The effect of single and repeated LPS injections within each diet-fed group 
(RD or HFD) was modest or undetectabl. On the other hand, it was previously 
described that locomotor impairment observed after nine months in female mice was 
induced with five monthly LPS (i.p.) injections [376]. Similar experiment conducted 
in male rats showed that single systemic LPS (5 mg/kg, i.p.) injection reduced 
locomotor activity in the open-field arena after seven days, but further exacerbation 
in motor hypoactivity was not observed after ten months [ 403]. Comparison between 
RD and HFD-fed mice and within same treatment indicated that there was no 
significant difference between locomotor activities of these mice. Therefore, these 
data suggest that high-fat diet and additional LPS treatment did not decrease motor 
activity. 
Mice coordination has been tested in the rotarod test and as it was described 
previously, this test is able to detect an imbalance in the dopamine system [376]. The 
ability of RD or HFD-fed mice to keep their balance on the rotarod apparatus during 
baseline was not different between the two groups. Nine months after the first 
saline/LPS injection, the motor coordination in both RD and HFD mice was 
impaired in comparison to their individual baseline abilities . Reduced motor 
performance in RD mice, which was also observed in saline-treated mice is probably 
a consequence of the aging of the animal as it has been shown that coordination 
ability of C57bl/6 mice declines with the passage of time [ 496]. The evaluation of 
LPS effect within each diet-fed group showed that decline in rotarod performance 
was not further affected by single or repeated LPS injections. Even though previous 
studies have reported the first significant decline in the rotarod test after 7 months 
post-injection in five LPS-injected female mice [376], in the present studies similar 
results were not shown after nine months. The present results appear to be in 
agreement with the recent study in which locomotor disabilities were not 
exacerbated after 10 months after the first systemic LPS injection [403]. The direct 
comparison between RD and HFD-fed mice within each treatment revealed that 
reduced coordination in HFD-fed mice was significantly more pronounced. These 
observations may suggest that this significant decrease in the coordination of HFD-
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fed mice may have resulted from a decline in the striatal dopamine level or loss of 
dopamine neurons. Although the HFD group was fed a fat enriched diet for a several 
months, these mice did not gain a significant amount of body weight (chapter 4). 
Thus, decreased rotarod performance in HFD mice was not due to increased body 
weight, which was described as one of the elements that might reduce the balance of 
mice on rotarod apparatus [ 497]. However, as it will be described in chapter 4, these 
mice were metabolically obese. 
Consumption of a high-fat diet did not impair the muscle strength in mice as it was 
demonstrated with the grid test. Therefore, coordinative disabilities observed in 
HFD-fed mice could not be attributed to the possible impairment of neuromuscular 
function. 
Twelve months after first saline/LPS injection mice were subjected to L-
DOP A/carbidopa test with the aim of evaluating if the reduction in motor 
coordination in the rotarod could be attributed to the decrease of dopamine in the 
nigrostriatal circuit. Results obtained from RD-fed mice showed that single and 5-
times LPS-injected mice positively responded to the L-DOP A/carbidopa treatment, 
which suggests that loss of dopamine overall might have been modest. On the other 
hand, reduced, but not significantly, motor abilities of single and repeated LPS-
inj ected HFD-fed mice were not improved with L-DOPA/carbidopa treatment. One 
of the possible explanations is the fact that HFD-fed mice have slower clearance of 
dopamine from synaptic clefts due to the impaired function of DAT [471]. This 
suggests that HFD-fed mice had systemic "overflow" of dopamine and additional 
supplementation in the form of L-DOP A/carbidopa did not improve the motor 
impairment that was previously described in these mice. 
The pole test, as described previously, is used in an assessment of bradykinesia 
(slowness of movement), which is also one of the symptoms related with 
nigrostriatal dysfunction [388]. Two parameters are used in this test: a) time to tum 
around and b) time to climb down the pole. Animals that show signs of bradykinesia 
need more time to turn around and climb down the pole. The single and repeated 
LPS injections slightly increased the time of RD and HFD-fed mice to tum around 
with no obvious effect on mice's abilities to climb down the pole. Comparison 
between RD and HFD-fed mice showed that HFD-fed mice had the tendency to take 
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more time to tum around and significantly more time to climb down the pole. This 
data could be supported with the behavioral experiments performed on DAT-/- mice 
that were shown to display a motor deficit in the pole test, which was related to the 
hyperdopaminergic tone in dorsolateral neostriatum [ 498]. Therefore this statement 
might imply that reduced DAT function in HFD-fed mice could have resulted in 
symptoms of bradykinesia. 
The stepping test was used to assess akinesia, symptom that is characterized by the 
impairment to initiate steps and it was related with the loss of positive TH-neurons 
[ 457]. Single and five monthly LPS injections tended to decrease the number of 
adjusted steps in RD-fed mice, whereas LPS treatment did not produce any decrease 
in HFD-fed mice. Comparison between RD and HFD-fed mice indicated that HFD-
fed mice had a significantly fewer number of adjusted steps. For example, akinesia 
has been pharmacologicaly induced in mice by inhibition of D2 receptors [ 499]. 
Since high-fat diet feeding and obesity in mice was associated with decreased 
density of D2 receptors [500], lower availability of D2 receptors in HFD-fed mice 
could have induced symptoms of akinesia. 
The hind limb clasping test has been used for the evaluation of dyskinesia (presence 
of involuntary movement and diminished voluntary movements). Mice were scored 
based on the severity of the condition as it was described in detail in chapter 2. 
Although single and repeated LPS injections did not impair the symptoms in RD and 
HFD-fed mice, the comparison between the two groups indicated that HFD-fed mice 
had shown significant neurological/motor impairment. Clasping behavior has been 
observed in DAT -/- mice [501] implying that the motor impairments observed in 
HFD-fed mice might be related with a reduced level of dopamine transporters. 
Collectively, these data suggest that LPS treatment induced modest or undetectable 
effects in both RD and HFD-fed mice. Locomotor and coordinative impairments 
were more emphasized between RD and HFD-fed mice and might have been related 
with decreased striatal dopamine and/or impaired dopamine neurotransmission. 
Single and repeated LPS inflammatory challenge was not exacerbated by high-fat 
diet consumption. 
2) Long-term effect of single and rep eated LPS inflammatory challenges and high-fat 
diet consumption in anxiety/depressive-like behavior. 
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Anxiety-like behavior in RD and HFD-fed mice was evaluated in the open-field test. 
The ratio of central over total distance (CD/TD) was used as an indicator of animal 
anxiety towards the open illuminated environment. Baseline comparison between 
RD and HFD-fed mice suggests that there was no difference between these two 
groups. Nine months after the first saline/LPS injection, there was no significant 
decline within each treated group (Sal, LPS-1 T and LPS-5T) of RD and HFD-fed 
mice. Similarly, no effects of single and repeated LPS injections within each diet-fed 
group were observed. Finally, direct comparison between RD and HFD-fed mice did 
not reveal any significant differences. Although, high-fat diet consumption in rodents 
has been linked to anxiety-like behavior [502] , in the current test results did not 
indicate that HFD-fed mice suffered from increased anxiety-like behavior. 
The elevated plus maze test was used to assess the effect of long-term high-fat diet 
consumption and LPS inflammatory challenge on anxiety-like behavior. It has been 
demonstrated that high-fat diet consumption induced anxiety-like behavior, which 
was observed by the reduced time that rats spent in the open arm of elevated plus 
maze [503]. There were tendencies of single and repeated LPS-injected mice, fed 
either a RD or HFD to spend less time in open arms of the maze, whereas no 
particular LPS effect was observed on time mice spent in c!osed arm of the maze. 
Comparison between RD and HFD mice suggested that high-fat diet did not induce 
anxiety-like a behavior in mice. 
The third test used in the assessment of anxiety-like behavior in mice was novelty-
suppressed feeding test. The role of the dopamine system in regulating anxiety has 
been previously described in chapter 3 .1.2. Briefly, activation of glutamate releasing 
neurons in the limbic system by CRH leads to anxiety-like behavior, whereas release 
of dopamine in mid-brain induced by CRH evokes less fearful behavior [ 433]. As it 
was de.scribed in chapter 3 .4.2, the novelty suppressed feeding test is a behavioral 
paradigm where a food-deprived animal has to overcome its natural fear of a novel 
environment and approach to food pallet in the centre of the arena in order to feed. 
The results obtained from the novelty suppressed feeding test indicated that LPS 
treatment did not produce or exacerbate anxiety-like behavior in RD and HFD-fed 
mice. The elapsed time that mice took to approach to the food pallet in centre of 
arena indicated that HFD-fed mice were significantly more anxious than RD mice. In 
order to understand if this delayed latency for HFD-fed mice to eat was due to the 
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anxiety and not due to the factor of being less hungry, mice were individually placed 
in their original home cages and the amount of consumed food was recorder over the 
next 5 minutes. The results obtained from both RD and HFD groups showed that 
mice from both groups consumed a similar amount of food, suggesting that HFD-fed 
mice were indeed more anxious than RD mice. 
As it may be concluded, anxiety-like behavior in HFD-fed mice was only confirmed 
in the novelty suppressed feeding test, whereas analysis of the results obtained from 
open-field and elevated plus maze suggested that HFD-fed mice did not show 
anxiety-like behavior. The explanation for this non-consolidating data has been 
addressed with the possibility that 16 hours of fasting in HFD mice could have 
evoked heightened anxiety in these mice. It was observed that 24 hours of short-term 
fasting, which is considered as a physiological stressor, increased anxiety in HFD-
fed mice, as their burrowing increased in comparison to when these mice were in a 
fed state [504]. Burrowing resembles digging or nesting in rodents and reflects 
depressive/anxiety-like behavior in rodents [505]. Similarly, short-term exposure to 
HFD increased anxiety in mice, as observed by increased burrowing behavior [502]. 
It has been demonstrated that 16 hours overnight fasting increased the plasma level 
of corticosterone by 2-fold in WT mice [506] . Moreover, it has been shown that six 
weeks of HFD consumption in mice resulted in increased anxiety-like behavior and 
HPA hypersensitivity to stress [507]. Thus there is a possibility that food deprivation 
increased the anxiety behavior in HFD-fed mice that could not have been detected in 
the previous two behavioral tests. 
High-fat diet consumption has been shown to promote depressive-like behavior in 
rodents [508]. Depressive-like behavior was assessed in the forced-swimming test. 
There was a tendency for 5-times LPS-injected RD mice to struggle less and float 
more, suggesting that repeated LPS challenges partially induced depressive-like 
behavior. On the other hand, the effect of single and repeated LPS inflammatory 
challenges did not induce or exacerbate the depressive-like behavior in HFD-fed 
mice. The comparison between RD and HFD-fed mice showed that HFD-fed mice 
tended to struggle less, swim more and float less. These data suggest that HFD-fed 
mice did not show signs of depressive behavior. 
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Overall, data suggests that LPS treatment did not induce or exacerbate 
anxiety/depressive-like behavior in either RD or HFD-fed mice. The only significant 
effect of HFD that has been observed was in the anxiety-like behavior in novelty 
suppressed feeding test, which might have been driven by stress due to overnight 
fasting. 
3) Long-term effect of single and repeated LPS inflammatory challenges and high-fat 
diet consumption on memory and cognition. 
The possible role of LPS inflammatory challenge and high-fat diet consumption on 
cognitive impairment in mice was assessed with prepulse inhibition test. As it was 
described before in chapter 3 .4.3 cognitive functions are processed by the 
hippocampus. Single and repeated LPS injections did not alter the cognitive 
functions in either RD or HFD-fed mice. The detailed comparison between the two 
groups, indicated that HFD-fed mice showed a certain degree of cognitive 
impairment in all three treated groups (Sal, LPS-1 T and LPS-5T) based on lower 
inhibition of the startle response. As it was previously described in the chapter 3.4.3, 
the deletion of DAT in mice is related to the deficit in the prepulse inhibition test 
[380]. Since it has been demonstrated that chronic high-fat diet consumption reduced 
the availability of DAT in striatum [380], this suggests that reduced dopamine 
reuptake may lead to the cognitive deficit observed in HFD-fed mice [ 4 71]. 
The role of proinflammatory cytokines in hippocampal-dependent memory was 
described in an animal model [509-511]. Acute peripheral administration of LPS in 
rodents induced the expression of IL-1 ~ in the brain, which was associated with 
spatial memory impairment in a water maze [509-511]. Memory impairment in the 
current study was assessed in the Morris water maze test. As it was described before, 
mice were trained during four days to allow them to memorize the position of the 
submerged platform (0.5 cm from water surface) in order to stop swimming and to 
escape from the water. On the forth day, the platform was removed from the water 
tank and the number of visits to the right quadrant and exact position (target 
crossing) of the platform were used . as parameters for assessment of their memory 
capabilities. The effect of single and repeated LPS injections on memory functions 
was not observed in HFD-fed mice, while only modest decline in spatial memory 
was noticed in 5-times LPS-injected mice fed a RD. It has been demonstrated that 
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sustained express10n of IL-1 ~ in hippocampus of IL-1 ~ (XAT) transgenic mice 
impaired spatial memory of mice in Morris water maze test [512], which suggests 
that hippocampal levels of IL-1 ~ after repeated LPS injections were not sufficient to 
induce significant memory decline in the current study. On the other hand, there was 
tendency for the HFD-fed mice to have fewer visits to the quadrant and exact 
location of the removed platform. It is suggested that a high-fat diet induces chronic 
neuroinflammation in the brain that may constitute the link with memory impairment 
[446]. In particular, levels of proinflammatory cytokines such as TNF-a and IL-6 
were found elevated in the cortex of HFD-fed mice [446] . Moreover, recent studies 
have associated the desensitization of protein kinase B (Akt) signaling pathway that 
is coupled to leptin receptor in the hippocampus of HFD-fed mice to spatial memory 
impairment [513] , emphasizing the important role of leptin signaling integrity in the 
brain. Cognitive decline in HFD-fed mice was also attributed to the desensitization 
of NMDA receptors in the hippocampus and it was also observed that this process 
was compatible with the development of leptin resistance [ 514]. On the other hand, 
insulin resistance in HFD-fed mice decreased the release of dopamine and its 
clearance from synaptic clefts [ 12]. As it was reported that insulin resistance 
contributes to cognitive decline [ 448], this might explain a possible connection 
between dopamine signaling and insulin resistance-induced cognitive decline. In 
regards to the role of the dopamine system in memory function, it was previously 
described ( chapter 3 .4.3) that D 1 receptors are associated with hippocampus-
mediated learning. Long-term exposure to palatable food in rats reduced the 
expression of the DI receptor in nucleus accumbens [475] suggesting that similar 
alteration in DI expression could have occurred in the hippocampus. 
These observations suggest that high-fat diet consumption partially induced memory 
impainnent through the impairment in neurotransimision in the hippocampus, which 
could have been related with leptin resistance and possibly to down-regulation of D 1 
receptor expression. Cognitive impairments induced by long-term high-fat diet 
consumption could have been related with lower activity of DAT. 
Conclusions: 
AIM 1: Long-term effect of systemic LPS challenge on behavioral outcomes, 
exerted through the IL-1 pathway. 
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- The long-term effects of single and/or repeated LPS challenges modulating the 
behavior of the three mouse genotypes (WT, Casp-1-/- and IL-lra-/-) were modest or 
non-detectable. 
- Significant differences in behavioral outcomes were observed among the three 
genotypes. Genotype effect was observed in the following parameters: 
• IL-lra-/- mice showed a time-dependent reduction in locomotor activities in 
the open-field test and coordinative abilities in the rotarod test. Time-
dependent increase in anxiety-like behavior was observed in the open-field 
and later in the elevated plus maze test. IL-lra-/- mice did not display 
cognitive impairment. 
• Casp-1-/- mice had preserved locomotor activity but showed tendencies 
towards decreased coordinative abilities in the rotarod test. Casp-1-/- mice 
demonstrated anxiety-like behavior in open-field test, but also tended to show 
anxiolytic behavior in the elevated plus maze test by the end of the in vivo 
study. Moreover, Casp-1-/- mice displayed altered cognitive function in the 
prepulse inhibition test. 
AIM 2: Long-term effects of high-fat diet consumption and systemic LPS 
challenge on behavioral outcomes. 
- Long-term high-fat diet consumption did not exacerbate LPS effect on behavioral 
outcomes. 
- Significant differences in behavioral outcomes were observed between two diet-fed 
groups of mice. Diet effect was observed in the following parameters: 
• · High-fat diet-fed mice demonstrated impaired coordinative motor ability in 
Jhe rotarod test, but not locomotor activities in the open-field test. HFD-fed 
. mice showed symptoms of akinesia, bradykinesia and dyskinesia. 
• . HFD-fed mice showed sign or anxiety-like behavior in the novelty 
suppressed feeding test, possibly induced by overnight fasting. 
• High-fed mice showed impairment in cognitive function and tended to have 
reduced memory function. 
131 
132 
4. Effect of peripheral inflammatory 
challenge and high-fat diet on metabolic 
outcomes. 
4.1 Introduction 
Metabolic perturbations such as type-2 diabetes, insulin resistance, glucose 
intolerance and leptin resistance may alter the proper function of the dopamine 
system ( chapter 1.11) and possibly be related to some of the behavioral outcomes 
that have been described in chapter 3. 
As it was described before, single systemic LPS injection in male mice caused 
significant and delayed loss of dopamine neurons after seven months [376]. The 
intraperitoneal LPS injection induced activation of the innate immune system and 
concomitant release of proinflammatory cytokines such as IL-1 and TNF-a in the 
periphery and within the brain [3]. It has been shown that increased serum level of 
IL-1 induced transient diabetes in rats [515] and TNF-a has been linked with insulin 
resistance in obese mice [ 516]. 
According to WHO, the prevalence of obesity has doubled from 1980 to 2008 [318] . 
Obesity is considered as a state of low-grade chronic inflammation since food high 
in fat and sugar can act as an inflammatory component triggering the activation of 
TLR4 in innate immune cells [6]. With the correspondent activation of the innate 
immune- system, it is proposed that there might be a connection between obesity 
induced metabolic disorders, inflammation and neurodegenerative diseases [7-9]. 
High-fat consumption is related with weight gain, which further contributes to the 
development of type-2 diabetes, glucose intolerance, leptin and insulin resistance as 
described in chapter 1.11 . Thus, obesity can trigger chronic inflammatory and 
metabolic imbalances affecting dopaminergic neurotransmission. 
For example, it has been shown that dopamine content was reduced in the 
nigrostriatal system of diabetic rats [ 1 OJ . In human studies, diabetes has been shown 
to augment motor impairment in Parkinson's disease patients [ 51 7]. Development of 
insulin resistance in high-fat diet-fed rats reduced dopamine release and its reuptake 
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in the synaptic vesicles [12]. In regards to leptin, leptin resistance may not influence 
the basal level of dopamine, but it can reduce the total capacity of dopamine cells to 
secret dopamine [ 11]. In fact, it has been shown that leptin regulates the expression 
of dopamine transporters [13]. 
Since obesity is considered as a low-grade chronic inflammatory state, the additional 
implementation of single and/or repeated LPS injections as peripheral inflammatory 
challenge was hypothesized to exacerbate metabolic disorders that are observed in 
obesity [6]. For example, the acute LPS inflammatory challenge augmented the IL-
1 ~ induced immune activity in the periphery and the brain in diabetic db/db (leptin 
receptor deficient) mice, which was associated with a loss of IL-1 ~ counter-
regulation [ 518]. 
In the current study, several metabolic outcomes were assessed to understand the 
possible impact of high-fat diet induced obesity in combination with long-term 
effects of LPS injections. Therefore, glucose tolerance, insulin and leptin levels were 
measured as possible factors affecting the dopamine system. Before an assessment of 
these biochemical markers, animal food intake, body weight and body length were 
monitored over time in order to better understand the effect of LPS and high-fat diet 
consumption on the development of metabolic disorders. 
4.1.1 Control of food intake by CNS and the role of leptin in feeding control 
Food intake is a process controlled by the CNS and it is stimulated by sensations 
such as hunger, craving, pleasure and sense of reward [519]. The hypothalamus is 
the main brain region responsib le for food intake [520]. An essential hypothalamic 
control over the feeding process through integration of nutritional information is 
established by neuropeptides that are secreted from two neuronal populations 
situated in the arcuate nucleus [521, 522]. One neuronal population secretes 
neuropeptides that stimulate the appetite, also known as orexigenic peptides: 
neuropeptide Y (NPY) and agouti-related protein (AGRP) [521, 523], whereas the 
other one secrets anorexigenic peptides such as pro-opiomelanocortin (POMC) and 
cocaine- and amphetamine-regulated transcripts (CART) [521, 523]. The neurons 
that secret orexigenic and anorexigenic peptides predominantly project their axons to 
other neurons located in · PVN, lateral hypothalamic area (LHA), perifomical area 
(PFA), ventromedial and dorsomedial nuclei [519,524]. 
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Blood glucose level was thought to be a key initiator of feeding behavior [525] until 
it was discovered that other factors released from adipose tissue could signal the 
brain and control food intake [526]. In that sense, leptin [328] and insulin [527] were 
recognized as essential factors in controlling body weight and feeding behavior, 
whereas the communication between the gut and the brain has been considered to be 
mostly involved in control of satiety, regardless of metabolic requirement. The key 
role of leptin is carried out via its receptors (ObRb) expressed in the hypothalamus 
[523]. Leptin receptors are primarily expressed in several regions of the 
hypothalamus, such as arcuate nucleus, PVN, the dorsomedial nucleus and lateral 
hypothalamic area [523]. During fasting, leptin decreases the activity of NPY and 
AGPR neurons and the secretion of the orexigenic peptides (NPY and AGRP) [528, 
529]. Orexigenic neurons project to PVN and stimulate food intake and decrease of 
energy expenditure, contributing in that manner to weight gain [519] . In a fed state, 
an increase in leptin level stimulates secretion of anorexigenic peptides such as a-
melanocyte-stimulating hormone (a-MSH) and CART from arcuate nucleus that 
further project to LHA and PFA, which results in reduction of food intake and 
weight loss [529, 530]. Leptin also inhibits appetite through activation of dopamine 
and GABA neurons in the mesolimbic pathway [531]. 
In human and animals studies it was shown that under pathological conditions 
induced by activation of the innate immune system, food intake is disturbed as 
appetite decreases [532, 533]. Systemic inflammation causes disruption of neuronal 
circuits between periphery and the brain resulting in an imbalance of homeostasis of 
food intake and energy expenditure, which collectively leads to the development of 
anorexia and weight loss [534]. This pathological condition of anorexia is caused not 
only by bacterial products but may also be caused by high levels of cytokines [535]. 
Mice deficient in TLR4 exposed to LPS were shown to be resistant to anorexia 
[536]. Similarly, IL-lRl-/- mice showed resistance to weight loss after being 
challenged with IL-1~ [537]. Activation of both TLR4 and IL-lRl elicit 
inflammatory reactions via common signaling pathways, which involves recruitment 
of MyD88 [538]. In MyD88-deficie.nt animals, LPS-induced synthesis of cytokines 
in the brain was significantly attenuated, which further prevented anorexia [538]. 
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The effect of a high-fat diet on increased food intake is partially regulated via 
obesity-induced diabetes. Hyperphagia (a state of increased food intake) is tightly 
regulated by the hypothalamic NPY [539]. Since obesity is linked to the 
development of insulin resistance and hyperinsuilnemia it has been demonstrated 
that acute hyperinsuilnemia, stimulates the secretion of NPY, which in tum leads to 
increased appetite and food intake [540]. In particular, it is believed that diabetes in 
rats may alter the ability to utilize fat and carbohydrates from food [541]. Therefore, 
as a consequence of alteration in fuel oxidation, it is thought that diabetes may 
indirectly influence the expression of NPY that in tum would lead to increased food 
intake. 
For all of the above, the putative effect of LPS inflammatory challenge and high-fat 
diet-induced obesity on food intake was assessed and will be discussed in chapter 
4.4.1. 
4.1.2 Effect of inflammation and high-fat diet consumption on body weight gain 
In order to maintain the homeostatic balance, food intake, energy expenditure and 
storage of excess energy in the form of fat reserves has to be regulated by the actions 
of CNS. The CNS communicates with peripheral organs sensing the status of energy 
reserves and balancing it with the control of food intake and energy expenditure. As 
it was described before, leptin controls weight gain by suppressing appetite [329]. Its 
plasma levels correlates with fat mass and body weight. Thus, leptin levels rise with 
increased body weight or fall during weight loss [542]. 
Several inflammatory markers such as IL-1 and TNF-a were shown to stimulate 
leptin release [543]. It has been found that TNF-a stimulates leptin production 
through interaction with its receptor on adipocytes [544]. Likewise, acute exposure 
to LPS in fasting animals resulted in elevated levels of circulating leptin to almost 
the same extent as it was found in fed animals [545]. Overall, increased leptin levels 
during inflammation reduce food intake and lead to weight loss [ 546]. 
Consumption of a high-fat diet positively correlates with accumulation of adipose 
tissue [ 54 7]. The extent of weight gain is partially influenced by the irregular 
oxidative rate of ingested fat-enriched food [548]. On the other hand, continued 
feeding on a high-fat diet induces central leptin resistance accompanied with weight 
gain [549]. 
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The effect of single and repeated LPS inflammatory challenge and high-fat diet food 
intake on body weight gain will be discussed in the section 4.4.2. 
4.1.3 Effect of inflammation and high-fat diet on longitudinal body growth 
The bone longitudinal growth and muscle development are dependent on growth 
hormone (GH), which is secreted from the pituitary gland located in sella turcica 
base of the brain. The secretion of GH is stimulated by the growth hormone-
releasing hormone (GHRH), which is released from neurosecretory nuclei of the 
hypothalamus [550]. The control over GH secretion is also modulated by its inhibitor 
namely, growth hormone-inhibiting hormone (GHIH). There are other factors that 
may interfere with the normal release of GH from the pituitary, such as nutrient 
content, other hormones, stress and inflammatory factors [ 5 51]. 
Inflammation may dysregulate normal bone growth by altering secretions of some 
hormones and mineral content necessary for bone development. Through cytokine 
action, inflammation may exert a negative impact on bone remodeling. IL-1 was 
shown to contribute to bone resorption [552] and decreased secretion of GH [553]. 
The consumption of a high-fat diet may also interfere with bone growth by affecting 
the secretion of GH [ 5 54]. It has been shown that children fe1 a high-fat diet before 
exercise had reduced secretion of GH, suggesting that food high in calories may 
negatively interfere with normal growth and development [554]. 
The possible effect of single and repeated LPS inflammatory challenge and high-fat 
diet on longitudinal growth will be discussed in chapter 4.4.3 . 
4.1.4 Effect of biochemical parameters on dopamine circuit 
As it was previously described in the general introduction, alteration in insulin and 
leptin ·levels may affect proper function of the dopamine circuitry. Under normal 
conditions, leptin and insulin are positive regulators of dopamine release from the 
TH-neurons. The release of dopamine from substantia nigra to the striatum is 
dependent on ATP-sensitive K+ channels activity and its function is directly related 
to the level of glucose [361]. Since it has been shown that both hormones are 
involved in glucoregulation [360], it could be hypothesized that this process might 
be a co~ection of insulin and leptin-mediated dopamine secretion. 
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On the other hand, high levels of leptin and insulin may negatively influence the 
function of dopamine neurons. For example, leptin resistance in mice fed a high-fat 
diet has been related with decreased expression of TH enzyme [366]. Leptin and 
insulin insensitivity are suggested to influence down-regulation of D2 receptors in 
leptin-deficient obese rodents [368]. In particular, insulin resistance has been 
negatively correlated with dopamine release and its clearance from synaptic cleft in 
high-fat diet-fed mice [12]. 
The possible effect of single and repeated LPS inflammatory challenge and high-fat 
diet consumption on glucose tolerance, blood levels of insulin and leptin will be 
discussed in chapter 4.4.4. 
4.2 Objectives 
To determine the effect of single or repeated LPS inflammatory challenges and high-
fat diet consumption on: 
1) Food intake; 
2) Body weight gain; 
3) Longitudinal body growth, bone remodeling; and 
4) Glucose tolerance and level of hormones such as leptin and insulin. 
4.3 Brief methodology 
1) Food intake was measured every week for seven months. At the end of every 
seven days, the leftover food from the cage was weighted and recorded. Food 
intake was expressed as an average of food weight (in kcal) per animal and 
normalized by animal body weight (BW). 
2) The mouse ' s body weight was measured weekly over a period of twelve 
months. Mice were weighted and their body weight was recorded. Final 
results were expressed as a mean value of total number of animals/per group. 
Towards the end of in vivo experiments, body composition (percentage of fat 
mass and weight of lean mass) was determined by DEXA scan. 
3) The mouse ' s body length ( from anus to nose) was measured at the baseline 
and after 13 months. Towards the end of in vivo experiments, animal BMC 
and BMD were determined by DEXA scan. 
4) At the end of 13 months starting from the first saline/LPS injection, mice 
were subjected to intraperitoneal glucose tolerance test in order to assess their 
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glucose tolerance according to their treatment. Two months later, mice were 
euthanized and their blood collected and plasma levels of leptin and insulin 
were assessed by ELISA method. 
4.4 Results 
4.4.1 Effect of LPS inflammatory challenge and high-fat diet on food intake 
As it was previously described ( chapter 4.1.1 ), food intake may be influenced by 
inflammation. 
Figure 4.1 (A, C and E) shows averaged food intake (kcal/g) of WT, Casp-1-/- and 
IL-Ira-/- mice that was measured weekly over a period of seven months. The food 
intake of IL-Ira-/- mice was reported for saline and 5-times LPS-injected mice since 
the one time LPS-injected group was mixed with their heterozygote littermates in 
their home cage. As it may be observed in figure 4.1 (A, C and E) food intake was 
not affected by single or repeated LPS inflammatory challenges in any of the three 
genotypes. 
Figures 4.1 (B, D and F) displays food intakes adjusted by body weight of each 
genotype and for each treatment (Sal, LPS-1 T and LPS-5T). The comparison within 
each genotype revealed that repeated LPS inflammatory challenges significantly 
increased food intake in WT mice, whereas it was decreased in IL-lra-/- mice (figure 
4.1 B and F). On the other hand, neither single nor repeated LPS inflammatory 
challenges altered food intake in Casp-1-/- mice (figure 4.1 D). 
Figure 4.1 G was constructed by collapsing all the results on food intake from figure 
4.1 (A, . C and E) in order to compare food intake among the three different 
genotypes within each treatment (Sal, LPS-1 T and LPS-5T). Food intake of Casp-1-
/- mice in the saline-treated group was significantly higher when compared to WT 
and IL-.lra-/- mice. Additionally, food intake in IL-Ira-/- mice was reduced with 
repeated LPS injections. 
Food intake was normalized by body weight for each genotype and summarized in 
figure 4.1 H. IL-Ira-/- mice were shown to have increased food consumption per 
gram/BW versus both Casp-I-/- and WT mice in the saline-treated group. This trend 
was not observed in the five LPS-treated group, as food intake in WT mice tended to 
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increase, whereas repeated inflammatory challenge decreased food consumption in 
IL-Ira-/- mice. 
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Figure 4.1: Effect of LPS inflammatory challenge on food intake: Food intake 
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(kcal) of WT, Casp-1-/- and IL-lra-/- mice was measured on a weekly basis for seven 
months and the results were expressed as a mean/per cage since 3-5 animals were housed in 
a single cage. Comparison within each genotype: Average food intake of A) WT, C) Casp-1 -
/- and E) IL-lra-/- mice was analyzed by one-way ANO VA (Tukey' s post-hoc test) or 
unpaired T-test. Percentage of food intake normalized by body weight ofB) WT, D) Casp-1-
/- and F) IL-lra-/- mice was analyzed by one-way ANOVA (Tukey' s post-hoc test) or 
unpaired T-test. Comparison within each treatment: Figure G) shows collapsed data from 
figures A), C) and E) that were analyzed among the three genotypes and within each 
treatment by one-way ANOVA (Tukey's multiple comparison test). Figure H) shows 
collapsed data from figures B), D) and F) that were analyzed among the three genotypes and 
within each treatment by one-way ANO VA (Tukey' s multiple comparison test). Error bars 
represent standard errors. *p<0.05 vs. Sal; +p<0.05 , +++p<0.0001 vs. Casp-1 -/-; /\p<0.05, 
/\/\p<0.001, /\/\/\p<0.0001 vs. WT. 
The effect of high-fat diet consumption and LPS treatment on food intake was 
assessed as it was previously described in figure 4.1. The data on food intake of RD 
and HFD-fed mice arre presented in the figure 4.2 (A and C) and adjusted to the 
body weight in figure 4.2 (B and D). Food intake was not significantly altered by 
single and/or repeated LPS inflammatory challenges in both RD and HFD groups 
(figure 4.2 A and C). Adjusted food intake to the body weight showed that only 
repeated LPS inflammatory challenges increased food consumption in RD-fed mice 
(figure 4.2 B), while single and repeated LPS injections did not alter food intake in 
HFD-fed mice (figure 4.2 D). 
As it is presented in figure 4.2 E, food consumption was significantly higher in HFD-
fed mice in comparison to RD group and it was not altered by LPS treatment. 
Similarly, normalized data of food intake versus corresponding body weights of RD 
and HFD mice in figure 4.2 F indicated that HFD-fed mice had an overall increased 
calorie intake. These results indicate that in the experimental paradigm high-fat diet 
consumption increased energy intake. 
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Figure 4.2: Effects of peripheral inflammatory challenge and high-fat diet 
consumption on food intake: Food intake was measured on a weekly basis. Results were 
expressed as a mean/per cage, since 3-5 animals were housed in a single cage. Comparison 
within each diet: Average food intake of A) RD and C) HFD-fed mice collected over a 
period of seven months was analyzed by one-way ANOVA (Tukey's post-hoc test) . 
Percentage of food intake normalized by body 'Yeight of B) RD and D) HFD-fed mice was 
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analyzed by one-way AN OVA (Tukey' s post-hoc test) . Comparison within each treatment: 
E) Collapsed data from figures A) and C) were analyzed between RD and HFD-fed mice and 
within each treatment by unpaired T-test. F) Collapsed data from figures B) and D) were 
analyzed between RD and HFD-fed mice and within each treatment by unpaired T-test. 
Error bars represent standard errors . *p<0.05 vs. Sal, /\Mp<0.0001 vs. RD . 
4.4.2 Effect of LPS inflammatory challenge and high-fat diet on body weight 
Difference in body weight measured for three genotypes (WT, Casp-1-/- and IL-lra-
/-) between O and 12 months is presented in figure 4.3 (A, C and E). As it may be 
observed in the figure 4.3 (A, C and E) after twelve months period, all three 
genotypes had significantly gained body weight. 
In order to assess the effect of single and repeated LPS injections on weight gain 
within each genotype (WT, Casp-1 -/- and IL-lra-/-, respectively), percentage of 
difference between O and 12 months was calculated for each treatment (figure 4.3 B, 
D and F). Body weight gain was not significantly altered by single or repeated LPS 
injections in all three genotypes . Only 5-times LPS injections tended to decrease 
body weight gain in WT mice (figure 4.3 B). 
Figure 4.3 G was constructed to evaluate the genotype differences for each 
experimental group at baseline (time O month). Body weight of the three 
experimental treatments at O month were collapsed and presented by genotypes. As it 
may be observed (figure 4.3 G), Casp-1-/- mice were 15% heavier than WT mice 
(p<0.0001). On the other hand, IL-lra mice were 8% lighter than WT mice (p<0.05) 
and 20% lighter than Casp-1-/- mice (p<0.0001). 
Figure 4.3 I was constructed to evaluate the genotype differences in body length at 
baseline (time O month) since there was a difference in initial body weight among 
genotypes. The body length of all three treatments at O month was collapsed and 
presented by individual genotypes. As it may be observed, Casp-1-/- mice were 
longer by 15% than WT mice (p<0.0001). IL-lra mice were smaller by 2.15% than 
WT mice (p<0.05) and smaller by 11 % than Casp-1-/- mice (p<0.0001). 
In order to assess differences among the three genotypes in body weight gam 
according to individual treatment, percentages of differences that were calculated for 
each genotype in figure 4.3 (B, D and F) were collapsed in the figure 4.3 H. The 
comparison among saline-treated group revealed that weight gain of Casp-1-/- and 
IL-lra-/- mice were significantly lower than that of WT mice (figure 4.3 H). A 
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similar trend was observed in groups injected with single or repeated LPS injections, 
where only significant differences in body weight were observed between WT and 
IL-Ira-/- mice (figure 4.3 H). 
Casp-1-/- mice were significantly heavier by 15% than WT mice at O month, which 
could explain their lower final weight gain (figure 4.3 C and D). The comparison of 
the absolute values of body weight data at the end of experiment showed no 
significant differences between both Casp-1-/- and WT mice. In the case of IL-1 ra-/-
mice, although their body weight was significantly lower than that of WT mice by 
8%, the percentage of body weight gain after 12 months was also lower in 
comparison to WT mice. Thus, final body weight measurements of IL-Ira-/- mice 
remained significantly lower than that of both WT and Casp-1-/- mice at the end of 
12 months. IL-Ira-/- mice are already known as a strain of mice that are prone to 
growth retardation [555] and therefore their weight gain was also reduced 
significantly in comparison to WT mice (figure 4.3 H). In conclusion, weight gain 
was affected by genotype but not by inflammatory challenge. The decreased weight 
gain in IL-Ira-/- mice suggests that growth retardation was not additionally affected 
by LPS injections. 
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Figure 4.3: Effect of LPS inflammatory challenge on body weight gain: 
Comparison within each genotype: Absolute values of body weight data of A) WT, C) Casp-
1-/- and E) IL-Ira-/- mice were measured at O and 12 months and compared within each 
treatment by paired T-test. Final weight gain of B) WT, D) Casp-1-/- and F) IL-lra-/- mice 
was normalized versus initial baseline weight and expressed as percentage of difference, 
calculated by the formula previously described in the legend to figure 3.1. Data were 
analyzed by one-way ANO VA (Tukey' s multip le comparison test). G) Initial body weight 
data measured at .0 month were collapsed from figures A), C) and E) and analyzed by one-
way ANOVA fo llowed by Tukey's post-hoc test. I) Body lengths of three genotypes 
measur"ed at O month were analyzed by one-way ANOVA followed by Tukey's post-hoc 
test. Comparison within each treatment: H) Percentages of differences in body weight gain 
were compared among genotypes within each treatment by one-way ANOVA followed by 
Tukey's post-hoc ·test. Error bars represent standard errors. **p<0.001 , ***p<0.0001 vs. 0 
month; /\p< 0.05 , /\/\;\p< 0.0001 vs. WT; +++p<0.0001 vs. Casp-1-/-. 
In ord~r to ascertain the effect of high-fat diet consumption and LPS treatment on 
metabolic outcomes, body weight gain was· determined in mice fed a RD and HFD. 
The body weights of RD and HFD-fed mice are presented in the figure 4.4 (A and C) 
showing _body weight gain between O and 12 months. As it may be observed in figure 
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4.4 (A and C), after a period of twelve months, both RD and HFD-fed mice have 
significantly gained weight. 
In order to assess the effect of single and repeated LPS injections on weight gain 
within each diet (RD and HFD, respectively), in figure 4.4 (B and D) percentages of 
difference between O and 12 months were calculated for each treatment. The weight 
gain was slightly reduced, but not significantly, with five LPS injections in both RD 
and HFD-fed mice. 
Figure 4.4 E was constructed to evaluate the differences in body weight between two 
diet-fed groups at baseline (time O month). As expected, there were no significant 
differences in the initial body weight observed between RD and HFD-fed mice. 
Similarly, figure 4.4 G was constructed to evaluate the initial differences in body 
length between RD and HFD-fed mice (time O month). Body length was similar in 
both diet-fed mice. 
In order to assess differences in body weight gain between RD and HFD groups, the 
percentage of differences calculated for each diet in figure 4.4 (B and D) were then 
collapsed in figure 4.4 F and organized by treatment. The comparison between RD 
and HFD-fed mice indicated that body weight gain was similar in both groups . 
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Figure 4.4: Effects of LPS inflammatory challenge and high-fat diet on body 
weight: Comparison within each diet: Absolute values of body weight data of A) RD and 
C) HFD-fed mice were measured at O and 12 months and compared within each treatment by 
paired T-test. Final weight gain of B) RD and D) HFD-fed mice was normalized versus 
initial baseline weight and expressed as percentage of difference, calculated by the formula 
previously described in the legend to figure 3.1. Data were analyzed by one-way ANOVA (Tuk:ey's multiple comparison test). E) Initial body weight data of RD and HFD-fed mice 
that were measured at O month were collapsed from figures A) and C) and analyzed by 
unpaired T-test. G) Body length data of RD and HFD-fed mice that were measured at 0 
month were analyzed by unpaired T-test. Comparison within each treatment: F) Percentages 
of differences in body weight gain were compared between two diet-fed groups and within 
each treatment by unpaired T-test. Error bars represent standard errors. *p<0.05, **p<0.001, 
***p<0.0001 vs. 0 month. 
4.4.3 Body composition 
In order to evaluate body composition in the three genotypes, the percentage of body 
fat mass, weight of lean mass, BMD and BMC were assessed with DEXA scan. 
Figure 4.5 (A, C and E) displays percentages of body weight of the three genotypes 
(WT, Casp-1-/- and IL-lra-/-, respectively) in order to assess the effect of single and 
repeated LPS injections on fat mass accumulation. The group of single LPS injected 
IL-lra-/- mice was not scanned in DEXA apparatus since no differences were 
previously found in LPS-5T injected IL-lra-/- group. 
In regard to WT mice, percentage of body fat mass significantly decreased by 28% 
with five LPS injections (p<0.05) (figure 4.5 A). However, accumulation of fat mass 
was not affected with single and repeated LPS injections in Casp-1-/- and IL-1-ra -/-
mice (figure 4.5 C and E). 
Comparison among genotypes and within saline-treated groups indicated that 
accumulation of fat mass in IL-lra-/- mice was significantly lower by 43% in 
comparison to WT mice (p<0.01) and by 45% in comparison to Casp-1-/- mice 
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(p<0.0I) (figure 4.5 G). In 5-times LPS-injected groups, the percentage of fat tissue 
in WT mice was significantly lower by 37% in comparison to Casp-I-/- mice 
(p<0.05) while IL-Ira-/- mice had 47% lower accumulation of fat tissue than Casp-I-
/- mice (p<0.00I) (figure 4.5 G). 
Collectively, these data indicate that five LPS injections induced significantly lower 
fat mass accumulation in WT mice. Casp-I-/- mice were protected against LPS 
induced loss of fat tissue, whereas IL-Ira-/- mice had significantly lower 
accumulation of fat that was not additionally affected by LPS inflammatory 
challenge. 
Figure 4.5 (B, D and F) shows the weight of lean tissue of the three genotypes (WT, 
Casp-I-/- and IL-Ira-/-, respectively) in order to assess the effect of single and 
repeated LPS injections on lean tissue remodeling. The LPS inflammatory challenge 
did not alter the lean tissue composition in any of the three genotypes. 
Overall comparison among genotypes indicated that IL-Ira-/- mice in general had a 
lower weight of lean tissue than WT and Casp- I-/- mice, regardless of treatment 
(figure 4.5 H). IL-Ira-/- mice are smaller and this factor was subsequently reflected 
in the weight of lean tissue. 
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Figure 4.5: Effect of LPS inflammatory challenge on body fat mass and lean 
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tissue remodeling: Comparison within each genotype: Percentage of body fat mass of A) 
WT C) Casp-1-/- and E) IL-lra-/- mice was analyzed by one-way ANOVA (Tukey' s 
multiple comparison test) or unpaired T-test. Weight of lean mass of B) WT, D) Casp-1-/-
and F) IL-Ira-/- mice was analyzed by one-way ANOVA (Tukey ' s multiple comparison test) 
or unpaired T-test. Comparison within each treatment: G) Percentages of body fat mass were 
analyzed among genotypes and within each treatment by one-way ANOV A (Tukey' s 
multiple comparison test). H) Weight of lean mass was analyzed among genotypes and 
within each treatment by one-way ANOVA (Tukey's multiple comparison test). Error bars 
represent standard errors. *p<0.05 vs. Sal; Ap<0.05, Mp<0.01 , and AMp<0.001 vs . WT; 
++p<0.01 and +++p<0.001 vs. Casp-1-/-. 
The bone analysis was further performed by DEXA scan, using parameters such as 
BMDandBMC. 
Figure 4.6 (A, D and G) shows the final body length of three genotypes (WT, Casp-
1-/- and IL-Ira-/-, respectively) measured 13 months after the first saline/LPS 
injection. The body length was not affected by single and/or repeated LPS injections 
in any of the three genotypes. 
Figure 4.6 J displays the body length of all three genotypes (WT, Casp-1-/- and IL-
lra-/-, respectively), in order to evaluate the differences among the genotypes within 
each treatment. Genotype comparison revealed that IL-Ira-/- mice had shown 
retardation in longitudinal growth, regardless of treatment and this was significantly 
different by 13% versus WT (p<0.0001) and by 15% v.:ersus Casp-1-/- mice 
(p<0.0001). 
Figure 4.6 (B, E and H) displays the data on BMC of the three genotypes (WT, 
Casp-1-/- and IL-Ira-/-, respectively) in order to assess in more detail the effect of 
LPS treatment on bone composition. As it may be observed in the figure 4.6 B, LPS 
inflammatory challenge decreased BMC in WT mice and this loss was significant by 
18% with five LPS injections (p<0.05). Similarly, single LPS injection reduced 
BMC by 26% (p<0.0001) and by 16% with repeated LPS injections (p<0.001) in 
Casp-1-/- mice (figure 4.6 E). Repeated LPS injections did not reduce BMC in IL-
lra-/~ mice (figure 4.6 H). 
Evaluation of BMC among the three genotypes in saline-treated groups . (figure 4.6 
K) showed that Casp-1-/- mice had significantly higher BMC by 23% in comparison 
to WT (p<0.0001) and by 33% versus IL-Ira-/- mice (p<0.0001). The IL-Ira-/- mice 
had the least BMC in comparison to other two genotypes, by 15% lower versus WT 
mice (p<0.001). Single LPS injection reduced BMC in WT and Casp-1-/- mice. 
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Repeated LPS injections reduced the BMC of WT and Casp-1-/- mice to the similar 
level as it observed in IL- lra-/- mice, but the differences between WT and Casp-1-/-
mice still remained. In summary, longitudinal growth of IL-lra-/- mice was related 
with BMC. Casp-1-/- mice had increased BMC, which was not reflected in body 
length. 
Figure 4.6 (C, F and I) displays the data of BMD of the three genotypes (WT, Casp-
1-/- and IL-lra-/-, respectively) , in order to assess the effect of LPS inflammatory 
challenge on bone resorption. As it may be observed in figure 4.6 C, LPS treatment 
decreased the BMD in WT mice and it reached significance in five LPS-injected 
group. Repeated LPS injections reduced BMD by 18% versus WT-Sal (p<0.0001) 
and by 16% versus WT-LPS-lT (p<0.001). Similarly, single LPS injection reduced 
BMD by 25% (p<0.0001) and by 15% with repeated LPS injections in Casp-1-/-
mice (figure 4.6 F). Repeated LPS injections did not reduce BMD in IL-lra-/- mice 
(figure 4.6 I). 
Evaluation of BMD among the three genotypes in saline-treated groups (figure 4.6 
L) shO\ ed that Casp-1-/- mice had significantly higher BMD by 12.5% in 
comparison to WT (p<0.001 ) and by 25 % versus IL- lra-/- mice (p<0.0001). Single 
LPS injection reduced BMD in WT and Casp-1-/- mice. Repeated LPS injections 
reduced the BMD of WT and Casp-1-/- mice to the similar level as it observed in IL-
lra-/- mice, but the differences between WT and Casp-1 -/- mice still remained. 
Overall, repeated systemic LPS inflammatory challenges reduced BMD in WT and 
Casp-1-/- mice and, in particular, reduction in BMD of Casp-1-/- mice was also 
observed with single LPS injection. 
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Figure 4.6: Effect of LPS inflammatory challenge on body length, BMC and 
BMD: Body length, BMC and BMD were measured thirteen months after the first 
saline/LPS injection by DEXA scan. Comparison within each genotype: Absolute body 
length values of A) WT D) Casp-1-/- and G) IL-lra-/- mice were measured at 13 months and 
compared within each genotype by one-way AN OVA (Tukey' s multiple comparison test) or 
unpaired T-test. Data on BMC ofB) WT, E) Casp-1-/- and H) IL-Ira-/- mice were compared 
within each genotype by one-way ANOVA (Tukey's multiple comparison test) or unpaired 
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T-test. Data on BMD of C) WT, F) Casp-1-/- and I) IL-lra-/- mice were compared within 
each genotype by one-way ANOVA (Tukey' s multiple comparison test) or unpaired T-test. 
Comparison within each treatment: J) Body length data were collapsed from figures A), D) 
and G) and compared within each treatment by one-way ANOVA followed by Tukey's post-
hoc test. K) BMC data that were collapsed from figures B), E) and H) were compared within 
each treatment by one-way ANOVA followed by Tukey' s post-hoc test. L) BMD data that 
were collapsed from figures C), F) and I) were compared within each treatment by one-way 
ANO VA followed by Tukey' s post-hoc test. Error bars represent standard errors. *p<0.05 , 
**p<0.001 , ***p<0.0001 vs. Sal; ##p<0.001 vs. LPS-lT; +++p<0.0001 vs. Casp-1-/-; "p<0.05, 
/\,/'\p<0.001 , """p<0.0001 vs. WT. 
Percentages of body fat mass in RD and HFD-fed mice were further assessed by 
DEXA scan. In figure 4.7 (A and C) are displayed percentages of body weight of RD 
and HFD-fed mice. As it may be observed in figure 4.7 A, percentage of body fat 
mass in RD-fed mice significantly decreased with five LPS injections, whereas 
single LPS injection had no effect. Similarly, accumulation of fat mass in HFD-fed 
mice decreased, but not significantly, with five LPS injections (figure 4.7 C). 
Diet comparison of body fat mass composition in WT mice showed that HFD-fed 
mice in general had a higher percentage of fat accumulation in comparison to RD 
group, although it reached significant difference only in the saline-treated group 
(figure 4.7 E) . 
Figure 4.7 (B and D) shows the weight of lean tissue of mice fed with either RD or 
HFD, respectively. Neither single nor repeated LPS injections decreased the weight 
of lean tissue in either of the diet-fed groups. 
Overall comparison between RD and HFD-fed mice indicated that HFD saline-
treated group of mice had a lower weight of lean tissue than RD, whereas no effect 
was observed with single and repeated LPS injections (figure 4.7 F). 
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Figure 4.7: Effects of LPS inflammatory challenge and high-fat diet on fat mass 
and lean tissue remodeling: Comparison within each diet: Percentages of body fat mass 
of A) RD and C) HFD-fed mice were analyzed by one-way ANOVA (Tukey's multiple 
comparison test). Weight of lean tissue of B) RD and D) HFD-fed mice was analyzed by 
one-way ANOVA (Tukey's multiple comparison test). Comparison within each treatment: 
E) Percentages of body fat mass were analyzed between RD and HFD-fed mice and within 
each treatment by unpaired T-test. F) Weight of lean tissue was analyzed between RD and 
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HFD-fed mice and within each treatment by unpaired T-test. Error bars represent standard 
errors. *p<0.05 vs. Sal; /\p<0.05 vs. RD. 
Differences in BMC and BMD between RD and HFD-fed mice were further 
analyzed by DEXA scan. 
Body length in RD and HFD-fed mice was not altered by single or repeated LPS 
injections (figure 4.8 A and D). Similarly, body length was not different between RD 
and HFD-fed mice (figure 4.8 G). 
Figure 4.8 (B and E) displays data on BMC of RD and HFD-fed mice in order to 
assess the effect of LPS inflammatory challenge on bone composition. As it may be 
observed in figure 4.8 B, LPS treatment decreased BMC in RD-fed mice and this 
loss was significant with five LPS injections. Conversely, single LPS injections 
tended to increase BMC in HFD-fed mice and it reached significance with five LPS 
injections (figure 4.8 E). 
Despite similar body length in both RD and HFD groups (figure 4.8 G), the BMC 
was decreased in HFD-fed mice in the saline-treated group, whereas BMC of HFD 
mice was significantly higher than that of RD mice in the LPS-5T injected group 
(figure 4.8 H). Collectively, the data suggest that LPS treatment decreased BMC in 
RD-fed mice, whereas it caused a tendency for BMC to increase in HFD-fed mice. 
Thus, the comparison by treatment, shown in figure 4.8 H suggests that HFD alone 
caused a decrease in BMC, whereas in combination with LPS-5T it caused the 
opposite effect. 
Figure 4.8 (C and F) displays data on BMD of RD and HFD-fed mice in order to 
assess the effect of LPS inflammatory challenge on bone resorption. As it may be 
observed in figure 4.8 C, LPS treatment decreased the BMD in RD-fed mice and it 
reached significance in five LPS-injected group. On the other hand, single and 
repeated LPS injections did not decrease BMD in HFD-fed mice (figure 4.8 F). 
Similar to the results of BMC (figure 4.8 H), the BMD was decreased in HFD-fed 
mice in the saline-treated group, whereas BMD of HFD mice was significantly 
higher than that of RD mice in the LPS-5T injected group (figure 4.8 I). 
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Figure .i.8: Effects of LPS inflammatory challenge and high-fat diet on body 
length,_ BMC and BMD: Comparison within each diet: Body length data of A) RD and 
D) HFP-fed mice measured at 13 months were compared by one-way ANOVA (Tukey's 
multiple comparison test). Data on BMC of B) -RD and E) HFD-fed mice were compared by 
one-way ANOVA (Tukey's multiple comparison test) unless otherwise indicated. Data on 
BMD of C) RD and F) HFD-fed mic~ were compared by one-way ANOVA (Tukey's 
multiple comparison test). Comparison within each treatment: G) Body length data were 
collapsed from figures A) and D) and compared within each treatment by unpaired T-test. H) 
Data on BMC were collapsed from figures B) and E) and compared within each treatment by 
unpaired T-test. I) Data on BMD were collapsed from figures C) and F) and compared 
within each treatment by unpaired T-test. Error bars represent standard errors . *p<0.05, 
***p<0.001 vs. Sal; ##p<0.001 vs. LPS-lT; /\p<0~05 , /\/\p<0.01, /\/\/\p<0.001 vs. RD. 
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4.4.4 Effect of LPS and high-fat diet on IPGTT, plasma insulin and leptin levels 
Blood glucose level was determined in three genotypes (WT, Casp-1-/- and IL-lra-/-
) as they were subjected to IPGTT test at the end of 15 months of in vivo studies. 
Figure 4.9 (A, C and E) shows the concentration of glucose (mmol/L) measured in 
the blood of the three genotypes (WT, Casp-1 -/- and IL-lra-/-, respectively) and for 
three treatments (Sal, LPS-1 T and LPS-5T). Single and repeated LPS injections did 
not alter the glucose tolerance in all three genotypes as it was confirmed by area 
under the curve analysis (figure 4.9 B, D and F). 
In figure 4.10 (A, C and E) results that were obtained from IPGTT test of three 
genotypes are compared within each treatment (Sal, LPS-1 T and LPS-5T, 
respectively). As it may be observed from figures 4.10 A, C and E, baseline glucose 
levels of IL-Ira-/- mice were significantly lower by 20-40% versus the other two 
genotypes (p<0.0001). 
Upon glucose injection, IL-Ira-/- mice showed to be significantly more glucose 
tolerant versus WT and Casp-1-/- mice in saline-treated groups (figure 4.10 B). Even 
though IL-Ira-/- showed to be hypoglycemic in LPS-treated groups (figure 4.10 C 
and E), single and repeated LPS injections reduced the glucose tolerance in IL-1-ra -
/- mice in comparison to WT and Casp-1-/- mice (figure 4.10 D and F). 
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Figure 4.9: Effect of LPS inflammatory challenge on blood glucose level in 
IPGTT test: Mice were fasted for 6 hours and were injected (i.p.) with 2g/kg of glucose 
solution [393]. Blood glucose level was measured at 0 min before injection and 30, 60, 90 
and 120 min after the injection, Comparison within each genotype: Blood glucose levels of 
A) WT, C) Casp-1-/- and E) IL-Ira-/- mice were analyzed by one-way ANOVA (Tukey's 
multiple comparison test). Glucose tolerance in B) WT, D) Casp-1-/- and F) IL-Ira-/- mice 
161 
was analyzed by area under the curve (AUC) and compared within each genotype by one-
way ANOVA fo llowed by Tukey's post-hoc test. Error bars represent standard errors. 
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Figure 4.10: Effect of LPS inflammatory challenge on blood glucose level in 
IPGTT test: Mice were fasted for 6 hours and were injected (i.p.) with 2g/kg of glucose 
solution. Blood glucose level was measured at O min before injection and 30, 60, 90 and 120 
min after the injection. Comparison within each treatment: Blood glucose levels of A) 
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Saline, C) LPS-1 T and E) LPS-5T treated mice were measured in the three different 
genotypes and analyzed by one-way ANOVA (Tukey' s multiple comparison test) . Glucose 
tolerance in B) Saline, D) LPS-1 T and F) LPS-5T treated mice was analyzed by area under 
the curve (AUC) and compared within each treatment by one-way ANOV A followed by 
Tukey's post-hoc test. Error bars represent standard errors. **p<0.001, ***p<0.0001 vs. WT 
and Casp-1-/-; A/\/\p<0.0001 vs. WT, ++p<0.001 vs. Casp-1-/-. 
At the end of the studies mice were euthanized and their plasma insulin level was 
measured by ELISA method in order to assess the long-term effects of LPS on 
functionality of glycemic control. 
Figure 4.11 (A, B and C) represents the insulin level of three genotypes (WT, Casp-
1-/- and IL-lra-/-, respectively) in order to assess the effect of single and repeated 
LPS injections. As it may be observed in figure 4.11 (A, B and C), single and five 
LPS injections did not significantly alter the insulin level in any of the three 
genotypes. 
Comparison among the genotypes indicated that Casp-1-/- mice tended to have 
elevated levels of insulin in comparison to other genotypes and in particular this was 
significantly different versus IL-Ira-/- mice (figure 4.11 D). Data gathered from 
three treatments and analyzed within each genotype, indicate that IL-lra-/- mice had 
overall lower levels of insulin ( figure 4 .11 E). Casp-1-/- had higher level of insulin 
-
than IL-lra-/- but it was not significant versus WT mice (figure 4.11 E). 
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Figure 4.11: Effect of long-term LPS treatment on plasma level of insulin: The 
level of insulin in blood plasma was measured by ELISA kit and concentration was 
expressed in ng/ml. Comparison within each genotype: Levels of plasma insulin in A) WT, 
B) Casp-1-/- and C) IL-lra-/- mice were compared by one-way ANOV A followed by 
Tukey' s multiple comparison test. Comparison within each treatment: D) Data collapsed 
from figures A), B) and C) were analyzed within each treatment by one-way A OVA 
followed by Tukey' s post-hoc test. E) Data summarized from figure D) were analyzed by 
one-way A1 OVA followed by Tukey ' s post-hoc test. Error bars represent standard errors. 
/V\p<0.001 vs. WT; +p<0.05, +-+p<0.0001 vs . Casp-1-/-. 
Similarly, leptin levels were measured in blood plasma. The leptin level of IL-1 ra-/-
mice is not shown as it was extremely low or below detection. IL-Ira-/- mice tended 
to additionally lose 4-15% of their body weight during the time from DEXA scan 
and euthanasia, which might explain the extremely low levels of plasma leptin. 
In figure 4.12 (A and B), the effect of single and repeated LPS injections was 
assessed in WT and Casp-1-/- mice, respectively. As it may be observed, leptin 
levels were not altered by LPS treatment in either genotype. Direct comparison 
between the two genotypes indicated that leptin levels were similar or tended to be 
ele ated in WT mice when compared to Casp-1-/- mice (figure 4.12 C). 
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In figure 4.12 (D and E), leptin levels of two genotypes (WT and Casp-1-/- mice, 
respectively) were normalized by fat mass. The ratio between leptin and fat mass 
indicates that secretion of leptin in both WT and Casp-1-/- mice was not altered by 
LPS inflammatory challenge. Genotype comparison in saline and one time LPS-
injected group indicates that leptin/fat mass ratio was significantly lower in Casp-1-/-
mice than in WT mice (figure 4.12 F). These significant differences were not evident 
in the 5-times LPS-injected mice (figure 4.12 F). Overall, the data suggest that Casp-
1-/- mice had lower secretion of leptin from adipose tissue. 
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Figure 4.12: Leptin level measured in blood plasma: Level of plasma leptin was 
measured by ELISA kit and its concentration was expressed in pg/ml. Comparison within 
each genotype: Plasma leptin levels in A) WT and B) Casp-1 -/- mice was compared by one-
way ANOV A (Tukey' s multiple comparison test) . Leptin levels of D) WT and E) Casp-1-/-
mice were normalized versus corresponding values of fat mass measured by DEXA scan and 
analyzed by one-way ANOVA followed by Tukey's post-hoc test. Comparison within each 
treatment: C) Leptin levels were compared between genotypes and within each treatment by 
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unpaired T-test. F) Leptin/fat mass ratio was compared between two genotypes within each 
treatment by unpaired T-test. Error bars represent standard errors. /\p<0.05 vs. WT, #p<0.05 
vs. LPS-1 T. 
In order to assess the additional effects of long-term high-fat diet consumption anf 
LPS treatment on metabolic outcomes, IPGTT test, insulin and leptin levels tests 
were performed. 
Figure 4.13 (A and C) presents the glucose level determined in IPGTT test of RD 
and HFD-fed mice in order to assess the effect of single and repeated LPS injections. 
As it may be observed, single or five LPS injections did not significantly alter 
glucose levels in RD and HFD groups . Moreover, the AUC analysis in the figure 
4.13 (B and D) suggests that LPS treatment did not alter the glucose tolerance in 
either diet-fed mice. 
With regards to the effect of diet, comparison within saline-treated groups indicated 
that HFD-fed mice had a higher baseline level of glucose and showed a significant 
increase in glucose intolerance at 60, 90 and 120 minutes after glucose injection 
(figure 4.14 A). Similarly, HFD-fed mice injected with either single or repeated LPS 
injections showed higher baseline glucose levels and lower glucose tolerance at 
various points in time (figure 4.14 C and E). Further analysis revealed that HFD-fed 
mice were glucose intolerant as shown in saline and single LPS-injected groups 
(figure 4.14 B and D), while there was a tendency for 5-times LPS-injected HFD-fed 
mice to be more glucose intolerant versus RD-fed mice (figure 4.14 F). 
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Figure 4.13: Effects of LPS inflammatory challenge and high-fat diet on blood 
glucose level in IPGTT test. Mice were fasted for 6 hours and were injected (i.p .) with 
2g/kg of glucose solution. Blood glucose level was measured before injection (0 min) and 
30, 60, 90 and 120 min after the glucose administration. Comparison within each diet: Blood 
glucose levels of A) RD and C) HFD-fed mice were analyzed by one-way ANOVA (Tukey's multiple comparison test). Glucose tolerance in B) RD and D) HFD-fed mice was 
analyzed by AUC and differences were compared by one-way ANOVA (Tukey's multiple 
comparison test). Error bars represent standard errors. 
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Figure 4.14: Effects of LPS inflammatory challenge and high-fat diet on blood 
glucose level in IPGTT test. Mice were fasted for 6 hours and were injected (i.p.) with 
2g/kg of glucose solution. Blood glucose level was measured before injection (0 min) and 
30, 60, 90 and 120 min after the glucose administration. Comparison within each treatment: 
Blood glucose levels in A) Saline, C) LPS-1 T and E) LPS-5T treated mice were compared 
between two different diet-fed groups and analyzed by unpaired T-test. Glucose tolerance in 
B) Saline, D) LPS-1 T and F) LPS-5T treated mice was analyzed by AUC and differences 
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were compared by unpaired T-test. Error bars represent standard errors. *p<0.05, **p<0.001 , 
***p<0.0001 vs. RD. 
Single and repeated LPS injections in RD and HFD mice did not significantly alter 
insulin level (figure 4.15 A and B). Direct comparison between two different diet-fed 
groups indicates that HFD-fed mice had higher levels of insulin than RD mice and it 
reached significance in the saline-treated group (figure 4.15 C). 
Data gathered from three treatments (figure 4.15 C) and compared between two diet-
fed groups, suggests that HFD-fed mice were hyperinsulinemic (figure. 4.15 D). 
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Figure 4.15: Effects of LPS inflammatory challenge and high-fat diet on insulin 
level in the blood: Level of insulin in the blood plasma was measured by ELISA kit and 
concentrat ion was expresse.d in ng/ml. Comparison within each diet: Insulin levels of A) RD 
and B) HFD-fed mice were analyzed by one-way ANOVA (Tukey's multiple comparison 
test). Comparison within each treatment: C) Data collapsed from figures A) and B) were 
analyzed within each treatment by unpaired T-test. D) Data summarized from figure C) were 
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analyzed by unpaired T-test. Error bars represent standard errors. 1\/\p<0.01 , /\/\/\p<0.001 vs. 
RD. 
In figure 4.16 (A and B), the effect of single and repeated LPS injections on leptin 
levels was assessed in RD and HFD-fed mice, respectively. As it may be observed, 
leptin levels were not altered by LPS treatment in either of the diet-fed groups. 
Direct comparison between two diet-fed groups, indicates that leptin level was 
elevated in HFD-fed mice and it reached significance versus RD-fed mice in the 
saline-treated group (figure 4.16 C). 
In figure 4.16 (D and E), leptin levels were normalized with fat mass data of RD and 
HFD-fed mice that was obtained from the DEXA scan. Ratio between leptin and fat 
mass indicates that secretion of leptin from fat depots in both RD and HFD-fed was 
not altered by LPS treatment. 
Diet comparison indicated that leptin/fat mass ratio was similar to the previously 
described leptin level in RD and HFD groups, suggesting that secretion of leptin was 
not altered by LPS treatment (figure 4.16 F). As it may be observed, a number of 
mice in figure 4.16 (C and F) do not match, as some of mice were not scanned by 
DEXA apparatus, due to the health problem. 
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Figure 4.16: Effects of LPS inflammatory challenge and high-fat diet on leptin 
blood level: Comparison within each diet: Levels of plasma leptin of A) RD and B) HFD-
fed mice were compared by one-way AN OVA (Tukey' s multiple comparison test). Leptin 
levels of D) RD and E) HFD-fed mice were normalized versus corresponding values of fat 
mass tissue measured by DEXA scan and analyzed by one-way ANOV A followed by 
Tukey's post-hoc test. Comparison within each treatment: C) Leptin levels were compared 
between RD and HFD-fed mice by unpaired T-test. F) Leptin/fat mass ratio was compared 
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between RD and HFD-fed mice by unpaired T-test. Error bars represent standard errors. 
#p<0.05 vs. LPS-1 T, /\p<0.05 vs. RD. 
Since HFD-fed mice did not significantly gain weight despite increased food intake, 
a new set of mice was used to ascertain if frequent behavioral tests in addition to the 
five monthly (i .p.) injections could have interfered with body weight gain. These 
frequent interventions could have induced mild-chronic stress affecting weight gain 
in HFD-fed mice. Therefore, a new set of mice that were exposed to a minimum 
number of behavioral tests, but not injected, was used to ascertain the possible effect 
of frequent interventions (i .p. injections and repeated behavioral tests) on metabolic 
outcomes. 
For this purpose, the following two groups of mice were studied: 
- Non -injected WT mice fed a regular diet (RD-NI) (n=l0) 
- Non- injected WT mice fed a high-fat diet (HFD-NI) (n=l0) 
Mice were kept under the same environmental conditions that were previously 
described in chapter 2. The new set of mice (RD-NI and HFD-NI) was subjected to 
the metabolic tests as it was described for the previous set of experimental mice. 
Then, they were compared with the saline-injected RD and HFD-fed mice. 
Brief methodology: 
1) Metabolic studies: Mice were subjected to IPGTT test and body composition 
was determined by DEXA scan at the end of 13 months. At the end of 15 
months of in vivo studies, plasma levels of leptin and insulin were 
ascertained. 
Metabolic studies: 
Figure. 4.1 7 (A and C) shows the results of the IPGTT test conducted in saline-
injected and non-injected RD and HFD-fed mice, respectively. As it may be 
observed both groups of HFD-fed mice were shown to be less glucose tolerant at 60, 
90 and 120 min after the glucose injection (figure 4.1 7 A and C) . In particular, HFD-
NI mice showed first signs of glucose intolerance just 30 min post-injection (figure 
4.17 C). Moreover, the AUC analysis in figure 4.17 (B and D) suggests that both 
HFD and HFD-NI mice were glucose intolerant. 
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With regards to the effect of treatment, the comparison between RD and RD-NI mice 
showed no difference in glucose tolerance between these two groups (figure 4.17 E 
and F) . In the case of high-fat diet-fed mice, there was a tendency for HFD-NI mice 
to be less glucose tolerant than HFD-fed mice (figure 4.17 G) . HFD-NI mice reached 
significance versus HFD-fed mice 30 min after glucose inj ection (figure 4.17 G). 
The AUC analysis has shown that HFD-NI mice displayed a trend to be more 
glucose intolerant than HFD-fed mice (figure 4.17 H) . 
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Figure 4.17: IPGTT test in saline-injected and non-injected RD and HFD-fed 
mice: Mice were fasted for 6 hours . Thereafter, they were injected (i.p.) with 2g/kg of 
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glucose solution . Blood glucose level was measured before injection (0 min) and 30, 60, 90 
and 120 min after i.p. glucose administration. Blood glucose levels were compared A) and 
C) between two different diets ; E) and G) and between two treatments. Data were analyzed 
by unpaired T-test. B) and D) Diet; F) and H) Treatment effect on glucose tolerance was 
analyzed by AUC and differences were compared by unpaired T-test. Error bars represent 
standard errors. *p<0.05, **p<0.001, ***p<0.0001. 
In order to evaluate the differences in body composition of saline-injected and non-
injected RD and HFD-fed mice, data on body weight, percentage of fat mass and 
weight of lean tissue are shown in figure 4.18 . 
Figure 4.18 (A and D) displays the body weights of injected (RD and HFD) and non-
injected (RD-NI and HFD-NI) mice, respectively. There was no difference in body 
weight between RD and HFD-fed mice (figure 4.18 A). On the other hand, non-
injected (HFD-NI) were significantly heavier by 27% than RD-NI mice (p<0.0001) 
(figure 4.18 D). The comparison between treatments and within same diet revealed 
that HFD-NI mice were significantly heavier by 24% than HFD mice (p<0.0001), 
whereas no difference in body weight was observed between RD and RD-NI mice 
(figure 4.18 G). These data suggest that the stress of injection and the repeated 
behavioral interventions could have interfered with body weight gain in injected 
HFD-fed group. Interestingly, although there were no significant differences 
between both injected RD-fed and HFD-fed mice, the injected HFD-fed mice were 
metabolically obese. 
In fact, DEXA scan studies have shown that injected HFD mice had approximately 
27% more accumulation of fat tissue than injected RD mice (p<0.05) (figure 4.18 B). 
Similarly, HFD-NI mice had accumulated 39% more fat mass than RD-NI mice 
(p<0.0001) (figure 4.18 E). Comparison between treatments and within same diet 
revealed that HFD-NI mice had significantly more fat tissue by 25 % than HFD mice 
(p<0.05), whereas no difference was observed between RD and RD-NI mice (figure 
4.18 H). Overall, this difference in the percentage of fat content between injected 
HFD and non-injected HFD-fed mice (HFD-NI) strengthens the concept that 
repeated behavioral interventions and injections impaired body weight gain and fat 
accumulation in injected HFD-fed mice. 
Analysis of lean tissue shows that injected HFD-fed mice had lower weight of lean 
tissue than RD mice (figure 4.18 C), whereas no significant differences were 
observed between the weight of lean tissue of RD-NI and HFD-NI mice (figure 4.18 
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F). Comparison between treatments and within the same diet revealed that HFD-NI 
mice had significantly more lean tissue than HFD, whereas no significant differences 
were observed between RD and RD-NI mice (figure 4.18 I). 
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Figure 4.18: DEXA scan of injected and non-injected RD and HFD fed mice: 
Comparison between diets: Data on A) and D) Body weight; B) and E) Percentages of body 
fat mass and C) and F) weight of lean tissue within each diet were analyzed by unpaired-T 
test. Comparison between treatments: Data on G) Body weight, H) percentages of body fat 
mass and I) weight of lean ti ssue were compared between injected and non-injected RD and 
HFD-fed mice within each diet and analyzed by unpaired T-test. Error bars represent 
standard errors. *p<0.05 , ***p<0.0001 ; /\p<0.05 , /\/\/\p<0.0001 vs. HFD. 
At the end of the in vivo studies, levels of insulin and leptin were measured in 
plasma. Levels of insulin were elevated in both HFD and HFD-NI mice (figure 4.19 
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A and B). The comparison within the same diet indicated that RD-NI had higher 
plasma insulin than RD (p<0.01) (figure 4.19 C). Similarly, insulin was higher in 
HFD-NI than in HFD-fed mice (p<0.01) (figure 4.19 C). 
Plasma leptin was elevated in both HFD and HFD-NI mice in comparison to their 
control groups (p<0.05 and p<0.001, respectively) (figure 4.19 D and E). The 
comparison within each diet showed that RD-NI had elevated, but not significantly, 
plasma leptin levels than injected RD-fed mice, whereas HFD-NI mice had 
significantly more plasma leptin levels than that of HFD-fed mice (p<0.05) (figure 
4.19F). 
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Figure 4.19: Insulin and leptin levels in injected and non-injected RD and HFD 
fed mice: Comparison between diets: Data on A) and B) Plasma insulin; D) and E) Leptin 
levels were compared by unpaired T-test. Comparison between treatments: Data on C) 
Insulin and F) leptin levels were compared by unpaired T-test. Error bars represent standard 
errors. *p<0.05 , **p<0.01 , ***p<0.0001 ; ##p<0.01 vs. RD ; Ap<0.05 , Mp<0.01 vs. HFD. 
Overall , data obtained from non-injected RD and HFD-fed mice suggest that saline 
injections could have produced mild-chronic stress that disabled mice fed a high-fat 
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diet from gaining significantly more weight than their control group. Non-injected 
HFD-fed mice gained significantly more weight, had more accumulated fat tissue 
and higher levels of leptin and insulin than injected HFD-fed mice. In spite of these 
significant differences, the injected HFD-fed mice still showed to be metabolically 
obese since they displayed glucose intolerance and had higher plasma levels of 
insulin and leptin in comparison to their control group (injected RD-fed mice). 
4.5 Discussion 
Metabolic perturbations such as type-2 diabetes, insulin resistance and obesity have 
been implicated in the etiology of several neurodegenerative disorders [556, 557]. In 
a recent study it has been shown that cognitive and motor functions in patients 
suffering from neurodegenerative disorders were improved when metabolic 
homeostasis was restored with acquired therapies [558]. Diabetes has been shown to 
reduce the content of dopamine within the nigrostriatal system [1 OJ. Low levels of 
insulin in streptozotocin-induced diabetic rats were associated with decreased 
mRNA expression of DAT and tyrosine-hydroxylase in SNpc [559]. In parallel with 
the previous statement, increased phosphorylation of insulin receptor substrate-2, a 
marker of insulin resistance was observed in striatum of dopamine depleted 6-
OHDA-mouse model of Parkinson' s disease [560]. Correlation between type-2 
diabetes and Parkinson's disease was reported in more than 50% of cases [560]. 
Insulin injection into mice brains increases the activity of DAT in substantia nigra 
[561], but chronic hyperinsulinemia has been shown to reduce the expression of 
insulin receptors in the BBB, which leads to central insulin resistance [562]. Chronic 
high-fat diet consumption in mice induced insulin resistance and decreased the 
release and clearance of dopamine from TH-neurons [12]. It has been shown that in 
ob/ob mice that are genetically prone to obesity and diabetes, also have low 
expression of TH enzyme in dopamine neurons [531]. Therefore the general aim of 
this chapter was to ascertain the long-term effect of systemic LPS inflammatory 
challenge and high-fat diet consumption on the occurrence and progression of 
metabolic disorders that may lead to impaired dopaminenergic-mediated 
neurotransmission and contribute to depletion of dopamine neurons. 
AIM 1: Long-term effect of systemic LPS challenge on metabolic outcomes, 
exerted through the IL-1 pathway. 
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The IL-1 mediated signaling is not only implicated in the inflammatory process, it 
also plays a major role in general energy homeostasis. In this section, the 
physiological and pathological role of IL-1 was examined on feeding behavior, body 
composition, glucose tolerance and plasma levels of insulin and leptin. With regards 
to the physiological role of IL-1, major differences in metabolic functions were 
observed among the three genotypes (WT, Casp-1 -/- and IL-lra-/-): 
• Casp-1-/- mice displayed increased food intake that was not followed by an 
increase of body weight. Assessment of body composition confirmed that 
increased food intake in Casp-1-/- mice did not result in increased 
accumulation of fat tissue and no change was observed in weight of lean 
tissue. Despite similar body length to WT mice, Casp-1-/- mice had increased 
BMC and BMD. Casp-1-/- mice were not glucose intolerant but had 
. increased plasma levels of insulin that was accompanied by a decrease of 
plasma leptin. 
• IL-lra-/- mice showed increased food intake, growth retardation and 
decreased accumulation of body fat mass. Decreased longitudinal growth was 
accompanied by reduced BMC, but possible over-stimulation of IL-1 
signaling in IL-lra-/- mice resulted in diminished BMD. IL-lra-/- mice were 
more insulin sensitive and showed reduced plasma insulin. Decreased fat 
mass was accompanied by low levels of leptin that in most cases was below 
the sensitivity of the assay. 
The long-term effect of LPS inflammatory challenge, has altered some of the 
metabolic features that were described above: 
• Repeated LPS inflammatory challenge increased food intake in WT mice 
when adjusted to the body weight. Although single and repeated LPS 
injections tended to reduce the body weight gain, DEXA scan showed that 
body fat mass was only reduced with repeated LPS injections. Although, 
longitudinal growth was not affected by LPS inflammatory challenge, BMD 
and BMC were reduced in the 5-times LPS-injected mice. In WT mice, 
systemic LPS treatment neither reduced glucose tolerance nor did it alter 
plasma levels of leptin and insulin. 
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• Food consumption of Casp-1-/- mice was not altered by LPS administration. 
There was no reduction in body weight gain, and as it was later confirmed by 
DEXA scan, body fat mass and lean tissue did not decrease. Although there 
was no difference in body length, single and repeated LPS injections 
decreased BMD and BMC. However, systemic LPS inflammatory challenge 
neither induced glucose intolerance nor it did alter the insulin and leptin 
level. 
• Repeated LPS inflammatory challenge reduced the food intake in IL-lra-/-
mice but without affecting their weight gain, the body fat mass and lean 
tissue. Similarly, neither longitudinal growth nor BMD and BMC were 
reduced. However, single and repeated LPS injections reduced the insulin 
sensitivity in IL-lra-/- mice without affecting insulin and leptin levels. 
The role of IL-1 and LPS inflammatory challenge on the modulation of the feeding 
process was ascertained in groups of WT, Casp-1-/- and IL-lra-/- mice. Single and 
repeated LPS injections did not alter food intake in the three genotypes. When food 
intake was adjusted to body weight then it was observed that systemic LPS 
inflammatory challenge increased the food intake in 5-times LPS-injected WT mice, 
decreased food intake in IL-lra-/- mice and no LPS effect w~s observed in Casp-1-/-
mice. The reduced feeding in IL-lra-/- mice by repeated LPS injections is in 
agreement with previous study where exogenous administration of IL-1 in rats 
reduced the feeding through the mechanism that is regulated by central 
melanocortin- 3/ 4 receptors (MC3/4 R's) [563]. Similarly, intraperitoneal 
administration of LPS in mice induced anorexia via IL-1 mediated central action in 
the hypothalamus [564]. The genotype comparison indicated that food intake of 
Casp-1-/- mice was elevated in saline-treated group. Food intake was previously 
shown to be elevated in high-fat _diet-fed Casp-1-/- mice [565]. Similarly, food intake 
was h1gher in IL-lra-/- mice. It is suggested that under physiological conditions, 
over-activation of IL-1 signaling might be too weak to suppress the feeding process 
and only a large excess of IL-1.can suppress the appetite [566]. 
Systemic LPS inflammatory challenge did not decrease the body weight gain in any 
of the three genotypes. In the current study, single and repeated LPS injections did 
induce the body weight loss in the first week after the injection ( data not shown) but 
mice managed the recover their weight gain two to three weeks post-injection. As 
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shown previously, short-term LPS injection reduced the body weight gain in pre-
weanling rats [567]. The initial body weight measurements were taken when mice of 
all three genotypes (WT, Casp-1 -/- and IL-lra-/-) reached 40 days of age. The body 
weight data analysis indicated that Casp-1-/- mice were heavier, whereas IL-1 ra-/-
mice were the leanest. It has been observed earlier that IL-1-ra-/- mice suffered from 
growth retardation after the weaning and consequently had lower body weight [378]. 
Although, initial body weight of Casp-1 -/- mice was higher, in other study it was 
shown that 6-months old caspase-1 deficient mice had similar body weight as WT 
mice [568]. Similarly, body weight data taken after 12 months indicated that body 
weights of WT and Casp-1 -/- mice were similar. As it was mentioned above, Casp-1-
/- mice had increased food intake but their final body weight was similar to WT 
mice. It has been reported that caspase-1 deficient mice have higher energy 
expenditure [565]. As it was described in chapter 3, the locomotor activity of these 
mice was significantly higher, which also supports the idea of non-significant weight 
gain in Casp-1-/- mice. It has been shown that caspase-1 deficient mice fed a high-fat 
diet had increased food intake and lower accumulation of white adipose tissue than 
WT mice on the same diet [565, 569]. Moreover it has been shown that high-fat diet-
fed Casp-1-/- mice had smaller adipocytes but their differentiation was not impaired 
in absence of caspase-1 [568] . Similar study showed that decreased accumulation of 
fat in Casp-1-/- mice is due to decreased intestinal absorption of triglyceride and 
reduced production of hepatic very low-density lipoprotein-triglycerides [569]. 
Cumulatively, these observations suggest that increased energy expenditure and 
decreased triglyceride accumulation in fat depots of Casp-1-/- mice could have 
resulted in non-significant weight gain despite higher food intake. 
Body composition suggested that repeated LPS treatment decreased the body fat 
accumulation in WT mice. Results from in vitro studies indicated that IL-1 inhibits 
the synthesis of proteins involved in the transport of fatty acids to adipose tissues 
[570]. This might imply that ongoing peripheral inflammation in 5-times LPS-
injected WT mice might have reduced the accumulation of fat tissue and 
subsequently this could account for increased food intake. On the other hand, neither 
single nor repeated LPS inflammatory challenges decreased the fat accumulation in 
Casp-1-/- and IL-lra-/- mice. Since genotype comparison indicated that IL-lra-/-
mice had the least percentage of fat mass, it might be suggested that the amount of 
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accumulated fat in IL-lra-/- mice was so low that it could not be further decreased 
by repeated LPS interventions. Decreased accumulation of adipose tissue combined 
with increased food intake as a ratio of body weight has been associated with 
increased energy expenditure and defective adipogenesis in IL-lra-/- mice [571]. 
Deficiency in IL- lra led to altered morphology of white adipose tissue, which was 
associated with impaired differentiation of adipocytes [ 571]. In particular it was 
observed that lack of IL-lra in mice was followed by decreased expression of 
transcription factors involved in adipocyte differentiation [571]. 
As it was described previously, systemic administration of cytokines such as TNF-ex 
may stimulate fat degeneration [572, 573]; in a similar manner it has been shown 
that cytokines such as TNF-ex and IL-1 are involved in muscle atrophy [574, 575]. 
DEX.A scans have shown that long-term effects of single and repeated LPS 
inflammatory challenges did not induce muscle wasting in any of the three 
genotypes. 
Initial body length comparison among genotypes indicated that IL-lra-/- mice were 
the smallest, which is due to growth retardation [378], whereas Casp-1-/- mice were 
the longest. At the end of 13 months Casp-1-/- and WT mice had similar body 
lengths, whereas IL-lra-/- mice did not catch up with the other two genotypes. 
Assessment of bone composition suggested that repeated LPS injections reduced the 
BMD and BMC in WT mice. Proinflammatory cytokines contribute to bone 
resorption by stimulating the acti ity of osteoclasts, as it v as shown in cystic 
fibrosis, an example of systemic inflammation [576]. Similar reduction in BMD and 
BMC was observed in Casp-1-/- mice that ere induced with single and repeated 
LPS injections, whereas no LPS effect, as shown in IL-1 ra-/- mice. In regard to the 
LPS effect on bone resorption observed in Casp-1-/- mice, it has been shown that 
caspase-1 gene deficient mice are not protected against induced inflammatory 
arthritis as it as demonstrated that neutrophil serine proteinase-3 contributes to the 
production of bioacti e IL-1 ~ [ 5 77]. Genotype comparison indicated that Casp-1-/-
mice had higher BMD and BMC, hereas IL-lra-/- had the lowest in saline-treated 
groups. It as pre iously observed that Casp-1-/- mice had higher BMC than WT 
mice [569]. Similarly, IL-1 knockout mice (IL-lex-/-, IL-1~ -/- and IL-lex/~-/- mice) 
exhibited an increase in bone mass that as followed by a decrease in the number of 
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osteoclasts [578]. Conversely, an excess of IL-1, such as that found in IL-lra-/-
mice, was associated with development of arthritis and bone destruction [579]. Five 
LPS injections reduced the BMD and BMC in WT and Casp-1-/- to the level that 
was similar to IL-Ira-/- mice. 
Measurements of glucose tolerance indicated that IL-Ira-/- mice were more glucose 
tolerant than Casp-1-/- and WT mice in saline-treated groups. As it was described 
before, IL-Ira-/- mice are reported to have increased insulin sensitivity [566] . On the 
other hand, this glucose tolerance in IL-Ira-/- mice was diminished with single and 
repeated LPS injections. 
Single and repeated LPS injections did not impair insulin or leptin secretion in any of 
the three genotypes. One study has shown that IL-1 could be antidiabetic [580]. 
Conversely, other study demonstrated that IL-1 induced the death of pancreatic ~-
cells [581]. IL-Ira-/- mice are reported to have impaired insulin secretion that results 
in hypoinsulinemia [566]. As insulin has an important role in pre and post-natal 
growth [582], hypoinsulinemia in IL-Ira-/- mice could explain postnatal growth 
retardation in these mice. Normal prenatal growth in IL-Ira-/- mice could be 
attributed to normal in utero levels of insulin and pre-weaning supply of insulin from 
milk could account for normal body weight at the weaning. Similarly, leptin levels in 
IL-Ira-/- mice were extremely low (data not presented), which was associated with a 
very low percentage of fat by the end of the study. As it was previously reported, 
circulating leptin levels were reduced by 6-fold in IL-Ira-/- mice [571]. On the other 
hand, the secretion of insulin in Casp-1-/- mice was increased. The increase in 
plasma insulin in Casp-1-/- mice could have resulted from decreased secretion of 
leptin from adipose tissue. It has been shown that acute administration (i.p.) of IL-1 
in mice increases the serum level ofleptin and mRNA expression [583], which could 
suggest that a lack of IL-1 signaling in Casp-1-/- mice could have impaired the 
secretion of leptin from adipose tissue. Leptin levels in WT mice tended to be lower 
with repeated LPS injections, since their fat accumulation was lower. 
AIM 2: Long-term effects of high-fat diet consumption and systemic LPS 
challenge on metabolic outcomes. 
186 
In this section the effects of high-fat diet and LPS inflammatory challenge were 
examined on feeding behavior, body composition, glucose tolerance and plasma 
levels of insulin and leptin. 
Major differences in metabolic functions have been observed between HFD and RD-
fed mice, whereas LPS treatment did not exacerbate the metabolic outcomes in either 
diet-fed group of mice: 
• High-fat diet consumption increased the food intake, which was not further 
altered by systemic LPS treatment. On the other hand, repeated LPS 
injections increased food intake as a ratio of body weight in RD-fed mice. 
Despite increased food intake, HFD-fed mice had similar body weight to RD-
fed mice. In both diet-fed groups, LPS inflammatory challenge decreased, but 
not significantly, body weight. Decrease in body weight in both RD and 
HFD-fed mice with repeated LPS injections was further verified with DEXA 
scan as the accumulation of body fat was lower in RD mice, but not 
significantly, compared to HFD-fed mice. A minor reduction in lean tissue 
was observed in HFD-fed mice. Long-term effects of systemic LPS did not 
alter the longitudinal growth, but repeated inflammatory challenges 
decreased the BMC and BMD in RD-fed mice; mor·eover there was a trend 
for these parameters to be increased in HFD-fed mice. HFD-fed mice showed 
to be glucose intolerant and had higher plasma levels of insulin and leptin. 
No additional effects of LPS were observed on metabolic parameters 
(glucose tolerance, leptin and insulin level) in either diet-fed groups. 
Repeated LPS inflammatory challenges increased the food intake in RD mice. As it 
was described above, an increase in food intake in RD mice after five LPS injections 
could have been attributed to lower accumulation of fat tissue and lower, but not 
significantly so, plasma level of leptin. On the other hand, a high-fat diet did not 
exacerbate the effect of LPS treatment on the feeding process. Average food 
consumption was increased in. HFD-fed rnice and also remained higher relative to 
body weight. It has been already described that chronic high-fat diet consumption 
alters the homeostatic regulation of energy balance and leads to hyperphagia [584, 
585]. 
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There was a slight tendency for repeated LPS injections to reduce body weight in RD 
and HFD-fed mice. Surprisingly, despite higher food intake, HFD-fed mice had 
similar body weight to RD-fed mice and it remained similar with single and repeated 
LPS injections. We hypothesize that frequent interventions such as injections, body 
length measurements and behavioral assessments could have resulted in reduced 
weight gain in HFD-fed mice. As it was described in the current study (figure 4.18), 
a new batch of non-injected and high-fat-diet fed mice (HFD-NI) mice gained 
significantly more weight in comparison to saline-injected HFD-fed mice. These 
additional data suggest that frequent behavioral interventions coupled with (i.p.) 
injections might have affected weight gain. 
DEXA scans have shown that five LPS injections reduced percentage of 
accumulated fat tissue in RD-fed mice and similarly there was a trend in HFD-fed 
mice to have decreased percentage of fat. Although the food intake in five times 
LPS-injected RD and HFD-fed mice was higher or similar, respectively, reduction in 
fat accumulation could have been related to IL-1 signaling. As it was mentioned 
before, IL-1 inhibits he synthesis of proteins involved in the transport of fatty acid to 
adipose tissue in in vitro study [570]. It could be suggested that repeated LPS 
injections had a long-term negative effect on fat storage. Comparison between RD 
and HFD-fed mice has shown that HFD-fed mice had tendencies to have more 
accumulated fat tissue, which was expected from the higher food intake. 
Single and repeated LPS inflammatory challenge did not induce muscle atrophy in 
either RD or HFD-fed mice. It has been proposed that dyslipidaemia in high-fat diet-
fed rats could have resulted in activation of proinflammatory cascade, which could 
have led to atrophy of skeletal muscles [586]. In the current study, only the 
significant increase in the percentage of body fat of saline-treated HFD-fed mice 
might have been related with a decrease in lean tissue. No difference in the 
percentage of body fat was observed between RD and HFD-fed mice injected with 
either single or repeated LPS injections. 
The body length of both RD and HFD-fed mice was similar and the growth in these 
mice was not impaired by single or repeated LPS injections. Results obtained from 
DEXA scans suggested that BMC and BMD in RD-fed mice were decreased with 
repeated LPS injections. On the other hand, no effect of LPS inflammatory challenge 
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was observed on bone remodeling in HFD-fed mice. Comparison between the two 
diet-fed groups indicated that BMC and BMD were decreased in saline-treated HFD-
fed mice. Increased bone resorption has been observed in mice fed with a high-fat 
diet [587] and this observation supports the current findings. Repeated LPS 
injections reduced BMD and BMC in RD-fed mice but LPS treatment tended to 
show opposite effect in HFD-fed mice. It is unclear if some other metabolic factors 
could have had protective role in HFD-fed mice and this should be explored in future 
studies. 
Glucose tolerance was not impaired in both RD and HFD-fed mice by single or 
repeated LPS inflammatory challenges. As it was described in previous studies, 
high-fat diet fed mice are considered as a robust model for glucose intolerance and 
type-2 diabetes [588]. Similarly, in the current study, comparison between the two 
diet-fed groups revealed that HFD-fed mice were glucose intolerant in groups 
injected with either saline or single LPS injection, whereas there was a tendency for 
five LPS-injected HFD-fed mice to have impaired glucose tolerance. 
There was a trend for HFD-fed mice to have higher levels of plasma insulin than 
RD-fed mice and in particular it reached significance in the saline-treated group. In a 
similar manner, leptin level was elevated in HFD-fed - mice and its plasma 
concentration was related with the percentage of fat tissue. LPS inflammatory 
challenge did not alter either of the insulin or leptin plasma levels. Based on the data 
collected from IPGTT, elevated levels of plasma insulin suggest that HFD-fed mice 
were insulin resistant. These observations are in agreement with previous studies that 
h::_i.ve d~monstrated that a high-fat diet induces insulin resistance and this was 
associated with impaired expression oflipase in skeletal muscles [589]. 
Conclusions: 
Aim 1: Long-term effect of systemic LPS challenge on metabolic outcomes, 
exerted through the IL-1 pathway. 
• Deletion of caspase-1 and IL-lra signaling contributed to increased food 
intake. Repeated LPS injections reduced the food intake in IL-Ira-/- mice, 
whereas CNS central control over food intake was not impaired in Casp-l-/-
m1ce. 
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• Increased food intake did not contribute to weight gain nor excess fat mass 
accumulation in either Casp-1-/- or IL-lra-/- mice. In particular fat mass 
accumulation was decreased in absence of the active role of IL-lra. Casp-1-/-
mice were protected against LPS-induced decreases in both body weight gain 
and fat depots accumulation, whereas fat accumulation in IL-lra-/- was so 
low that probably it could not be further decreased by LPS intervention. 
• Absence of caspase-1 signaling contributed to increased BMD and BMC, 
whereas LPS-induced decrease of BMD and BMC was independent of 
caspase-1 mediated IL-1 ~ signaling pathway. 
• Absence of IL-lra signaling contributed to better insulin sensitivity probably 
due to increased metabolism, whereas absence of caspase-1 signaling did not 
improve the insulin sensitivity in Casp-1-/- mice. On the other hand, an 
excess of IL-1 signaling induced by LPS treatment reduced the insulin 
sensitivity in IL-lra-/- mice, whereas Casp-1-/- mice were not affected. 
• Absence of caspase-1 signaling contributed to the increased secretion of 
insulin, whereas insulin secretion was decreased in absence of IL-1 ra. Over-
stimulation of IL-1 signaling by LPS inflammatory challenge did not impair 
insulin in either Casp-1-/- or IL-lra-/- mice. 
• Lack of caspase-1 signaling contributed to reduced leptin secretion in Casp-
1-/- mice, whereas very low leptin secretion in IL-lra-/- mice was attributed 
to the very low amount of accumulated fat mass. LPS inflammatory 
challenge did not alter the leptin level. 
AIM 2: Long-term effects of high-fat diet consumption and systemic LPS 
challenge on metabolic outcomes. 
• High-fat diet consumption contributed to increased food intake. Repeated 
LPS inflammatory challenge increased the food intake in RD-fed mice, 
whereas high-fat diet did not exacerbate the LPS-induced inflammatory 
effect on food intake. 
• Despite higher food intake, final body weights in HFD-fed mice were not 
increased. However, HFD mice tended to have increased fat mass 
accumulation. Repeated LPS inflammatory challenge tended to reduce 
weight gain and body fat mass accumulation in both RD and HFD-fed mice. 
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• Longitudinal growth was not altered by high-fat consumption nor was it 
exacerbated by LPS inflammatory challenge. On the other hand, high-fat diet 
consumption tended to reduce BMD and BMC, whereas systemic LPS 
challenge had tendency to display opposite effect in HFD-fed mice. 
• High-fat diet consumption was associated with glucose intolerance that was 
not exacerbated by LPS inflammatory challenge as mice tended to lose 
weight. 
• High-fat diet consumption resulted in increased plasma levels of insulin and 
leptin, which was not exacerbated by LPS inflammatory challenge. 
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5. Effect of peripheral inflammatory 
challenge and high-fat diet on the 
degeneration of dopamine neurons 
5.1 Introduction 
The process of neuroinflammation in the substantia nigra is characterized by the 
activation of microglia cells [283], increased levels of proinflammatory cytokines 
(e.g. IL-1~) [590] and chemokines such as MCP-1. In particular, IL-1 has been 
shown to be the key inflammatory factor involved in many neurodegenerative 
diseases [591]. Neuroinflammation has been considered to play a major role in the 
neurodegeneration of dopaminergic neurons since it was observed that degeneration 
of these neurons occurs in an idiopatic manner in 90% of Parkinson's disease 
patients [592]. According to epidemiological and postmortem studies, a 
neuroinflammatory process was suggested to contribute to the progression of 
Parkinson's disease [ 5 93]. Studies conducted in rodents suggest that chronic 
exposure to neurotoxins may predispose dopamine neurons to degeneration with 
advanced aging [594]. In a similar manner, epidemiologicaf studies have suggested 
possible implications of pesticides in the pathogenesis of Parkinson's disease [595]. 
Degeneration of dopaminergic neurons in rodents may be induced by several toxins 
( chapter 1.9) such as LPS, whose mechanism of action is established through the 
process of neuroinflammation. In regard to other inflammatory factors, IL-1 ~ and 
. . 
TNF-a are the main proinflammatory cytokines considered to be involved in LPS-
induced neurodegeneration of dopamine neurons [596]. As previously described in 
chapter 1.10.3 , these cytokines (i.e. IL-1~ and TNF-a) may affect dopamine neurons 
directly by inducing programmed cell death, or indirectly through activation of 
microglial cells (chapter 1.10.5.1). The LPS-induced neurotoxicity was first 
introduced in in vitro studies with rat mesencephalic cultures where it was shown 
that dopaminergic neurons were more susceptible to neurodegeneration than the 
other neuronal cells and this LPS-mediated toxicity occurred via activation of 
microglia [239, 596]. Moreover, a recent in vivo study conducted on mice 
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demonstrated that intracerebral infusion of LPS selectively induced degeneration of 
dopaminergic neurons without affecting cholinergic and serotonergic neurons [238]. 
The degree of dopaminergic neurodegeneration and duration of neuroinflammatory 
process varies according to the routes of injection and genotype, doses of LPS 
administration and age of the tested rodents. For example, it has been demonstrated 
that acute intranigral LPS injection (2µg) produces irreversible loss of dopamine 
neurons in SNpc within 21 days [597], but further decline has not been observed 
after a year from post-treatment [ 4 77]. In parallel with the previous statement, acute 
LPS intervention is accompanied with rapid activation of microglial cells but these 
cells revert to their ramified state in a very short period of time (30 days) [598]. On 
the other hand, chronic intranigral infusion of low doses of LPS (5ng) in rats 
produced delayed and progressive loss of dopaminergic neurons with significant 
activation of microglial cells [ 4 76]. In comparison with the inflammation induced 
directly in the CNS, systemic inflammation has been described as affecting the 
activity of resident immune cells in the brain that may be associated with a chronic 
neuroinflammatory state [599]. As described before in chapter 3.2, single systemic 
LPS injection (i.p.) induced the loss of dopamine neurons in the substantia nigra of 
male mice by 23% after 7 months and the loss progressed to 47% after 10 months 
[ 109]. Moreover, degeneration of dopamine neurons is exacerbated with higher 
doses of LPS, meaning that the degree of loss is also dose dependent [600]. 
Nigrostriatal injection of LPS produced greater loss of dopamine neurons in sixteen 
months old rats in comparison to younger ones (3 months old) [601], which suggest 
that older animals are more predisposed to neurodegeneration than younger animals. 
Collectively, these observations suggest that intranigral chronic neuroinflammation 
and systemic LPS administration may play a vital role in prolonged and significant 
loss of dopamine neurons [109, 599] that could further be exacerbated with higher 
dose ofLPS [600] and in older experimental group of rodents [601] . 
As previously described in chapter 3.2, high-fat diet consumption and metabolic 
perturbations ( chapter 4) that occur as a result of obesity may exacerbate the 
proinflammatory state induced by LPS and consequently alter the proper function of 
the nigrostriatal system. A recent study has shown that two months of high-fat diet 
feeding exacerbated the decrease of dopamine in the striatum in the MPTP-induced 
model of dopaminergic neurodegeneration [351]. Furthermore, it has been 
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demonstrated that mice fed a high-fat diet for 22 weeks had an increased level of 
proinflammatory proteins in the brain [602]. Even though there was no detectable 
difference in the number of CD68-positive microglial cells (measured as an index of 
microglia activation), it has been additionally observed that isolated microglial cells 
from high-fat diet-fed mice secreted more TNF-a in comparison to chow diet-fed 
mice [602]. These papers suggest that the inflammatory profile in the brain may be 
up-regulated with high-fat diet-induced obesity and possibly exacerbated the loss of 
dopamine neurons [3 51 ], which does not have to be necessarily correlated with the 
number of activated microglia [602]. 
Down-regulation of the neuroinflammatory process ameliorates the loss of 
dopamine neurons. For instance, down-regulation of inflammation by ciclooxigenase 
inhibitor-2 has been shown to attenuate the dopamine cell loss in rodents [603]. In a 
similar manner, pharmacological administration of human recombinant IL-1 receptor 
antagonist (anakinra) attenuated the loss of dopamine neurons and reduced the level 
of IL-1 with the nigrostriatal injection of Toll-like receptor-3 agonist 
polyinosinic:polycytidylic acid in rats [158], suggesting that the neuroinflammatory 
process may play a maJor role m the progression of dopaminergic 
neurodegeneration. 
5.2 Objectives 
The aim of this chapter is to assess the effect of high-fat diet and LPS inflammatory 
challenge on activation of microglial cells and their concomitant role in the 
degeneration of dopamine neurons, measured by TH staining. Additionally, plasma 
level ofMCP-1 have been measured in order to assess the proinflammatory profile in 
the peripheral organs and to ascertain if this inflammatory profile is related with the 
inflammatory status of the brain. 
5.3 Brief methodology 
Frozen mouse brains were cut on cryostat and processed for immunohistochemical 
analysis. Eight evenly spaced frozen sections that encompassed the entire region of 
substantia nigra were cut and stained with rabbit anti-tyrosine hydroxylase antibody, 
a positive marker of dopamine neurons and rat anti-mouse CD68 monoclonal 
antibody, a marker of activated microglia/macrophages. The unilateral side of the 
substantia nigra was used for quantification of TH-positive neurons and CD68-
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positive microglial cells. Slides were quantified under the microscope and a total cell 
count of eight slides per animal was recorded as for the final result. In order to assess 
the plasma level of MCP-1 chemokine, an ELISA test was performed from the blood 
plasma. 
5.4 Results 
In order to assess the effect of LPS inflammatory challenge on neuronal degeneration 
of dopamine neurons, the total number of TH-positive neurons was quantified from 
eight evenly spaced frozen sections of the brain that encompassed the entire region 
of the substantia nigra. 
In figure 5.1 (A, B and C), the total cell count of dopamine neurons of WT, Casp-1-/-
and IL-lra-/- mice is presented in order to assess the effect of single or repeated LPS 
treatment on neuronal degeneration. As it is presented in figure 5 .1 A, single or 
repeated LPS injections did not significantly decrease the number of dopamine 
neurons in WT mice. Similarly, repeated LPS treatment did not exacerbate the loss 
of dopamine cells in the Casp-1-/- and IL-lra-/- group of mice in comparison to their 
corresponding saline-treated groups (figure 5.1 B and C). For that reason the effect 
of single LPS injection on TH-positive cells was not further evaluated in Casp-1-/-
and IL-lra-/- groups. 
In order to assess the role of the IL-1 pathway on dopaminergic neurodegeneration, 
the total count of TH-positive cells was compared among three different genotypes 
within the same treatment (figure 5.1 D). As presented inside the saline-treated 
group, the lack of IL-1 ra led to a reduction of up to 24% of dopamine neurons in IL-
1 ra-/- mice in comparison to Casp-1-/- (p<0.001) and WT mice (p<0.05). Similarly, 
the same trend was observed among the three genotypes that received five LPS 
injections, suggesting that the loss of dopamine neurons in IL-lra-/- mice was not 
additionally affected by LPS treatment (figure 5 .1 D). A positive TH-staining of 
dopamine neurons in SNpc of WT, Casp-1-/- and IL-lra-/- mice that were injected 
with saline, or five monthly LPS injections is presented in figure 5.2. 
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Figure 5.1: Effect of LPS inflammatory challenge on degeneration of dopamine 
neurons: Fifteen months after the first saline/LPS injections mtce brains were harvested 
and 32 consecutive slides (rostral to caudal: -2.65 to -3.61 mm posterior from bregma) were 
collected. The total number of TH-positive cells from eight evenly spaced frozen sections 
were evaluated from the unilateral side of SNpc and presented individually by different 
genotypes A) WT, B) Casp-1 -/- and C) IL-lra-/- mice, in order to assess the effect of LPS 
treatment. Data were analyzed by one-way ANO VA (Tukey' s post-hoc test) and unpaired T-
test. D) The total number of TH-positive neurons was. compared among three different 
genotypes within each treatment by one-way ANOVA followed by Tukey's post-hoc test. 
Error bars represent the standard errors. /\p<0.05 vs . WT; ++p<0.001, +++p<0.0001 vs. Casp-1-
/-: 
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Figure 5.2: Immunostaining of TH-positive neurons in saline and five monthly 
LPS-injected mice: Frozen sections were stained with anti-TH antibody 15 months after 
the first saline/LPS injection. Positive TH-immunostaining of saline-injected mice: A) WT, 
C) Casp-1-/- and E) IL-Ira-/-; and 5-times LPS-injected mice: B) WT, D) Casp-1-/- and F) 
IL-Ira-/-. 
In order to further understand the implication of activated microglial cells in the 
neurodegeneration of dopamine neurons, activated microglia/macrophages were 
stained with CD68 marker and counted in the area of the SN pc and SN pr. 
In figure 5.3 (A, B and C), total count of CD68-positive cells of WT, Casp-1-/- and 
IL-Ira-/- mice treated with saline or repeated LPS injections is presented. The effect 
of a single LPS injection on the activation of microglia cells was not assessed since it 
was previously shown ( figure 5 .1) that single exposure to LPS did not significantly 
reduce the number of dopaminergic neurons. As presented in figure 5.3 A, repeated 
LPS injections did not significantly increase the number of activated microglia in 
WT mice. Similarly, five LPS injections did not increase the number of activated 
microglia either in Casp-1-/- or in IL-Ira-/- mice (figure 5.3 Band C). 
The role of the IL-1 signaling pathway in activation of microglia cells was assessed 
in the three different genotypes and compared within the same treated group (figure 
5.3 D). In the saline-treated group, Casp-1-/~ mice had a significantly lower number 
of activated microglia (approximately 50%) in comparison to WT and IL-lra-/-
mice, suggesting that these mice show an overall lower inflammatory cascade within 
the brain. No significant difference between IL-Ira-/- and WT mice was observed. 
Similarly, the same trend in the _activation of microglia cells was shown in groups 
treated with five LPS injections. These data suggest that IL-1 signaling was involved 
in the activation of microglial resident immune cells. A positive CD68-staining of 
activated microglia cells in the substantia nigra of WT, Casp-1-/- and IL-Ira-/- mice 
that were injected with saline, or five monthly LPS injections is presented in figure 
5.4. 
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Figure 5.3: Effect of LPS inflammatory challenge on activation of microglia 
cells: Eight evenly spaced frozen sections that encompassed the entire substantia nigra were 
stained with CD68, a marker for activated microglia. Total count of CD68-positive cells 
were counted in the region of substantia nigra (SN) in groups of A) WT, B) Casp-1-/- and C) 
IL-lra-/- mice and analyzed by unpaired T-test. D) Genotype comparison of the total number 
of CD68-positive cells was analyzed within each treatment by one-way ANOV A followed 
by Tukey' s post-hoc test. Error bars represent standard errors. /\/\p<0.001 vs . WT; 
+++p<0.0001 vs. Casp-1-/-. 
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Figure 5.4: Immunostaining of CD68-positive microglia cells in saline and five 
monthly LPS-injected mice: Frozen sections were stained with anti-CD68 antibody 15 
months after the saline/LPS injection. Positive CD68-immunostaining in sa1ine-injected 
mice: A) WT, C) Casp-1 -/- and E) IL-Ira-/-; and 5-times LPS-injected mice: B) WT, D) 
Casp-1-/- and F) IL-lra-/-. 
MCP-1 is a chemokine produced by a variety cells types such as endothelial cells, 
epithelial cells, fibroblast, astrocytes, smooth muscle and microglia [604-606]. 
Stimulated by various stimuli, such as pro inflammatory ( e.g. TNF-a and IL-1) 
cytokines and endotoxins [607], MCP-1 up-regulates the migration of monocytes, 
natural killer cells and memory T lymphocytes to the site of injury or inflammation 
[608]. For example, the plasma level of MCP-1 has been elevated in the serum of 
humans with sepsis [609]. Systemic LPS injections in mice was shown to up-
regulate MCP-1 levels in the brain [610]. In particular it was shown that MCP-1 
expression was noticed 30 min after systemic LPS administration in areas that are 
devoid of the BBB [ 611] and 6-8 hours later, MCP-1 expression was observed 
throughout the brain parenchyma [612]. In tum, the neuroinflammatory process may 
contribute to the infiltration of immune cells from the periphery into the SN pc [ 613]. 
The infiltration of neutrophiles was observed in SN pc of rodents that were subjected 
to intranigral LPS injection and were detected by expression of MCP-1 marker 
[613]. 
In mice with hepatic inflammation, peripheral TNF-a was required to induce 
expression of MCP-1 in microglia and concomitantly to contribute to the recruitment 
of peripheral monocytes into the brain [614]. As TNF-a levels were markedly 
decreased in plasma (within 3 hours) to the baseline point (below detection) and 
remained undetectable during the following ten months after single systemic LPS 
injection (5 mg/kg) [l 09, 403], it may be suggested that recruitment oflocal immune 
cells into the brain was limited. On the other hand, TNF-a has been found elevated 
in the brain ten months after a single systemic LPS injection (5 mg/kg) [l 09, 403], 
which suggests that this level could have originated from activated resident immune 
cells in the brain. In connection with the previous statement, peripheral LPS 
administration was reported to induce production of MCP-1 in the brain by 
macrophage/microglia cells [611], astrocytes [612] and endothelial cells [611]. 
Therefore, it is uncertain if single or repeated systemic LPS injections in the current 
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study could have up-regulated the MCP-1 for a longer period in the periphery and 
contributed to the infiltration of peripheral immune cells into the brain. 
In this study, the level of MCP-1 was measured in the blood plasma in order to 
determine if MCP-1 in the periphery could affect changes in the brain. As presented 
in figure 5.5 A, MCP-1 levels increased, but not significantly, after repeated LPS 
injections in WT mice. In contrast, the concentration ofMCP-1 was decreased with a 
single LPS injection and significantly attenuated with five LPS injections in Casp-1-
/- mice (figure 5.5 B). Similarly to Casp-1-/- mice, plasma level ofMCP-1 in IL-lra-
/- group was significantly decreased with single and repeated LPS injections (figure 
5.5 C). 
In figure 5.5 D, MCP-1 level is compared among different genotypes within the 
same treatment in order to understand the role of IL-1 in regulation of MCP-1. As it 
may be observed, the levels of MCP-1 were elevated in saline-treated group of Casp-
1-/- and IL-Ira-/- mice, but there was no significant difference between genotypes. A 
similar trend was shown with a single LPS injection. However, repeated LPS 
injections did induce increase in MCP-1 plasma level in WT mice that was 
significant in comparison to Casp-1-/- mice. These observations suggest that the 
level of MCP-1 in the periphery is not tightly regulated -by the IL-1 signaling 
pathway. 
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Figure 5.5: Plasma level of MCP-1 chemokine: The MCP-1 level was measured from 
blood plasma and concentration was expressed in µg/mL The effect of LPS treatment on 
MCP-1 level in A) WT, B) Casp-1-/- and C) IL-lra-/- mice was analyzed by one-way 
ANOVA (Tukey' s multiple comparison test). D) Level of MCP-1 was compared among 
different genotypes within same treated group by one-way ANOVA followed by Tukey's 
post-hoc test. *p<0.05, **p<0.01 vs. Sal, /\p<0.05 vs. WT. 
In order to assess the effect of LPS treatment and a high-fat diet on the degeneration 
of dopamine neurons, groups of mice fed either a regular or high-fat diet were 
analyzed separately in figure 5.6 (A and B). As it may be observed in WT mice fed a 
regular diet, single and repeated LPS injections tended to reduce the total number of 
dopamine neurons, but this was not significant (figure 5.6 A). On the other hand, 
repeated LPS injections did induce significant loss of dopamine neurons by 11 % in 
high-fat diet-fed mice (p<0.05) (figure 5.6 B). 
Data of both groups were collapsed from figures 5.6 A and B in order to evaluate the 
additional effect of high-fat diet consumption on the loss of dopamine neurons. As 
may be observed in figure 5 .6 C, there was not a significant reduction in dopamine 
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neurons m saline or LPS-treated groups, suggesting that the loss of TH-positive 
neurons was not induced or exacerbated by long-term high-fat diet consumption. 
Similarly, quantification of TH-positive cells in SNpc of HFD-NI mice, yielded no 
differences (data not shown). A positive TH-staining of dopamine neurons in SNpc 
of RD and HFD-fed mice that were injected with saline, or five monthly LPS 
injections is presented in figure 5.7. 
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Figure. 5.6: Effects of high-fat diet and LPS inflammatory challenge on the loss 
of dopamine neurons: Total number of TH-positive cells from eight evenly spaced frozen 
sections were evaluated from the unilateral side of SNpc and presented individually by diets 
A) RD and B) HFD-fed mice, in order to assess the effect of LPS treatment. Data were 
analyzed by one-way ANOVA (Tukey's post-hoc test). D) Total number of TH-positive 
neurons was compared between two different diets within each treatment by unpaired T-test. 
Error bars represent the standard errors. *p<0.05 vs. Sal. 
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Figure 5.7: Immunostaining of TH-positive neurons in saline and five monthly 
LPS-inj ected mice: Frozen sections were stained with anti -TH antibody 15 months after 
first saline/LPS injection. Positive TH-immunostaining of saline-inj ected mice: A) RD and 
C) HFD; and 5-times LPS-inj ected mice: B) RD and D) HFD. 
In order to assess the long-term effect of high-fat diet consumption and LPS 
treatment on microglia activation, frozen brain sections were stained with CD68 
microglia marker and quantified. In figures 5.8 A and B the effect of repeated LPS 
injections was assessed separately m RD and HFD groups. Repeated LPS 
inflammatory challenge increased, but not significantly, the activation of microglial 
cells in RD-fed mice whereas this effect was not observed in HFD-fed mice. 
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In figure 5.8 D, groups of mice fed with two different diets were compared within 
same treatment in order to evaluate the effect of a high-fat diet in the activation of 
microglia cells. As may be observed, the total number of activated microglia cells in 
the SN region was not changed in saline-treated groups, but it was significantly 
increased in RD-fed mice injected with five LPS injections. These observations 
suggest that a high-fat diet did not induce or exacerbate the activation of microglia 
cells. Similarly, quantification of CD68-positive cells in the substantia nigra of HFD-
NI mice, yielded no differences ( data not shown). A positive CD68-staining of 
activated microglia cells in the SN of RD and HFD-fed mice that were injected with 
saline, or five monthly LPS injections is presented in figure 5.9. 
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Figure 5.8: Effects of high-fat diet and LPS inflammatory challenge on the 
activation of microglia cells: Eight evenly spaced frozen sections that encompassed the 
entire region of the SN were stained with CD68, marker for activated microglia. The total 
number of CD68-positive cells was counted in the region of the SN in groups fed A) RD and 
B) HFD and analyzed by unpaired T-test. D) Comparison of total number of CD68-positive 
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cells between groups fed with different diets and within each treatment. Data were analyzed 
by unpaired T-test. Error bars represent standard errors. Mp<0.001 vs. RD . 
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Figure 5.9: Immunostaining of CD68-positive microglia cells in saline and five 
monthly LPS-injected mice: Frozen sections were stained with anti-CD68 antibody 15 
months after first saline/LPS injection. Positive CD68-immunostaining of saline-injected 
mice: A) RD and C) HFD; and 5-times LPS-inj ected mice: B) RD and D) HFD. 
The effect of LPS inflammatory challenge and high-fat diet on plasma level of MCP-
1 was assessed in order to better understand a possible connection of peripheral 
inflammation with an inflammatory outcome in the CNS . 
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In figures 5.10 A and B, the effect of single and repeated LPS injections on MCP-1 
levels was evaluated in mice fed with either RD or HFD. Repeated LPS 
inflammatory challenge increased, but not significantly, the level of MCP-1 in RD-
fed mice, while a single LPS injection did not produce any effect (figure 5.10 A). 
Long-term exposure to high-fat diet did not increase the level of MCP-1 in concert 
with single or repeated LPS inflammatory challenges (figure 5.10 B). 
Comparison between groups fed with different diets and within the same treatment 
(figure 5.10 C) revealed that levels of MCP-1 were similar in both HFD and RD-fed 
mice injected with either saline or a single LPS injection. The only difference 
observed was in five times LPS injected mice where RD-fed mice had elevated 
levels of MCP-1 in comparison to HFD-fed mice, but this was not statistically 
different. 
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Figure 5.10: MCP-1 level in plasma: The MCP-1 level was assessed from blood 
plasma and concentration was expressed in µg/ml. The effect •Of LPS treatment on MCP-1 
levels in the group of mice fed either A) RD or, B) HFD was analyzed by one-way ANOVA 
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(Tukey ' s multiple comparison test). D) Level of MCP-1 was compared between groups fed 
with different diets and within the same treatment by unpaired T-test. Error bars represent 
standard errors. 
5.5 Discussion 
For this study to determine the role of the IL-1 signaling pathway and possible 
exacerbation of systemic LPS inflammatory challenge by high-fat diet on prolonged 
and progressive degeneration of dopamine neurons, the experimental model 
previously described by Yuxin Liu, et al. was used [376]. 
AIM 1: Long-term effect of systemic LPS challenge on inflammatory outcomes, 
exerted through the IL-1 pathway. 
Major differences in activation of microglia cells and final cell count of dopamine 
neurons were observed among the three genotypes (WT, Casp-1-/- and IL-Ira-/-). On 
the other hand, the effect of LPS treatment was modest or undetectable. 
• Activation of microglia cells in Casp-1-/- mice was significantly lower and 
not exacerbated by repeated LPS injections. TH-positive cell count was 
similar to WT mice and was not decreased by repeated LPS administrations. 
Plasma levels of MCP-1 were significantly reduced by five monthly LPS 
injections. 
• Total CD68-positive cell count in IL-lra-/- mice was not significantly 
elevated in comparison to WT mice, nor it was further increased by LPS 
treatment. Despite the similar number of activated microglia cells in 
comparison to WT mice, a decrease in dopamine neurons was significant in 
IL-lra-/- mice and it was not further exacerbated by repeated LPS injections. 
Single and repeated LPS injections decreased plasma level ofMCP-1. 
• Repeated LPS injections did not significantly decrease dopamine neurons in 
the substantia nigra of WT mice nor was the final count of CD68-positive 
cells increased. There was a trend for the plasma level of MCP-1 to be 
elevated with five LPS injections. 
Significant differences in degeneration of dopamine neurons were observed among 
genotypes. The progressive loss of dopaminergic neurons was observed in IL-lra-/-
mice, whereas dopamine neurons remained relatively intact in Casp-1-/- mice, 
indicating the relevance of the IL-1 signaling pathway in neurodegeneration. In 
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comparison to the previously described model [376], single and repeated LPS 
injections reduced the number of TH-positive neurons in WT mice but this loss was 
not significantly different to their corresponding saline-treated group. The modest 
loss of TH-positive neurons with five monthly LPS injections in WT mice might 
have been accompanied by a slightly increased number of activated microglial cells. 
On the other hand, it is unclear if the increased level of MCP-1, (increased but not 
statistically different compared with saline-injected WT mice), could have 
contributed to the elevated number of microglial cells. 
Degeneration of dopamine neurons in IL-Ira-/- mice was not further exacerbated 
with five monthly administrations of LPS. This observation might suggest that the 
24% loss of dopamine neurons in both saline and LPS-treated groups could not be 
further exacerbated with additional systemic inflammation challenge. The loss of 
neurons might have been accompanied with elevated cell numbers of activated 
microglia but this was not statistically different from WT mice. This implies that 
excess production of IL-1 by activated microglia in IL-Ira-/- mice may not have 
increased activation of microglia, but it could have mediated apoptotic death of 
dopamine cells. More specifically, dopaminegic neurons are shown to be susceptible 
to excitotoxicity induced by glutamate [ 615]. Cytokines control dopamine release 
indirectly via stimulation of glutamate release from astrocytes [233] . In in vitro 
studies conducted on mixed neuronal-glial primary cell cultures (microglia, 
astrocytes and cortical neurons) isolated from IL-lra-/- and WT mice, basal and 
excitotoxins (NMDA and AMP A (promote Ca2+ influx into the cell)-induced cell 
death of cortical neurons in ILl-ra-/- mice was significantly higher than in the cell 
. . 
culture of WT mice [616]. In particular, it was demonstrated that IL-lra secreted 
from microglia prevented the excitotoxicity in cortical cell culture isolated from WT 
mice [ 616]. Astrocytes have been. shown to be the primary target for the action of IL-
1 [617]. In addition, toxins such as rotenone (used in rodent model of Parkinson's 
disease) and the herbicide paraquat are shown to increase vulnerability of dopamine 
neu:r:ons to excitotoxicity by potentiating cellular responses to glutamate 
neurotoxicity and by increasing Ca2+ influx [618, 619]. These observations imply 
that excess of IL-1 ~ produced by activated microglia cells could have induced 
secretiori of glutamate from astrocytes and promote additional excitotoxic 
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degeneration of dopamine neurons in IL-lra-/- mice in absence of the neutralizing 
effect of IL-1 ra secreted from the microglia. 
Measured levels ofMCP-1 in the plasma of IL-lra-/- mice have indicated that single 
and repeated LPS injections had significantly reduced the level of MCP-1. Similar 
decrease in MCP-1 was observed in five LPS injected Casp-1-/- mice. For example, 
it was previously shown that partial hepatectomy in IL-lra-/- mice increased MCP-1 
level in the blood after four hours but a week later the levels of MCP-1 appeared to 
drop below the initial baseline despite an elevated plasma level of IL-1 ~ [ 620]. It 
might be assumed that MCP-1 expression and secretion in blood was associated with 
some other metabolic alterations and was not dependent on IL-1 signaling. 
Therefore, future studies should be carried out in order to determine the regulation of 
MCP-1 secretion in the blood. 
The absence of caspase-1 signaling significantly reduced the number of activated 
microglial cells (approx. 50%) and concomitantly this might have protected the 
dopamine neurons in Casp-1-/- mice against repeated LPS-induced degeneration. It 
was previously shown that IL-1 plays important role in the activation of microglia 
cells [ 621]. It has been demonstrated that Casp-1-/- mice had a decreased expression 
of CD68 in the liver in diet-induced steatohepatitis [622]. Moreover, caspase-11 -/-
mice are demonstrated to be resistant against intranigral LPS-induced degeneration 
of TH-positive cells and had significantly less activated microglial cells in SNpc 
[ 623]. In particular, caspase-11 is reported to contribute to the secretion of IL-1 ~ 
[624]. With regards to the signal transduction of LPS, both caspase-1 -/- and 
caspase-11 -/- mice are highly resilient to septic shock induced by live Escherichia 
coli or LPS [625, 626]. In conclusion, Casp-1-/- mice have been protected against 
repeated LPS systemic inflammation after fifteen months from the first saline/LPS 
injection. 
AIM 2: Long-term effects of high-fat diet consumption and systemic LPS 
challenge on inflammatory outcomes. 
• Long-tenn feeding on a high-fat diet coupled with repeated systemic LPS 
injections induced loss of dopamine neurons but it was not accompanied with 
increased number of activatated microglia cells. MCP-1 plasma levels were 
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similar to RD-fed mice and were not further exacerbated by single and 
repeated LPS injections. 
There was no substantial evidence that long-term high-fat diet consumption 
exacerbated the loss of dopamine neurons in SNpc of WT mice. Repeated LPS 
injections had induced 11 % loss of TH-positive cells in mice fed a high-fat diet, but 
this loss was not different from the total number of dopamine neurons that were 
quantified in five LPS-injected RD-fed mice. Surprisingly, HFD-fed mice had 
significantly less number of activated microglial cells in comparison to five times 
LPS-injected RD mice. As described in the introduction ( chapter 5 .1) microglia cells 
in HFD-fed mice could have additionally produced more proinflammatory cytokines 
such as TNF-a [602] that could have finally led to a similar degree of dopaminergic 
neurodegeneration in both HFD and RD-fed mice. 
The plasma level of MCP-1 was not elevated or further affected by LPS treatment in 
HFD-fed mice. In that regard, the condition of excessive food intake and fat 
accumulation was shown to trigger hyperactive adipocytes to release MCP-1 that 
further stimulates infiltration of macrophages into the adipose tissue [332]. In 
parallel to the previous statement, the MCP-1 plasma level was shown to be elevated 
in two-month old mice that were fed a high-fat diet in a period of two months [351]. 
In the current study, HFD-fed mice tended to have higher accumulation of fat, but it 
did not result in a higher plasma level of MCP-1. As described before, adipose cell 
enlargement leads to the secretion of chemokines ( e.g. MCP-1) [ 627], suggesting 
that MCP-1 could not have been elevated in HFD-fed mice since body weight gain in 
these 15 month-old mice was in stagnation. 
Conclusions: 
AIM 1: Long-term effect of systemic LPS challenge on inflammatory outcomes, 
exerted through the IL-1 pathway: 
Major differences in inflammatory outcomes in the substantia nigra were observed 
among the three genotypes (WT, C~sp-1-/- and IL-Ira-/-), whereas LPS effect was 
modest. 
• Dysregulation in the IL-1 signaling pathway observed in IL-Ira-/- could have 
potentially contributed to the degeneration of dopamine neurons in SNpc. 
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Loss of dopamine neurons could not be solely attributed to activation of 
microglia cells. 
• Low inflammatory state m Casp-1-/- contributed to the protection of 
dopamine neurons. 
AIM 2: Long-term effects of high-fat diet consumption and systemic LPS 
challenge on inflammatory outcomes. 
• Repeated systemic LPS inflammatory challenge induced a loss of dopamine 
neurons to a certain degree in RD and HFD-fed mice, which could not have 
been further exacerbated by low-grade chronic inflammation induced by 
high-fat diet consumption. 
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6. Discussion 
A chronic, self-perpetuating neuroinflammatory process induced by activated 
microglial · cells in the brain is associated with the progression of dopaminergic 
neurodegeneration [628]. A neuroinflammatory process may be elicited by various 
inflammatory challenges such as viruses and bacteria, environmental toxins, chronic 
inflammatory disorders (rheumatoid arthritis) and neuronal brain injuries [628-631]. 
Studies conducted in rodents suggest that chronic exposure to neurotoxins may 
advance dopaminergic neurodegeneration during aging [594]. In particular, 
dopamine neurons have been described to be relatively more susceptible to 
neuroinflammatory process than other neuronal subsets [238]. 
LPS stimulates the production of proinflammatory cytokines from local innate and 
adaptive immune cells [301] that further activate their own production by pericytes 
in the region of CVO's and choroid plexus [62], endothelial cells of CVO's [63] and 
BBB [64]. Moreover, LPS is also a potent stimulator of the TLR4 - NF-KB signaling 
pathway within the microglial cells, which elicits cytokine production via activation 
of caspase-1 [632]. The activation of the neuroinflammatory cascade, in particular 
the IL-1 ~ and TNF-a pathways, are potent stimulators of miproglial cells activation 
[633]. Microglia cells are mostly abundant in the region of substantia nigra; up to 
12% of these cells were estimated to be within this brain region [237]. Activated 
microglial cells phagocyte injured dopaminergic neurons during the early phase of 
their apoptosis [634]. Moreover, microglia cells can facilitate the initiation of the 
programmed-cell death of dopaminergic neurons via pro inflammatory cytokines ( e.g. 
IL-1~ and TNF-a) [260]. Damaged or dying dopaminergic neurons can also 
feedb';1ck positively the neuroinflaµimatory cascade driven by microglia cells by 
releasing neuromelanin, a byoproduct of catecholamine metabolism, which up-
regulates the NF-KB signaling pathway in microglial cells that in tum produce 
proinflammatory cytokines [296]. Thus, this positive feedback loop develops a self-
perpetuating neuroinflammatory process. 
Aging is characterized by increased basal level of proinflammatory cytokines such as 
IL-1~, IL-6 and TNF-a in the periphery and the brain [301, 635]. Age-related 
priming of microglial cells is suggested to facilitate an environment that could be 
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described as a low-grade chronic neuroinflammation [636]. In a similar manner, 
high-fat diet consumption and obesity are also considered to facilitate a low-grade 
chronic inflammatory state [ 6] that could potentiate the up-regulation of 
peripherally-induced inflammation and exacerbate the loss of dopaminergic neurons. 
As it was previously shown, systemic LPS-induced inflammatory challenge caused a 
prolonged and delayed neurodegeneration of dopamine neurons [376]. Also, chronic 
low-grade central infusion of LPS caused prolonged neurodegeneration that was 
attributed to priming of microglia cells [ 4 7 6]. Therefore, it could be suggested that 
an acute high dose of systemic and/or low-grade chronic infusion of LPS may induce 
microglial cell priming and a self-perpetuating neuroinflammatory process that 
induces neurodegeneration of dopamine neurons, which progress over time. 
6.1 AIM 1: Long-term effect of systemic LPS challenge on behavioral, 
metabolic and inflammatory outcomes, exerted through the IL-1 
· pathway. 
In these studies, the data obtained from behavioral, metabolic and histological 
analysis suggested that the most important differences occurred among mice of the 
three different genotypes (WT, Casp-1-/- and IL-Ira-/- mice). 
As presented in chapter 3, evaluation of motor activities in open-field test has shown 
that Casp-1-/- mice displayed increased; whereas, IL-lra-/- mice showed initial 
hypoactivity and time-dependent decrease in locomotor activity. These data are in 
agreement with a previous study, where systemic administration of IL-1 ~ suppressed 
locomotor activities in mice [478], whereas mice lacking IL-lRl-/- signalling 
displayed increased locomotor activities [ 4 79]. Overall, data are suggesting that 
motor activities are inversely related with IL-1 ~ signalling pathway. 
Over a course of nine months, IL-lra-/- mice also displayed coordinative disabilities 
in the rotarod test. Decrease in both balance and motor activity could be attributed to 
the loss of dopamine neurons in SNpc and an extremely low level of leptin. It was 
suggested that leptin signaling in POMC neurons of severely obese, hypoactive and 
diabetic Lepr db/db mice increased locomotor activity [637]. Similarly, it has been 
demonstrated that juvenile db/db mice (5-6 weeks old) had lower locomotor activity 
in the open-field test than age-matched WT mice [638]. Our studies show that 
despite an increased o erall locomotor activity within the open-field test, Casp-1-/-
mice showed a trend of a time-dependent decrease in coordination in the rotarod test, 
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over a nme months period. We hypothesize that this mentioned trend in time-
dependent decrease in coordination of Casp-1-/- mice could not be associated with 
dopamine depletion since these mice did not show signs of akinesia, a symptom that 
is usually · associated with dopamine content deficiency [ 461]. This data might 
suggest that coordinative abilities in Casp-1-/- were partially protected. On the other 
hand, the saline-injected IL-lra-/- mice displayed a profound decrease in motor 
coordination that reached significant differences versus saline-injected WT mice 
(figure 3 .2). Interestingly, this difference was not exacerbated after the 
administration of LPS (figure 3 .2). Moreover, the administration of LPS (1 T and ST) 
increased the variability in the experimental groups of the three genotypes and the 
significant differences among them were lost as shown in figure 3.2. Collectively, 
data suggest that during baseline conditions, an overall inflammatory state, due to the 
lack of IL-lra, as observed in IL-lra-/- mice, led to a major decrease in coordinative 
abilities. Thus, an IL-1 ~-induced neuroinflammatory process might have been 
involved in exacerbation of the coordinative disabilities observed in IL-lra-/- mice in 
a time-dependent manner during baseline conditions. 
In relation to non-motor symptoms, such as an anxiety/depressive-like behavior, 
Casp-1-/- mice displayed a tendency of anxiolytic behavior_ in elevated plus maze 
test; whereas, the IL-lra-/- mice showed anxiety-like behavior and it progressed in 
time-dependent manner in the open-field test. In regards to Casp-1-/- mice, another 
mouse strain with the impairment in the IL-1~ signaling pathway (IL-lRl-/-
deficient mice), was shown to display anxiolytic behavior in the elevated plus maze 
test [ 479]. Thus, anxiety behavior in IL-lra-/- mice could be attributed, at least in 
part to a neuroinflammatory process directed by IL-1 ~- Moreover, IL-lra-/- mice 
display decreased adipogenesis [571] and evidence of decreased plasma levels of 
leptin [571]. As previously stated, that leptin treatment ameliorated anxiety behavior 
in ob/ob mice [639]; it can not be ruled out that low levels of leptin in IL-lra-/- mice 
could .also facilitate increased anxiety behavior. It is reported in this thesis that IL-
lra-/- mice showed a remarkable decrease of dopamine neurons as well. Since 
depletion of dopamine in medial prefrontal cortex of rats induced anxiety-like 
behavior, as observed in the elevated plus maze test [640]; therefore, it might also be 
possible that decreased dopamine neurons in IL-lra-/- mice could also facilitate 
increased anxiety-like behavior. Collectively, the data of this thesis and literature 
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suggest that progression of anxiety-like behavior in IL-lra-/- mice could be 
attributed to increased IL-1 ~-induced neuroinflammation, extremely low levels of 
leptin and loss of dopamine neurons. 
Surprisingly, Casp-1-/- mice have appeared to develop anxiety-like behavior in the 
open-field test. However, this finding was not supported by another behavioral 
paradigm aimed at assessing anxiety behavior namely, the elevated plus maze test. 
Thus, it remains unclear if Casp-1-/- mice became more anxious in time-dependent 
manner and more studies should be carried out to further investigate this outcome. 
Anxiety behavior was described to be controlled by neuronal network that 
encompasses the hippocampal, cortical and afferents of the nucleus accumbens 
[641]. In particular, it has been demonstrated that dopamine action in dorsal 
hippocampus through its receptors (Dl and D2) modulates anxiety-like behavior 
[642]. Similarly, the functional interaction between NMDA and dopamine receptors 
in dorsal hippocampus has been recently associated with modulation of anxiety-like 
behavior [ 486]. In regard to a caspase-1 signaling, the inhibition of caspase-1 activity 
by the appropriate inhibitor (z-YVAD-FMK) has been shown to increase the NMDA 
receptor-mediated current in hippocampal slices in vitro [ 484, 485]. In connection 
with the previous statement, inhibition of NMDA signaling in dorsal hippocampus 
induced anxiolytic-like behavior in mice [ 486], suggesting time-related increase in 
activity of NMDA signaling in Casp-1-/- mice could have resulted in anxiety-like 
behavior in the open-field test. Overall, it could be suggested that increased IL-1 ~ 
signaling might be involved in regulation of anxiety-like behavior in IL-lra-/- mice. 
More studies are needed to clarify if Casp-1-/- mice become anxious in a time-
dependent manner. 
The prepulse inhibition test showed that pre-attentive function in Casp-1-/- mice was 
impaired, which could have possibly been associated with increased activity of D 1 
receptor [ 495] in the hippocampus as described in detail in the discussion of chapter 
3. The prepulse inhibition test did not show any substantial cognitive impairment in 
IL-lra-/- mice. These data suggest that cognitive function was not related to IL-1 ~ 
signaling. 
Final quantification of TH-positive neurons showed that dopamine neurons in Casp-
1-/- mice were intact and their number tended to be even higher than in WT mice. 
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This was accompanied with very low activation of microglia cells. On the other 
hand, the loss of dopamine neurons in IL-lra-/- mice could have been attributed to 
higher, but non-significant activation of microglial cells and overstimulation of IL-1 
signaling, as described in the discussion of chapter 5. It was previously shown that 
IL-1 plays an important role in the activation of microglia cells [ 621]. Overall, these 
data suggest that IL-1 ~ signaling was implicated in activation of microglia and 
subsequently played major role in dopaminergic neurodegeneration. 
Surprisingly, single and repeated LPS inflammatory challenges had very modest or 
no effect on behavioral outcomes that were accompanied with very low loss of 
dopamine neurons. It is uncertain if the modest loss of dopamine neurons in LPS-
injected WT mice may have been affected with LPS administration in mice at a very 
young age. In the current study, mice were injected when they reached 6 weeks of 
age, whereas in previous studies mice were injected after 10 weeks of age [3 7 6]. 
Basal inflammatory profile increases over time and it is uncertain if mice injected 
earlier with LPS could have recovered faster. In a previous study, 4-weeks old mice 
had better functional recovery and lower secretion of proinflammatory 
cytokines/chemokines by microglia than 10-weeks old mice in an experimental 
model describing the acute phase of spinal cord injury [643] .- Therefore, it could be 
hypothesized that LPS injections ~t a younger age might have resulted in faster 
recovery and a decreased loss of dopamine neurons in WT mice. 
Although LPS inflammatory challenge altered feeding behavior in WT and IL-lra-/-
mice and managed to induce decrease in BMD and BMC in WT and Casp-1-/- mice, 
other parameters such as glucose tolerance, insulin and leptin levels remained 
relatively unchanged. Overall, alteration in some of the metabolic parameters by LPS 
did not influence the behavioral outcomes, nor was it reflected on final count of 
dopamine neurons. However, repeated LPS treatments in WT mice increased the 
level of MCP-1 in plasma. It also appeared to a certain extent that long-term effects 
of LPS treatment caused a higher activation of microglia cells; however, this effect 
was only a trend that did not reach significant differences versus saline-injected 
mice. If this seemingly microglia activation occurred to a certain extent, this could 
have bee? associated with slight reduction of dopamine neurons observed in the WT 
mice treated with five monthly LPS injections. On the other hand, a significant 
decrease in MCP-1 levels of LPS-treated_ Casp-1-/- and IL-lra-/- are not well 
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understood, but could possibly suggest that inflammatory actions in the periphery do 
not necessarily have to be associated with the inflammatory status in the brain. As it 
was previously demonstrated, MCP-1 and TNF-a were still elevated in the brain 
nine months after single systemic LPS injection [109]; whereas, TNF-a level in the 
blood was reduced to baseline [109]. As previously described in chapter 5, partial 
hepatectomy in IL-lra-/- mice increased MCP-1 level in the blood after 4 hours 
[620]. A week later, the levels of MCP-1 tended to drop below the initial baseline 
despite an elevated plasma level of IL-1 ~ [ 620]. It might be assumed that MCP-1 
expression and secretion in blood were associated with some other metabolic 
alterations and were not dependent on IL-1 signaling. Therefore, future studies are 
needed to ascertain other possible regulators of MCP-1 secretion. Overall, Casp-I-/-
mice did not show LPS-induced decrease of dopamine neurons and also had a very 
low number of activated microglia cells. However, the repeated LPS inflammatory 
challenge did not induce a further decrease of dopamine neurons in IL-Ira-/- mice 
nor it increased the number of activated microglia cells. It could be hypothesized that 
the loss of dopamine neurons in IL-Ira-/- mice could not be further exacerbated by 
the LPS inflammatory challenge. Since IL-Ira-/- mice are known to suffer from 
postnatal growth retardation [582] , it might be hypothesized that neurogenesis of 
dopamine neurons may be impaired. In the future studies, time-dependent 
quantification of TH-positive cells in IL-Ira-I-mice should be carried out in order to 
better understand if the loss of dopamine neurons in IL-Ira-/- mice increases as they 
age. 
6.2 AIM 2: Long-term effects of high-fat diet consumption and systemic LPS 
challenge on behavioral, metabolic and inflammatory outcomes. 
High-fat diet feeding in mice did not result in impaired locomotor activity, which 
was confirmed by unaltered number of TH-positive cells in SNpc. Moreover, high-
fat diet feeding did not · result in increased number of activated microglial cells; 
however, previous study demonstrated that microglial cells in HFD-fed m1ce 
produced more TNF-a [602]. If the inflammatory cascade was exacerbated in the 
brain of HFD-fed mice, it has not resulted in the loss of dopamine neurons. On the 
other hand, repeated LPS inflammatory challenge induced 11 % loss of dopamine 
neurons in HFD-fed mice, but this loss was not reflected in decreased locomotor 
activity in the open-field test. It is possible that there might be a certain threshold in 
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order for the loss of dopaminergic neurons to be reflected as decreased locomotor 
activity. For instance, it was previously shown that a significant loss of 37% of 
dopamine neurons caused decreased locomotor activity in the open-field test [376]. 
Therefore, it might be suggested that the small 11 % loss of dopamine neurons could 
not have induced significant locomotor disability in 5-times LPS-injected HFD-fed 
mice. However, both saline and 5-times LPS-injected HFD-fed mice displayed 
similar time-dependent coordinative decrease in the rotarod test. Time-dependent 
decrease in coordinative ability could be associated with decreased activity of D2 
receptor, which could have been induced by insulin and leptin insensitivity [368], 
and lower synthesis of TH enzyme due to the leptin resistance [366]. Collectively, 
impaired dopaminergic neurotransmission in HFD-fed mice could have resulted in 
reduced coordinative skills in the rotarod test. High-fat diet-fed mice have also 
shown symptoms of bradykinesia, akinesia and dyskinesia. It has to be considered 
that changes in the rotarod test caused by HFD do not seem to occur as a 
consequence of body weight gain. In fact, body weight of HFD-fed mice was similar 
to that of RD-fed mice. Therefore, it seems that motor impairments observed in 
HFD-fed mice (bradykinesia, akinesia and dyskinesia) may not be attributed to 
general body gain. Although these motor symptoms could have been associated with 
the loss of dopamine neurons, HFD-fed mice did not respond to the L-DOPA test in 
a similar manner as RD-fed mice did. For example, akinesia has been 
pharmacologicaly-induced in mice by inhibition of D2 receptors [ 499] , and 
bradykinesia and dyskinesia were observed in DAT-/- mice [498, 501]. Since high-
fat diet consumption and obesity in mice were associated with reduced activity of 
DAT [ 471] and decreased density of D2 receptors [500], these factors could have 
collectively affected motor activities in HFD-fed mice, with intact dopamine 
neurons. 
Anxiety behavior in HFD-fed mice has been associated with insulin resistance as 
mice that develop spontaneous diabetes have displayed anxiety-like behavior in the 
elevated plus maze test [644]. In the current study, high-fat diet-fed mice did not 
show to be anxious in the open-field and elevated plus maze tests. However, 
significant anxiogenic behavior was observed in the novelty suppressed feeding test 
that might have been driven by overnight fasting, as described in the discussion of 
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chapter 3. On the other hand, LPS inflammatory challenge did not exacerbate the 
anxiety behavior of HFD-fed mice. 
HFD-fed mice demonstrated impaired cognitive function in the prepulse inhibition 
test and displayed a trend to have impaired memory function in the Morris water 
maze test. Cognitive impairment could be attributed to low activity of DAT in HFD-
fed mice as it was previously shown that DAT -/- mice had disrupted prepulse startle 
response [380]. Similarly, an age-dependent decrease in prepulse response was 
observed in db/db mice [638], suggesting a possible role of type-2 diabetes and 
leptin signaling dysfunction in cognitive processing. As it was previously described 
in the discussion of chapter 3, the desensitization of protein kinase B (Akt) signaling 
pathway that is coupled to leptin receptors in the hippocampus of high-fat diet-fed 
mice induced spatial memory impairment [513]. A cognitive decline in high-fat diet-
fed mice was also attributed to the desensitization of NMDA receptors in the 
hippocampus and it was also observed that this process was compatible with the 
development of leptin resistance [514]. Similarly, insulin resistance in high-fat diet-
fed mice decreased the release of dopamine and its clearance from synaptic clefts 
[12]. As it was reported that insulin resistance contributed to cognitive decline [448], 
this might explain a possible connection between dopamine signaling and insulin 
resistance-induced cognitive impairment in the prepulse inhibition test. These 
observations suggest that high-fat diet consumption induced cognitive and partially 
memory impairment through the altered neurotransmission in the hippocampus, 
which could have been related with leptin and insulin resistance. 
Overall, feeding mice a high-fat diet induced metabolic perturbations that were 
related with some of the behavioral alterations that were described above. The 
reduced number of TH-positive neurons with repeated LPS injections did not affect 
the behavioral outcomes: High-fat diet consumption did not exacerbate the loss of 
dopamine neurons under LPS inflammatory challenge in comparison to RD-fed wild 
type mice. The loss of dopamine neurons with repeated LPS injections could not be 
completely associated with relatively similar amount of CD68-positive microglia nor 
MCP-1 level; therefore, additional in depth experiments are needed to ascertain the 
inflammatory profile in LPS-injected HFD-fed mice. 
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In conclusion, on one hand, the data reported in this thesis suggest that dysregulation 
of the IL-1 signaling pathway observed in IL-lra-/- mice could have potentially 
contributed to the delayed degeneration of dopamine neurons in SNpc. This was 
observed by decreased locomotor and coordinative abilities. On the other hand, low 
inflammatory state in Casp-1-/- mice contributed to the protection of dopamine 
neurons and preserved motor activities; however, other behavioral outcomes could 
have been attributed to the altered dopamine-mediated neurotransmission. A long-
term effect of LPS inflammatory challenges tended to induce the dopamine 
neurodegeneration in RD-fed wild type mice. Although, repeated LPS injections 
induced a small depletion of dopaminergic neurons in HFD-fed mice, this loss was 
not further exacerbated by a low-grade chronic inflammation induced by high-fat 
diet consumption. 
6.3 Future directions 
In order to better understand the role of glutaminergic and dopamine-mediated 
neurotransmission and its modulation by metabolic disorders on behavioral 
outcomes, further studies are required at the level of dopamine receptors such as Dl , 
D2 and the dopamine transporter (DAT). Extensive inflammatory profiling in the 
periphery and the brain would be needed in IL-lra-/-, Casp-1-/- and HFD-fed mice. 
Initial baseline quantification of TH-positive neurons in IL-lra-/- mice would be 
valuable in order to determine possible differences among the three genotypes. In 
future studies, systemic LPS inflammatory challenge in older mice should be 
ascertained as this might elicit more profound effects on dopaminergic 
neurodegeneration. Since anti-inflammatory drugs such as anakinra ameliorated the 
neuroinflammatory process and toxin-induced degeneration of dopamine neurons in 
rodents [ 15 8], it could be proposed that nigrostriatal administration of IL-1 ra in IL-
lra-/- mice would down-regulate the neurodegenerative process in the substantia 
nigra. In order to explore and emphasize the importance of the IL-1 pathway in 
degeneration of dopamine neurons, effects of nigrostriatal administration of IL-1 ~ in 
Casp-1-/- mice could be tested and determined in future studies. 
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